PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
26314956-1	2015	Mitochondrial Lon protease (Lon) regulates several mitochondrial functions, and is inhibited by the anticancer molecule triterpenoid 2-cyano-3, 12-dioxooleana-1,9(11)-dien-28-oic acid (CDDO), or by its C-28 methyl ester derivative (CDDO-Me).	bardoxolone methyl	232-239	lon peptidase 1, mitochondrial	Homo sapiens	14-26
26264646-5	2015	Intravenous delivery of CDDO-Me using poly-lactic-glycolic-acid NP combination with subcutaneous Trp2 vaccine resulted in an increase of antitumor efficacy and apoptotic tumor tissue than Trp2 vaccine alone in B16F10 melanoma.	bardoxolone methyl	24-31	tRNA-Pro (anticodon AGG) 2-6	Homo sapiens	97-101
26264646-5	2015	Intravenous delivery of CDDO-Me using poly-lactic-glycolic-acid NP combination with subcutaneous Trp2 vaccine resulted in an increase of antitumor efficacy and apoptotic tumor tissue than Trp2 vaccine alone in B16F10 melanoma.	bardoxolone methyl	24-31	tRNA-Pro (anticodon AGG) 2-6	Homo sapiens	188-192
26497549-3	2015	Treatment of K-ras mutant MiaPaCa-2 and K-ras normal BxPC-3 cells with CDDO-Me elicited strong antiproliferative and proapoptopic responses in both cell lines in culture.	bardoxolone methyl	71-78	KRAS proto-oncogene, GTPase	Homo sapiens	13-18
26497549-3	2015	Treatment of K-ras mutant MiaPaCa-2 and K-ras normal BxPC-3 cells with CDDO-Me elicited strong antiproliferative and proapoptopic responses in both cell lines in culture.	bardoxolone methyl	71-78	KRAS proto-oncogene, GTPase	Homo sapiens	40-45
26497549-6	2015	Treatment with CDDO-Me significantly inhibited the growth of BxPC-3 xenografts and reduced the levels of p-Akt and p-mTOR in tumor tissue.	bardoxolone methyl	15-22	mechanistic target of rapamycin kinase	Homo sapiens	117-121
26459563-8	2015	Similar to the activation of Nrf2 by either silencing of Keap1 expression or by the reactive compound 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid methyl ester (CDDO-Me), RA839 prevented the induction of both inducible nitric-oxide synthase expression and nitric oxide release in response to lipopolysaccharides in macrophages.	bardoxolone methyl	162-169	nuclear factor, erythroid derived 2, like 2	Mus musculus	29-33
26314956-1	2015	Mitochondrial Lon protease (Lon) regulates several mitochondrial functions, and is inhibited by the anticancer molecule triterpenoid 2-cyano-3, 12-dioxooleana-1,9(11)-dien-28-oic acid (CDDO), or by its C-28 methyl ester derivative (CDDO-Me).	bardoxolone methyl	232-239	lon peptidase 1, mitochondrial	Homo sapiens	14-17
26053096-0	2015	Ca2+ influx-mediated dilation of the endoplasmic reticulum and c-FLIPL downregulation trigger CDDO-Me-induced apoptosis in breast cancer cells.	bardoxolone methyl	94-101	CASP8 and FADD like apoptosis regulator	Homo sapiens	63-70
26053096-6	2015	In addition, CDDO-Me rapidly reduced the protein levels of c-FLIPL (cellular FLICE-inhibitory protein) and overexpression of c-FLIPL blocked CDDO-Me-induced cell death, but not vacuolation.	bardoxolone methyl	13-20	CASP8 and FADD like apoptosis regulator	Homo sapiens	59-66
26053096-6	2015	In addition, CDDO-Me rapidly reduced the protein levels of c-FLIPL (cellular FLICE-inhibitory protein) and overexpression of c-FLIPL blocked CDDO-Me-induced cell death, but not vacuolation.	bardoxolone methyl	141-148	CASP8 and FADD like apoptosis regulator	Homo sapiens	125-132
26053096-7	2015	These results suggest that c-FLIPL downregulation is a key contributor to CDDO-Me-induced apoptotic cell death, independent of ER-derived vacuolation.	bardoxolone methyl	74-81	CASP8 and FADD like apoptosis regulator	Homo sapiens	27-34
26053096-8	2015	Taken together, our results show that ER-derived vacuolation via Ca2+ influx and ROS generation as well as caspase activation via c-FLIPL downregulation are responsible for the potent anticancer effects of CDDO-Me on breast cancer cells.	bardoxolone methyl	206-213	CASP8 and FADD like apoptosis regulator	Homo sapiens	130-137
26008822-8	2015	We also found that CDDO-Me inhibited the increases in ROS levels in the A53T flies and improved the neurodegenerative changes by activating the Nrf2/antioxidant response element signaling pathway.	bardoxolone methyl	19-26	cap-n-collar	Drosophila melanogaster	144-148
25733817-7	2015	Furthermore, CDDO-Me induced autophagy in both Ec109 and KYSE70 cells via suppression of the phosphoinositide 3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/Akt/mTOR) signaling pathway.	bardoxolone methyl	13-20	mechanistic target of rapamycin kinase	Homo sapiens	136-165
25614226-6	2015	Pretreatment with CDDO-Me significantly ameliorated W/D ratio, lung MPO activity, inflammatory cell infiltration, and inflammatory cytokine production in BALF from the in vivo study.	bardoxolone methyl	18-25	myeloperoxidase	Mus musculus	68-71
26134508-0	2015	Hsp90 Is a Novel Target Molecule of CDDO-Me in Inhibiting Proliferation of Ovarian Cancer Cells.	bardoxolone methyl	36-43	heat shock protein 90 alpha family class A member 1	Homo sapiens	0-5
26134508-3	2015	Here, we demonstrate that CDDO-Me directly interacts with Hsp90 in cells by cellular thermal shift assay.	bardoxolone methyl	26-33	heat shock protein 90 alpha family class A member 1	Homo sapiens	58-63
26134508-4	2015	CDDO-Me treatment leads to upregulation of Hsp70 and degradation of Hsp90 clients (ErbB2 and Akt), indicating the inhibition of Hsp90 by CDDO-Me in cells.	bardoxolone methyl	0-7	heat shock protein family A (Hsp70) member 4	Homo sapiens	43-48
26134508-4	2015	CDDO-Me treatment leads to upregulation of Hsp70 and degradation of Hsp90 clients (ErbB2 and Akt), indicating the inhibition of Hsp90 by CDDO-Me in cells.	bardoxolone methyl	0-7	heat shock protein 90 alpha family class A member 1	Homo sapiens	68-73
26134508-4	2015	CDDO-Me treatment leads to upregulation of Hsp70 and degradation of Hsp90 clients (ErbB2 and Akt), indicating the inhibition of Hsp90 by CDDO-Me in cells.	bardoxolone methyl	0-7	erb-b2 receptor tyrosine kinase 2	Homo sapiens	83-88
26134508-4	2015	CDDO-Me treatment leads to upregulation of Hsp70 and degradation of Hsp90 clients (ErbB2 and Akt), indicating the inhibition of Hsp90 by CDDO-Me in cells.	bardoxolone methyl	0-7	AKT serine/threonine kinase 1	Homo sapiens	93-96
26134508-4	2015	CDDO-Me treatment leads to upregulation of Hsp70 and degradation of Hsp90 clients (ErbB2 and Akt), indicating the inhibition of Hsp90 by CDDO-Me in cells.	bardoxolone methyl	0-7	heat shock protein 90 alpha family class A member 1	Homo sapiens	128-133
26134508-4	2015	CDDO-Me treatment leads to upregulation of Hsp70 and degradation of Hsp90 clients (ErbB2 and Akt), indicating the inhibition of Hsp90 by CDDO-Me in cells.	bardoxolone methyl	137-144	heat shock protein 90 alpha family class A member 1	Homo sapiens	68-73
26134508-4	2015	CDDO-Me treatment leads to upregulation of Hsp70 and degradation of Hsp90 clients (ErbB2 and Akt), indicating the inhibition of Hsp90 by CDDO-Me in cells.	bardoxolone methyl	137-144	erb-b2 receptor tyrosine kinase 2	Homo sapiens	83-88
26134508-4	2015	CDDO-Me treatment leads to upregulation of Hsp70 and degradation of Hsp90 clients (ErbB2 and Akt), indicating the inhibition of Hsp90 by CDDO-Me in cells.	bardoxolone methyl	137-144	heat shock protein 90 alpha family class A member 1	Homo sapiens	128-133
26134508-5	2015	Knockdown of Hsp90 significantly inhibits cell proliferation and enhances the anti-proliferation effect of CDDO-Me in H08910 ovarian cancer cells.	bardoxolone methyl	107-114	heat shock protein 90 alpha family class A member 1	Homo sapiens	13-18
26134508-6	2015	Dithiothreitol inhibits the interaction of CDDO-Me with Hsp90 in cells and abrogates CDDO-Me induced upregulation of Hsp70, degradation of Akt and cell proliferation inhibition.	bardoxolone methyl	43-50	heat shock protein 90 alpha family class A member 1	Homo sapiens	56-61
26134508-6	2015	Dithiothreitol inhibits the interaction of CDDO-Me with Hsp90 in cells and abrogates CDDO-Me induced upregulation of Hsp70, degradation of Akt and cell proliferation inhibition.	bardoxolone methyl	85-92	heat shock protein family A (Hsp70) member 4	Homo sapiens	117-122
26134508-6	2015	Dithiothreitol inhibits the interaction of CDDO-Me with Hsp90 in cells and abrogates CDDO-Me induced upregulation of Hsp70, degradation of Akt and cell proliferation inhibition.	bardoxolone methyl	85-92	AKT serine/threonine kinase 1	Homo sapiens	139-142
26134508-7	2015	This suggests the anti-ovarian cancer effect of CDDO-Me is possibly mediated by the formation of Michael adducts between CDDO-Me and reactive nucleophiles on Hsp90.	bardoxolone methyl	48-55	heat shock protein 90 alpha family class A member 1	Homo sapiens	158-163
26134508-7	2015	This suggests the anti-ovarian cancer effect of CDDO-Me is possibly mediated by the formation of Michael adducts between CDDO-Me and reactive nucleophiles on Hsp90.	bardoxolone methyl	121-128	heat shock protein 90 alpha family class A member 1	Homo sapiens	158-163
26134508-8	2015	This study identifies Hsp90 as a novel target protein of CDDO-Me, and provides a novel insight into the mechanism of action of CDDO-Me in ovarian cancer cells.	bardoxolone methyl	57-64	heat shock protein 90 alpha family class A member 1	Homo sapiens	22-27
26134508-8	2015	This study identifies Hsp90 as a novel target protein of CDDO-Me, and provides a novel insight into the mechanism of action of CDDO-Me in ovarian cancer cells.	bardoxolone methyl	127-134	heat shock protein 90 alpha family class A member 1	Homo sapiens	22-27
25939751-0	2015	Dimethyl fumarate and the oleanane triterpenoids, CDDO-imidazolide and CDDO-methyl ester, both activate the Nrf2 pathway but have opposite effects in the A/J model of lung carcinogenesis.	bardoxolone methyl	71-88	nuclear factor, erythroid derived 2, like 2	Mus musculus	108-112
25939751-5	2015	Although the triterpenoids and DMF both activated the Nrf2 pathway, CDDO-Im and CDDO-Me were markedly more potent than DMF.	bardoxolone methyl	80-87	nuclear factor, erythroid derived 2, like 2	Mus musculus	54-58
25939751-17	2015	Collectively, these results suggest that although CDDO-Im, CDDO-Me and DMF all activate the Nrf2 pathway, they target distinct genes and signaling pathways, resulting in opposite effects for the prevention of experimental lung cancer.	bardoxolone methyl	59-66	nuclear factor, erythroid derived 2, like 2	Mus musculus	92-96
25733817-6	2015	CDDO-Me significantly decreased B-cell lymphoma-extra large (Bcl-xl), B-cell lymphoma 2 (Bcl-2), cleaved caspase-9, and cleaved poly ADP ribose polymerase (PARP) levels but increased the expression level of Bcl-2-associated X (Bax).	bardoxolone methyl	0-7	BCL2 like 1	Homo sapiens	61-67
25733817-6	2015	CDDO-Me significantly decreased B-cell lymphoma-extra large (Bcl-xl), B-cell lymphoma 2 (Bcl-2), cleaved caspase-9, and cleaved poly ADP ribose polymerase (PARP) levels but increased the expression level of Bcl-2-associated X (Bax).	bardoxolone methyl	0-7	BCL2 apoptosis regulator	Homo sapiens	70-87
25733817-6	2015	CDDO-Me significantly decreased B-cell lymphoma-extra large (Bcl-xl), B-cell lymphoma 2 (Bcl-2), cleaved caspase-9, and cleaved poly ADP ribose polymerase (PARP) levels but increased the expression level of Bcl-2-associated X (Bax).	bardoxolone methyl	0-7	BCL2 apoptosis regulator	Homo sapiens	89-94
25733817-6	2015	CDDO-Me significantly decreased B-cell lymphoma-extra large (Bcl-xl), B-cell lymphoma 2 (Bcl-2), cleaved caspase-9, and cleaved poly ADP ribose polymerase (PARP) levels but increased the expression level of Bcl-2-associated X (Bax).	bardoxolone methyl	0-7	caspase 9	Homo sapiens	105-114
25733817-6	2015	CDDO-Me significantly decreased B-cell lymphoma-extra large (Bcl-xl), B-cell lymphoma 2 (Bcl-2), cleaved caspase-9, and cleaved poly ADP ribose polymerase (PARP) levels but increased the expression level of Bcl-2-associated X (Bax).	bardoxolone methyl	0-7	poly(ADP-ribose) polymerase 1	Homo sapiens	128-154
25733817-6	2015	CDDO-Me significantly decreased B-cell lymphoma-extra large (Bcl-xl), B-cell lymphoma 2 (Bcl-2), cleaved caspase-9, and cleaved poly ADP ribose polymerase (PARP) levels but increased the expression level of Bcl-2-associated X (Bax).	bardoxolone methyl	0-7	poly(ADP-ribose) polymerase 1	Homo sapiens	156-160
25733817-7	2015	Furthermore, CDDO-Me induced autophagy in both Ec109 and KYSE70 cells via suppression of the phosphoinositide 3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/Akt/mTOR) signaling pathway.	bardoxolone methyl	13-20	AKT serine/threonine kinase 1	Homo sapiens	172-175
25733817-7	2015	Furthermore, CDDO-Me induced autophagy in both Ec109 and KYSE70 cells via suppression of the phosphoinositide 3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/Akt/mTOR) signaling pathway.	bardoxolone methyl	13-20	mechanistic target of rapamycin kinase	Homo sapiens	176-180
25733817-9	2015	CDDO-Me also scavenged reactive oxygen species through activation of the nuclear factor (erythroid-derived 2)-related factor 2 (Nrf2) pathway in Ec109 and KYSE70 cells.	bardoxolone methyl	0-7	NFE2 like bZIP transcription factor 2	Homo sapiens	128-132
25733817-11	2015	CDDO-Me significantly downregulated E-cadherin but upregulated Snail, Slug, and zinc finger E-box-binding homeobox 1 (TCF-8/ZEB1) in Ec109 and KYSE70 cells.	bardoxolone methyl	0-7	cadherin 1	Homo sapiens	36-46
25733817-6	2015	CDDO-Me significantly decreased B-cell lymphoma-extra large (Bcl-xl), B-cell lymphoma 2 (Bcl-2), cleaved caspase-9, and cleaved poly ADP ribose polymerase (PARP) levels but increased the expression level of Bcl-2-associated X (Bax).	bardoxolone methyl	0-7	BCL2 associated X, apoptosis regulator	Homo sapiens	207-225
25733817-6	2015	CDDO-Me significantly decreased B-cell lymphoma-extra large (Bcl-xl), B-cell lymphoma 2 (Bcl-2), cleaved caspase-9, and cleaved poly ADP ribose polymerase (PARP) levels but increased the expression level of Bcl-2-associated X (Bax).	bardoxolone methyl	0-7	BCL2 associated X, apoptosis regulator	Homo sapiens	227-230
25733817-11	2015	CDDO-Me significantly downregulated E-cadherin but upregulated Snail, Slug, and zinc finger E-box-binding homeobox 1 (TCF-8/ZEB1) in Ec109 and KYSE70 cells.	bardoxolone methyl	0-7	snail family transcriptional repressor 1	Homo sapiens	63-68
25733817-7	2015	Furthermore, CDDO-Me induced autophagy in both Ec109 and KYSE70 cells via suppression of the phosphoinositide 3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/Akt/mTOR) signaling pathway.	bardoxolone methyl	13-20	protein tyrosine kinase 2 beta	Homo sapiens	119-135
25733817-11	2015	CDDO-Me significantly downregulated E-cadherin but upregulated Snail, Slug, and zinc finger E-box-binding homeobox 1 (TCF-8/ZEB1) in Ec109 and KYSE70 cells.	bardoxolone methyl	0-7	snail family transcriptional repressor 2	Homo sapiens	70-74
25733817-11	2015	CDDO-Me significantly downregulated E-cadherin but upregulated Snail, Slug, and zinc finger E-box-binding homeobox 1 (TCF-8/ZEB1) in Ec109 and KYSE70 cells.	bardoxolone methyl	0-7	zinc finger E-box binding homeobox 1	Homo sapiens	80-116
25733817-11	2015	CDDO-Me significantly downregulated E-cadherin but upregulated Snail, Slug, and zinc finger E-box-binding homeobox 1 (TCF-8/ZEB1) in Ec109 and KYSE70 cells.	bardoxolone methyl	0-7	zinc finger E-box binding homeobox 1	Homo sapiens	118-123
25733817-11	2015	CDDO-Me significantly downregulated E-cadherin but upregulated Snail, Slug, and zinc finger E-box-binding homeobox 1 (TCF-8/ZEB1) in Ec109 and KYSE70 cells.	bardoxolone methyl	0-7	zinc finger E-box binding homeobox 1	Homo sapiens	124-128
25733817-12	2015	CDDO-Me significantly decreased the expression of octamer-4, sex determining region Y-box 2 (Sox-2), Nanog, and B lymphoma Mo-MLV insertion region 1 homolog (Bmi-1), all markers of cancer cell stemness, in Ec109 and KYSE70 cells.	bardoxolone methyl	0-7	SRY-box transcription factor 2	Homo sapiens	61-91
25733817-12	2015	CDDO-Me significantly decreased the expression of octamer-4, sex determining region Y-box 2 (Sox-2), Nanog, and B lymphoma Mo-MLV insertion region 1 homolog (Bmi-1), all markers of cancer cell stemness, in Ec109 and KYSE70 cells.	bardoxolone methyl	0-7	SRY-box transcription factor 2	Homo sapiens	93-98
25733817-12	2015	CDDO-Me significantly decreased the expression of octamer-4, sex determining region Y-box 2 (Sox-2), Nanog, and B lymphoma Mo-MLV insertion region 1 homolog (Bmi-1), all markers of cancer cell stemness, in Ec109 and KYSE70 cells.	bardoxolone methyl	0-7	Nanog homeobox	Homo sapiens	101-106
25733817-12	2015	CDDO-Me significantly decreased the expression of octamer-4, sex determining region Y-box 2 (Sox-2), Nanog, and B lymphoma Mo-MLV insertion region 1 homolog (Bmi-1), all markers of cancer cell stemness, in Ec109 and KYSE70 cells.	bardoxolone methyl	0-7	BMI1 proto-oncogene, polycomb ring finger	Homo sapiens	158-163
25536195-2	2014	Synthetic triterpenoids, including CDDO-Me, act as anti-inflammatory and antioxidant modulators primarily by inducing the transcription factor Nrf2 to activate downstream genes containing antioxidant response elements (AREs).	bardoxolone methyl	35-42	NFE2 like bZIP transcription factor 2	Homo sapiens	143-147
25926128-6	2015	In addition to a higher induction of the key cytoprotective gene heme oxygenase-1 (38.9-fold increase for CDDO-Im and 26.5-fold increase for CDDO-Me), CDDO-Im also induced greater expression of heat shock proteins (5.5-fold increase compared to 2.8-fold for CDDO-Me).	bardoxolone methyl	141-148	heme oxygenase 1	Homo sapiens	65-81
25536195-5	2014	CDDO-Me was an effective radioprotector when given ~18 hours before radiation in epithelial cells (average dose modifying factor (DMF) = 1.3), and Nrf2 function was necessary for CDDO-Me to exert these radioprotective effects.	bardoxolone methyl	179-186	NFE2 like bZIP transcription factor 2	Homo sapiens	147-151
25536195-8	2014	A therapeutic window exists in which CDDO-Me protects normal cells from radiation by activating the Nrf2 pathway, but does not protect experimentally transformed or cancer cell lines.	bardoxolone methyl	37-44	NFE2 like bZIP transcription factor 2	Homo sapiens	100-104
25047252-3	2014	Since the synthetic triterpenoid methyl-2-cyano-3,12-dioxooleana-1,9-dien-28-oate (CDDO-Me) has been shown to inhibit AKT, MEK-1/2, and NF-kappaB, and to induce caspase-mediated apoptosis, we tested the therapeutic potential of this agent in murine lupus nephritis.	bardoxolone methyl	83-90	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	136-145
25047252-3	2014	Since the synthetic triterpenoid methyl-2-cyano-3,12-dioxooleana-1,9-dien-28-oate (CDDO-Me) has been shown to inhibit AKT, MEK-1/2, and NF-kappaB, and to induce caspase-mediated apoptosis, we tested the therapeutic potential of this agent in murine lupus nephritis.	bardoxolone methyl	83-90	thymoma viral proto-oncogene 1	Mus musculus	118-121
25047252-4	2014	METHODS: The synthetic triterpenoid CDDO-Me or placebo was administered to 2-month-old B6.Sle1.Sle3 mice or MRL/lpr mice, which develop spontaneous lupus.	bardoxolone methyl	36-43	systemic lupus erythmatosus susceptibility 1	Mus musculus	90-94
25047252-4	2014	METHODS: The synthetic triterpenoid CDDO-Me or placebo was administered to 2-month-old B6.Sle1.Sle3 mice or MRL/lpr mice, which develop spontaneous lupus.	bardoxolone methyl	36-43	systemic lupus erythmatosus susceptibility 3	Mus musculus	95-99
25047252-3	2014	Since the synthetic triterpenoid methyl-2-cyano-3,12-dioxooleana-1,9-dien-28-oate (CDDO-Me) has been shown to inhibit AKT, MEK-1/2, and NF-kappaB, and to induce caspase-mediated apoptosis, we tested the therapeutic potential of this agent in murine lupus nephritis.	bardoxolone methyl	83-90	mitogen-activated protein kinase kinase 1	Mus musculus	123-130
25047252-9	2014	At the mechanistic level, CDDO-Me treatment dampened MEK-1/2, ERK, and STAT-3 signaling within lymphocytes and oxidative stress.	bardoxolone methyl	26-33	mitogen-activated protein kinase kinase 1	Mus musculus	53-60
25047252-9	2014	At the mechanistic level, CDDO-Me treatment dampened MEK-1/2, ERK, and STAT-3 signaling within lymphocytes and oxidative stress.	bardoxolone methyl	26-33	Eph receptor B2	Mus musculus	62-65
25047252-9	2014	At the mechanistic level, CDDO-Me treatment dampened MEK-1/2, ERK, and STAT-3 signaling within lymphocytes and oxidative stress.	bardoxolone methyl	26-33	signal transducer and activator of transcription 3	Mus musculus	71-77
25047252-10	2014	Importantly, the NF-E2-related factor 2 pathway was activated after CDDO-Me treatment, indicating that CDDO-Me may modulate renal damage in lupus via the inhibition of oxidative stress.	bardoxolone methyl	68-75	nuclear factor, erythroid derived 2, like 2	Mus musculus	17-39
25047252-10	2014	Importantly, the NF-E2-related factor 2 pathway was activated after CDDO-Me treatment, indicating that CDDO-Me may modulate renal damage in lupus via the inhibition of oxidative stress.	bardoxolone methyl	103-110	nuclear factor, erythroid derived 2, like 2	Mus musculus	17-39
25105464-0	2014	The effect of ex vivo CDDO-Me activation on nuclear factor erythroid 2-related factor 2 pathway in white blood cells from patients with septic shock.	bardoxolone methyl	22-29	nuclear factor, erythroid derived 2, like 2	Mus musculus	44-87
25105464-2	2014	The objective of this study was to test the hypothesis that ex vivo methyl 2-cyano-3,12-dioxoolean-1,9-dien-28-oate (CDDO-Me) activates NRF2-regulated antioxidant genes in white blood cells from patients with septic shock and protects against LPS-induced inflammation and reactive oxidative species production.	bardoxolone methyl	117-124	NFE2 like bZIP transcription factor 2	Homo sapiens	136-140
25105464-4	2014	Real-time polymerase chain reaction was used to quantify the expression of NRF2 target genes (NQO1, HO-1, GCLM, and FTL) and IL-6 in peripheral blood mononuclear cells (PBMCs), monocytes, and neutrophils after CDDO-Me treatment alone or after subsequent LPS exposure.	bardoxolone methyl	210-217	NFE2 like bZIP transcription factor 2	Homo sapiens	75-79
25105464-6	2014	Treatment with CDDO-Me increased the gene expression of NQO1 (P = 0.04) and decreased the expression of HO-1 (P = 0.03) in PBMCs from patients with septic shock.	bardoxolone methyl	15-22	NAD(P)H quinone dehydrogenase 1	Homo sapiens	56-60
25105464-6	2014	Treatment with CDDO-Me increased the gene expression of NQO1 (P = 0.04) and decreased the expression of HO-1 (P = 0.03) in PBMCs from patients with septic shock.	bardoxolone methyl	15-22	heme oxygenase 1	Homo sapiens	104-108
25105464-7	2014	Purified monocytes exhibited significant increases in the expression of NQO1 (P = 0.01) and GCLM (P = 0.003) after CDDO-Me treatment.	bardoxolone methyl	115-122	NAD(P)H quinone dehydrogenase 1	Homo sapiens	72-76
25105464-7	2014	Purified monocytes exhibited significant increases in the expression of NQO1 (P = 0.01) and GCLM (P = 0.003) after CDDO-Me treatment.	bardoxolone methyl	115-122	glutamate-cysteine ligase modifier subunit	Homo sapiens	92-96
25105464-9	2014	Peripheral blood mononuclear cells showed a trend toward increased IL-6 gene expression after CDDO-Me treatment, whereas purified monocytes showed a trend toward decreased IL-6.	bardoxolone methyl	94-101	interleukin 6	Homo sapiens	67-71
25105464-14	2014	These data suggest that the NRF2 pathway is differentially responsive to CDDO-Me activation in peripheral blood cells from patients with septic shock and results in increased O2 production.	bardoxolone methyl	73-80	NFE2 like bZIP transcription factor 2	Homo sapiens	28-32
24859727-15	2014	At a dose shown to evoke maximal Nrf2 induction in the liver, CDDO-me appeared highly selective for known Nrf2-regulated proteins.	bardoxolone methyl	62-69	nuclear factor, erythroid derived 2, like 2	Mus musculus	106-110
25364233-5	2014	The role of the Kelch-like erythroid cell-derived protein with CNC homology-associated protein 1 (Keap1)/the nuclear factor erythroid 2-related factor 2 (Nrf2) pathway in the therapeutic activities of CDDO-Me will be discussed.	bardoxolone methyl	201-208	kelch like ECH associated protein 1	Homo sapiens	98-103
25364233-5	2014	The role of the Kelch-like erythroid cell-derived protein with CNC homology-associated protein 1 (Keap1)/the nuclear factor erythroid 2-related factor 2 (Nrf2) pathway in the therapeutic activities of CDDO-Me will be discussed.	bardoxolone methyl	201-208	NFE2 like bZIP transcription factor 2	Homo sapiens	109-152
25364233-5	2014	The role of the Kelch-like erythroid cell-derived protein with CNC homology-associated protein 1 (Keap1)/the nuclear factor erythroid 2-related factor 2 (Nrf2) pathway in the therapeutic activities of CDDO-Me will be discussed.	bardoxolone methyl	201-208	NFE2 like bZIP transcription factor 2	Homo sapiens	154-158
25364233-6	2014	CDDO-Me contains alpha,beta-unsaturated carbonyl groups on rings A and C that can generate reversible adducts with the thiol groups of Cys residues in target proteins such as Keap1 and IkappaB kinase.	bardoxolone methyl	0-7	kelch like ECH associated protein 1	Homo sapiens	175-180
24859727-10	2014	Only two proteins altered by CDDO-me in WT animals were similarly affected in Nrf2((-/-)) mice, demonstrating the high degree of selectivity of CDDO-me for the Nrf2:Keap1 signalling pathway.	bardoxolone methyl	144-151	nuclear factor, erythroid derived 2, like 2	Mus musculus	160-164
24859727-10	2014	Only two proteins altered by CDDO-me in WT animals were similarly affected in Nrf2((-/-)) mice, demonstrating the high degree of selectivity of CDDO-me for the Nrf2:Keap1 signalling pathway.	bardoxolone methyl	144-151	kelch-like ECH-associated protein 1	Mus musculus	165-170
24859727-12	2014	For example, CDDO-me (bardoxolone methyl) was investigated in clinical trials for the treatment of acute kidney disease, and dimethyl fumarate, recently approved for reducing relapse rate in multiple sclerosis, is a potent Nrf2 inducer.	bardoxolone methyl	13-20	nuclear factor, erythroid derived 2, like 2	Mus musculus	223-227
24859727-15	2014	At a dose shown to evoke maximal Nrf2 induction in the liver, CDDO-me appeared highly selective for known Nrf2-regulated proteins.	bardoxolone methyl	62-69	nuclear factor, erythroid derived 2, like 2	Mus musculus	33-37
25112275-1	2014	Here we report that leukemia cell lines and primary CD34+ leukemic blasts exposed to platelet rich plasma (PRP) or platelet lysates (PL) display increased resistance to apoptosis induced by mitochondria-targeted agents ABT-737 and CDDO-Me.	bardoxolone methyl	231-238	CD34 molecule	Homo sapiens	52-56
24837432-6	2014	Oral administration of CDDO-Me to mice with SMAD4-deficient T cells increased survival and suppressed intestinal epithelial neoplasia by decreasing production of inflammatory mediators and increasing expression of 15-PGDH.	bardoxolone methyl	23-30	hydroxyprostaglandin dehydrogenase 15 (NAD)	Mus musculus	214-221
25056779-5	2014	In the modified LLNA, CDDO-Me showed a significant decrease in lymph node weight and changes in expressions of the immunosuppression-related genes, Zfp459 and Fmo2.	bardoxolone methyl	22-29	zinc finger protein 459	Mus musculus	148-154
25056779-5	2014	In the modified LLNA, CDDO-Me showed a significant decrease in lymph node weight and changes in expressions of the immunosuppression-related genes, Zfp459 and Fmo2.	bardoxolone methyl	22-29	flavin containing monooxygenase 2	Mus musculus	159-163
24837432-7	2014	Induction of 15-PGDH by CDDO-Me was dose dependent in epithelial cells and was abrogated following treatment with TGF-beta signaling inhibitors in vitro.	bardoxolone methyl	24-31	hydroxyprostaglandin dehydrogenase 15 (NAD)	Mus musculus	13-20
24837432-8	2014	Furthermore, CDDO-Me-dependent 15-PGDH induction was not observed in Smad3-/- mice.	bardoxolone methyl	13-20	hydroxyprostaglandin dehydrogenase 15 (NAD)	Mus musculus	31-38
24903467-1	2014	BACKGROUND: Bardoxolone methyl, an Nrf2-activating and nuclear factor-kappaB-inhibiting semisynthetic oleanane triterpenoid compound, was evaluated in a phase 3 trial (BEACON) in patients with type 2 diabetes mellitus (T2DM) and stage 4 chronic kidney disease (CKD).	bardoxolone methyl	12-30	NFE2 like bZIP transcription factor 2	Homo sapiens	35-39
25152840-3	2014	The antiproliferative and apoptosis-inducing effects of CDDO-Me were associated with the inhibition of human telomerase reverse transcriptase (hTERT) mRNA, hTERT protein and reduction in hTERT telomerase activity.	bardoxolone methyl	56-63	telomerase reverse transcriptase	Homo sapiens	143-148
25152840-3	2014	The antiproliferative and apoptosis-inducing effects of CDDO-Me were associated with the inhibition of human telomerase reverse transcriptase (hTERT) mRNA, hTERT protein and reduction in hTERT telomerase activity.	bardoxolone methyl	56-63	telomerase reverse transcriptase	Homo sapiens	156-161
25152840-3	2014	The antiproliferative and apoptosis-inducing effects of CDDO-Me were associated with the inhibition of human telomerase reverse transcriptase (hTERT) mRNA, hTERT protein and reduction in hTERT telomerase activity.	bardoxolone methyl	56-63	telomerase reverse transcriptase	Homo sapiens	156-161
25152840-4	2014	CDDO-Me inhibited multiple transcription factors that regulate hTERT expression positively (Sp1, c-Myc and NF-kappaB) and negatively (CTCF, E2F-1 and MAD1).	bardoxolone methyl	0-7	telomerase reverse transcriptase	Homo sapiens	63-68
25152840-4	2014	CDDO-Me inhibited multiple transcription factors that regulate hTERT expression positively (Sp1, c-Myc and NF-kappaB) and negatively (CTCF, E2F-1 and MAD1).	bardoxolone methyl	0-7	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	97-102
25152840-4	2014	CDDO-Me inhibited multiple transcription factors that regulate hTERT expression positively (Sp1, c-Myc and NF-kappaB) and negatively (CTCF, E2F-1 and MAD1).	bardoxolone methyl	0-7	CCCTC-binding factor	Homo sapiens	134-138
25152840-4	2014	CDDO-Me inhibited multiple transcription factors that regulate hTERT expression positively (Sp1, c-Myc and NF-kappaB) and negatively (CTCF, E2F-1 and MAD1).	bardoxolone methyl	0-7	E2F transcription factor 1	Homo sapiens	140-145
25152840-4	2014	CDDO-Me inhibited multiple transcription factors that regulate hTERT expression positively (Sp1, c-Myc and NF-kappaB) and negatively (CTCF, E2F-1 and MAD1).	bardoxolone methyl	0-7	MAX dimerization protein 1	Homo sapiens	150-154
25152840-5	2014	CDDO-Me inhibited protein levels of DNA methyl transferases DNMT1 and DNMT3a, which also resulted in hypomethylation of hTERT promoter.	bardoxolone methyl	0-7	DNA methyltransferase 1	Homo sapiens	60-65
25152840-5	2014	CDDO-Me inhibited protein levels of DNA methyl transferases DNMT1 and DNMT3a, which also resulted in hypomethylation of hTERT promoter.	bardoxolone methyl	0-7	DNA methyltransferase 3 alpha	Homo sapiens	70-76
25152840-5	2014	CDDO-Me inhibited protein levels of DNA methyl transferases DNMT1 and DNMT3a, which also resulted in hypomethylation of hTERT promoter.	bardoxolone methyl	0-7	telomerase reverse transcriptase	Homo sapiens	120-125
24903467-1	2014	BACKGROUND: Bardoxolone methyl, an Nrf2-activating and nuclear factor-kappaB-inhibiting semisynthetic oleanane triterpenoid compound, was evaluated in a phase 3 trial (BEACON) in patients with type 2 diabetes mellitus (T2DM) and stage 4 chronic kidney disease (CKD).	bardoxolone methyl	12-30	ubiquitin like 5	Homo sapiens	168-174
23020131-3	2013	Based on screening results, five unique genes (GNPAT, SUMO1, SPINT2, FLI1, and SSX1) significantly potentiated the growth inhibitory effects of CDDO-Me and induced apoptosis in A375, a BRAF mutated melanoma line (P < 0.001).	bardoxolone methyl	144-151	glyceronephosphate O-acyltransferase	Homo sapiens	47-52
23919312-1	2013	Methyl-2-cyano-3,12 dioxoolean-1,9 diene-28-oate (CDDO-Me) is an antioxidative, anti-inflammatory modulator, which activates the nuclear factor-erythroid 2-related factor 2 (Nrf2)/antioxidant response element (ARE) pathway.	bardoxolone methyl	50-57	NFE2 like bZIP transcription factor 2	Homo sapiens	129-172
23919312-1	2013	Methyl-2-cyano-3,12 dioxoolean-1,9 diene-28-oate (CDDO-Me) is an antioxidative, anti-inflammatory modulator, which activates the nuclear factor-erythroid 2-related factor 2 (Nrf2)/antioxidant response element (ARE) pathway.	bardoxolone methyl	50-57	NFE2 like bZIP transcription factor 2	Homo sapiens	174-178
23919312-2	2013	While CDDO-Me has radioprotective activity through Nrf2 activation in vitro and in vivo, its ability to mitigate radiation-induced damage when provided after irradiation has not been studied.	bardoxolone methyl	6-13	NFE2 like bZIP transcription factor 2	Homo sapiens	51-55
23919312-5	2013	We observed that treatment with CDDO-Me within 30 min after irradiation improved both DNA damage repair and clonogenic survival independently of Nrf2.	bardoxolone methyl	32-39	NFE2 like bZIP transcription factor 2	Homo sapiens	145-149
23919312-6	2013	CDDO-Me activates the epidermal growth factor receptor (EGFR) related DNA repair responses.	bardoxolone methyl	0-7	epidermal growth factor receptor	Homo sapiens	22-54
23919312-6	2013	CDDO-Me activates the epidermal growth factor receptor (EGFR) related DNA repair responses.	bardoxolone methyl	0-7	epidermal growth factor receptor	Homo sapiens	56-60
23919312-7	2013	In the presence of CDDO-Me, EGFR is phosphorylated and translocates into the nucleus where it interacts with DNA-PKcs.	bardoxolone methyl	19-26	epidermal growth factor receptor	Homo sapiens	28-32
23919312-7	2013	In the presence of CDDO-Me, EGFR is phosphorylated and translocates into the nucleus where it interacts with DNA-PKcs.	bardoxolone methyl	19-26	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	109-117
23919312-8	2013	CDDO-Me-mediated mitigation activity can be abrogated through depletion of EGFR, ectopic overexpression of mutant EGFR or inhibition of DNA-PKcs.	bardoxolone methyl	0-7	epidermal growth factor receptor	Homo sapiens	75-79
23919312-8	2013	CDDO-Me-mediated mitigation activity can be abrogated through depletion of EGFR, ectopic overexpression of mutant EGFR or inhibition of DNA-PKcs.	bardoxolone methyl	0-7	epidermal growth factor receptor	Homo sapiens	114-118
23919312-8	2013	CDDO-Me-mediated mitigation activity can be abrogated through depletion of EGFR, ectopic overexpression of mutant EGFR or inhibition of DNA-PKcs.	bardoxolone methyl	0-7	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	136-144
23919312-10	2013	These results suggest that targeting EGFR using CDDO-Me is a promising radiation mitigator with potential utility for first responders to nuclear accidents.	bardoxolone methyl	48-55	epidermal growth factor receptor	Homo sapiens	37-41
23741300-7	2013	On day 7, CDDO-Me reduced total BALF protein by 50%, alveolar macrophage infiltration by 40%, neutrophil infiltration by 90% (p<=0.01), inhibited production of the inflammatory cytokines KC and IL-6 by over 90% (p<=0.001), and excess production of the pro-fibrotic cytokine TGFbeta by 50%.	bardoxolone methyl	10-17	interleukin 6	Homo sapiens	197-201
23741300-7	2013	On day 7, CDDO-Me reduced total BALF protein by 50%, alveolar macrophage infiltration by 40%, neutrophil infiltration by 90% (p<=0.01), inhibited production of the inflammatory cytokines KC and IL-6 by over 90% (p<=0.001), and excess production of the pro-fibrotic cytokine TGFbeta by 50%.	bardoxolone methyl	10-17	transforming growth factor beta 1	Homo sapiens	280-287
23741300-8	2013	CDDO-Me also inhibited alpha-smooth muscle actin and fibronectin mRNA by 50% (p<=0.05).	bardoxolone methyl	0-7	fibronectin 1	Homo sapiens	53-64
23486104-5	2013	Pretreatment of cells with N-acetylcycsteine, a general purpose antioxidant or overexpression of glutathione peroxidase (GPx) or superoxide dismutase-1 (SOD-1) blocked the telomerase inhibitory activity of CDDO-Me.	bardoxolone methyl	206-213	superoxide dismutase 1	Homo sapiens	129-151
23486104-5	2013	Pretreatment of cells with N-acetylcycsteine, a general purpose antioxidant or overexpression of glutathione peroxidase (GPx) or superoxide dismutase-1 (SOD-1) blocked the telomerase inhibitory activity of CDDO-Me.	bardoxolone methyl	206-213	superoxide dismutase 1	Homo sapiens	153-158
23486104-6	2013	Furthermore, blocking ROS generation also prevented the inhibition of hTERT gene expression, hTERT protein production and expression of a number of hTERT-regulatory proteins by CDDO-Me (e.g., c-Myc, Sp1, NF-kappaB and p-Akt).	bardoxolone methyl	177-184	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	192-197
23486104-8	2013	Together, these data suggest that inhibition of telomerase activity by CDDO-Me is mediated through a ROS-dependent mechanism; however, more work is needed to fully understand the role of ROS in down-regulation of hTERT gene and hTERT-regulatory proteins by CDDO-Me.	bardoxolone methyl	71-78	telomerase reverse transcriptase	Homo sapiens	213-218
23267148-5	2013	Likewise, NAC prevented the CDDO-Me-caused binding of fluorescein isothiocyanate (FITC)-tagged annexin V, cleavage of poly ADP-ribose polymerase-1 (PARP-1), procaspases-3, -8 and -9 and loss of mitochondrial membrane potential.	bardoxolone methyl	28-35	annexin A5	Homo sapiens	95-104
23267148-5	2013	Likewise, NAC prevented the CDDO-Me-caused binding of fluorescein isothiocyanate (FITC)-tagged annexin V, cleavage of poly ADP-ribose polymerase-1 (PARP-1), procaspases-3, -8 and -9 and loss of mitochondrial membrane potential.	bardoxolone methyl	28-35	poly(ADP-ribose) polymerase 1	Homo sapiens	118-146
23267148-5	2013	Likewise, NAC prevented the CDDO-Me-caused binding of fluorescein isothiocyanate (FITC)-tagged annexin V, cleavage of poly ADP-ribose polymerase-1 (PARP-1), procaspases-3, -8 and -9 and loss of mitochondrial membrane potential.	bardoxolone methyl	28-35	poly(ADP-ribose) polymerase 1	Homo sapiens	148-154
23267148-5	2013	Likewise, NAC prevented the CDDO-Me-caused binding of fluorescein isothiocyanate (FITC)-tagged annexin V, cleavage of poly ADP-ribose polymerase-1 (PARP-1), procaspases-3, -8 and -9 and loss of mitochondrial membrane potential.	bardoxolone methyl	28-35	caspase 3	Homo sapiens	157-181
23267148-7	2013	Together, these results indicate the pivotal role ROS play in the antiproliferative- and apoptosis-inducing activity of CDDO-Me in ovarian cancer cells; however, the role of ROS in the down-regulation of prosurvival AKT, mTOR, NF-kappaB and antiapoptotic BCL-2, BCL-xL, c-IAP1 and survivin warrants further investigation.	bardoxolone methyl	120-127	AKT serine/threonine kinase 1	Homo sapiens	216-219
23267148-7	2013	Together, these results indicate the pivotal role ROS play in the antiproliferative- and apoptosis-inducing activity of CDDO-Me in ovarian cancer cells; however, the role of ROS in the down-regulation of prosurvival AKT, mTOR, NF-kappaB and antiapoptotic BCL-2, BCL-xL, c-IAP1 and survivin warrants further investigation.	bardoxolone methyl	120-127	mechanistic target of rapamycin kinase	Homo sapiens	221-225
23267148-7	2013	Together, these results indicate the pivotal role ROS play in the antiproliferative- and apoptosis-inducing activity of CDDO-Me in ovarian cancer cells; however, the role of ROS in the down-regulation of prosurvival AKT, mTOR, NF-kappaB and antiapoptotic BCL-2, BCL-xL, c-IAP1 and survivin warrants further investigation.	bardoxolone methyl	120-127	nuclear factor kappa B subunit 1	Homo sapiens	227-236
23267148-7	2013	Together, these results indicate the pivotal role ROS play in the antiproliferative- and apoptosis-inducing activity of CDDO-Me in ovarian cancer cells; however, the role of ROS in the down-regulation of prosurvival AKT, mTOR, NF-kappaB and antiapoptotic BCL-2, BCL-xL, c-IAP1 and survivin warrants further investigation.	bardoxolone methyl	120-127	BCL2 apoptosis regulator	Homo sapiens	255-260
23267148-7	2013	Together, these results indicate the pivotal role ROS play in the antiproliferative- and apoptosis-inducing activity of CDDO-Me in ovarian cancer cells; however, the role of ROS in the down-regulation of prosurvival AKT, mTOR, NF-kappaB and antiapoptotic BCL-2, BCL-xL, c-IAP1 and survivin warrants further investigation.	bardoxolone methyl	120-127	BCL2 like 1	Homo sapiens	262-268
23267148-7	2013	Together, these results indicate the pivotal role ROS play in the antiproliferative- and apoptosis-inducing activity of CDDO-Me in ovarian cancer cells; however, the role of ROS in the down-regulation of prosurvival AKT, mTOR, NF-kappaB and antiapoptotic BCL-2, BCL-xL, c-IAP1 and survivin warrants further investigation.	bardoxolone methyl	120-127	baculoviral IAP repeat containing 2	Homo sapiens	270-276
23783243-3	2013	An increasing body of evidence supports a vital physiological role for Nrf2 in protection of the kidney against a number of diseases, and the pharmacological induction of Nrf2 by bardoxolone methyl (methyl-2-cyano 3,12-dioxooleano-1,9-dien-28-oate, CDDO-Me) has shown promise for the management of such pathologies.	bardoxolone methyl	249-256	NFE2 like bZIP transcription factor 2	Homo sapiens	171-175
23020131-3	2013	Based on screening results, five unique genes (GNPAT, SUMO1, SPINT2, FLI1, and SSX1) significantly potentiated the growth inhibitory effects of CDDO-Me and induced apoptosis in A375, a BRAF mutated melanoma line (P < 0.001).	bardoxolone methyl	144-151	small ubiquitin like modifier 1	Homo sapiens	54-59
23020131-3	2013	Based on screening results, five unique genes (GNPAT, SUMO1, SPINT2, FLI1, and SSX1) significantly potentiated the growth inhibitory effects of CDDO-Me and induced apoptosis in A375, a BRAF mutated melanoma line (P < 0.001).	bardoxolone methyl	144-151	serine peptidase inhibitor, Kunitz type 2	Homo sapiens	61-67
23020131-3	2013	Based on screening results, five unique genes (GNPAT, SUMO1, SPINT2, FLI1, and SSX1) significantly potentiated the growth inhibitory effects of CDDO-Me and induced apoptosis in A375, a BRAF mutated melanoma line (P < 0.001).	bardoxolone methyl	144-151	Fli-1 proto-oncogene, ETS transcription factor	Homo sapiens	69-73
23020131-3	2013	Based on screening results, five unique genes (GNPAT, SUMO1, SPINT2, FLI1, and SSX1) significantly potentiated the growth inhibitory effects of CDDO-Me and induced apoptosis in A375, a BRAF mutated melanoma line (P < 0.001).	bardoxolone methyl	144-151	SSX family member 1	Homo sapiens	79-83
23020131-3	2013	Based on screening results, five unique genes (GNPAT, SUMO1, SPINT2, FLI1, and SSX1) significantly potentiated the growth inhibitory effects of CDDO-Me and induced apoptosis in A375, a BRAF mutated melanoma line (P < 0.001).	bardoxolone methyl	144-151	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	185-189
23020131-6	2013	Our findings indicate that GNPAT, SUMO1, SPINT2, FLI1, and SSX1 play critical roles in synergy with inflammation pathways in modulating melanoma cell survival and could serve as sensitizing targets to enhance CDDO-Me efficacy in melanoma growth control.	bardoxolone methyl	209-216	glyceronephosphate O-acyltransferase	Homo sapiens	27-32
22177954-1	2012	Our previous studies have shown that methyl-2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oate (CDDO-Me), a oleanane synthetic triterpenoid induces apoptosis in prostate cancer cells by inhibiting the Akt/NF-kappaB/mTOR signaling cascade; however, the mechanism by which CDDO-Me inhibits Akt/NF-kappaB/mTOR signaling has remained undetermined.	bardoxolone methyl	91-98	nuclear factor kappa B subunit 1	Homo sapiens	287-296
23519253-0	2012	Telomerase reverse transcriptase (TERT) is a therapeutic target of oleanane triterpenoid CDDO-Me in prostate cancer.	bardoxolone methyl	89-96	telomerase reverse transcriptase	Homo sapiens	34-38
23519253-2	2012	However, the effect of CDDO-Me on human telomerase reverse transcriptase (hTERT) and its telomerase activity in prostate cancer cells has not been studied.	bardoxolone methyl	23-30	telomerase reverse transcriptase	Homo sapiens	74-79
23519253-3	2012	We investigated the role of hTERT in mediating the anticancer activity of CDDO-Me in prostate cancer cells in vitro and in vivo.	bardoxolone methyl	74-81	telomerase reverse transcriptase	Homo sapiens	28-33
23519253-4	2012	The inhibition of cell proliferation and induction of apoptosis by CDDO-Me in LNCaP and PC-3 prostate cancer cell lines was associated with the inhibition of hTERT gene expression, hTERT telomerase activity and a number of proteins that regulate hTERT transcriptionally and post-translationally.	bardoxolone methyl	67-74	telomerase reverse transcriptase	Homo sapiens	158-163
23519253-4	2012	The inhibition of cell proliferation and induction of apoptosis by CDDO-Me in LNCaP and PC-3 prostate cancer cell lines was associated with the inhibition of hTERT gene expression, hTERT telomerase activity and a number of proteins that regulate hTERT transcriptionally and post-translationally.	bardoxolone methyl	67-74	telomerase reverse transcriptase	Homo sapiens	181-186
23519253-4	2012	The inhibition of cell proliferation and induction of apoptosis by CDDO-Me in LNCaP and PC-3 prostate cancer cell lines was associated with the inhibition of hTERT gene expression, hTERT telomerase activity and a number of proteins that regulate hTERT transcriptionally and post-translationally.	bardoxolone methyl	67-74	telomerase reverse transcriptase	Homo sapiens	181-186
23519253-5	2012	Furthermore, ablation of hTERT protein increased the sensitivity of cancer cells to CDDO-Me, whereas its overexpression rendered them resistant to CDDO-Me.	bardoxolone methyl	84-91	telomerase reverse transcriptase	Homo sapiens	25-30
23519253-5	2012	Furthermore, ablation of hTERT protein increased the sensitivity of cancer cells to CDDO-Me, whereas its overexpression rendered them resistant to CDDO-Me.	bardoxolone methyl	147-154	telomerase reverse transcriptase	Homo sapiens	25-30
23519253-6	2012	In addition, inhibition of progression of preneoplastic lesions (i.e., low and high-grade prostate intraepithelial neoplasms, PINs) to adenocarcinoma of the prostate by CDDO-Me in TRAMP mice was associated with significant decrease in TERT and its regulatory proteins in the prostate gland.	bardoxolone methyl	169-176	tumor necrosis factor receptor superfamily, member 25	Mus musculus	180-185
23519253-6	2012	In addition, inhibition of progression of preneoplastic lesions (i.e., low and high-grade prostate intraepithelial neoplasms, PINs) to adenocarcinoma of the prostate by CDDO-Me in TRAMP mice was associated with significant decrease in TERT and its regulatory proteins in the prostate gland.	bardoxolone methyl	169-176	telomerase reverse transcriptase	Mus musculus	235-239
22747345-2	2012	Bardoxolone methyl is a potent, orally bioavailable Nrf-2 agonist.	bardoxolone methyl	0-18	NFE2 like bZIP transcription factor 2	Homo sapiens	52-57
22634319-1	2012	PURPOSE: Bardoxolone methyl, a novel synthetic triterpenoid and antioxidant inflammation modulator, potently induces Nrf2 and inhibits NF-kappaB and Janus-activated kinase/STAT signaling.	bardoxolone methyl	9-27	NFE2 like bZIP transcription factor 2	Homo sapiens	117-121
23045680-5	2012	Here, we report that Nrf2 activation by the synthetic triterpenoids, bardoxolone methyl (BARD) and 2-cyano-3,12-dioxooleana-1,9 (11)-dien-28-oic acid-ethyl amide, protects colonic epithelial cells against IR-induced damage, in part, by enhancing signaling of the DNA damage response.	bardoxolone methyl	69-87	nuclear factor, erythroid derived 2, like 2	Mus musculus	21-25
22609405-0	2012	Inhibition of cell proliferation and induction of apoptosis by oleanane triterpenoid (CDDO-Me) in pancreatic cancer cells is associated with the suppression of hTERT gene expression and its telomerase activity.	bardoxolone methyl	86-93	telomerase reverse transcriptase	Homo sapiens	160-165
22609405-3	2012	Here we report for the first time that inhibition of cell proliferation and induction of apoptosis by CDDO-Me in pancreatic cancer cell lines is associated with the inhibition of hTERT gene expression, hTERT telomerase activity and a number of proteins that regulate hTERT expression and activity.	bardoxolone methyl	102-109	telomerase reverse transcriptase	Homo sapiens	179-184
22609405-3	2012	Here we report for the first time that inhibition of cell proliferation and induction of apoptosis by CDDO-Me in pancreatic cancer cell lines is associated with the inhibition of hTERT gene expression, hTERT telomerase activity and a number of proteins that regulate hTERT expression and activity.	bardoxolone methyl	102-109	telomerase reverse transcriptase	Homo sapiens	202-207
22609405-3	2012	Here we report for the first time that inhibition of cell proliferation and induction of apoptosis by CDDO-Me in pancreatic cancer cell lines is associated with the inhibition of hTERT gene expression, hTERT telomerase activity and a number of proteins that regulate hTERT expression and activity.	bardoxolone methyl	102-109	telomerase reverse transcriptase	Homo sapiens	202-207
22609405-4	2012	Furthermore, abrogation or overexpression of hTERT protein altered the susceptibility of tumor cells to CDDO-Me.	bardoxolone methyl	104-111	telomerase reverse transcriptase	Homo sapiens	45-50
22609405-5	2012	These findings suggest that telomerase (hTERT) is a relevant target of CDDO-Me in pancreatic cancer cells.	bardoxolone methyl	71-78	telomerase reverse transcriptase	Homo sapiens	40-45
22177954-0	2012	Oleanane triterpenoid CDDO-Me inhibits Akt activity without affecting PDK1 kinase or PP2A phosphatase activity in cancer cells.	bardoxolone methyl	22-29	AKT serine/threonine kinase 1	Homo sapiens	39-42
22177954-1	2012	Our previous studies have shown that methyl-2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oate (CDDO-Me), a oleanane synthetic triterpenoid induces apoptosis in prostate cancer cells by inhibiting the Akt/NF-kappaB/mTOR signaling cascade; however, the mechanism by which CDDO-Me inhibits Akt/NF-kappaB/mTOR signaling has remained undetermined.	bardoxolone methyl	91-98	AKT serine/threonine kinase 1	Homo sapiens	196-199
22177954-1	2012	Our previous studies have shown that methyl-2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oate (CDDO-Me), a oleanane synthetic triterpenoid induces apoptosis in prostate cancer cells by inhibiting the Akt/NF-kappaB/mTOR signaling cascade; however, the mechanism by which CDDO-Me inhibits Akt/NF-kappaB/mTOR signaling has remained undetermined.	bardoxolone methyl	91-98	nuclear factor kappa B subunit 1	Homo sapiens	200-209
22177954-1	2012	Our previous studies have shown that methyl-2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oate (CDDO-Me), a oleanane synthetic triterpenoid induces apoptosis in prostate cancer cells by inhibiting the Akt/NF-kappaB/mTOR signaling cascade; however, the mechanism by which CDDO-Me inhibits Akt/NF-kappaB/mTOR signaling has remained undetermined.	bardoxolone methyl	91-98	mechanistic target of rapamycin kinase	Homo sapiens	210-214
22177954-1	2012	Our previous studies have shown that methyl-2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oate (CDDO-Me), a oleanane synthetic triterpenoid induces apoptosis in prostate cancer cells by inhibiting the Akt/NF-kappaB/mTOR signaling cascade; however, the mechanism by which CDDO-Me inhibits Akt/NF-kappaB/mTOR signaling has remained undetermined.	bardoxolone methyl	91-98	AKT serine/threonine kinase 1	Homo sapiens	283-286
22177954-1	2012	Our previous studies have shown that methyl-2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oate (CDDO-Me), a oleanane synthetic triterpenoid induces apoptosis in prostate cancer cells by inhibiting the Akt/NF-kappaB/mTOR signaling cascade; however, the mechanism by which CDDO-Me inhibits Akt/NF-kappaB/mTOR signaling has remained undetermined.	bardoxolone methyl	91-98	mechanistic target of rapamycin kinase	Homo sapiens	297-301
22177954-2	2012	Present studies show that Akt plays a critical role in the response of prostate cancer cells to CDDO-Me.	bardoxolone methyl	96-103	AKT serine/threonine kinase 1	Homo sapiens	26-29
22177954-3	2012	Silencing of Akt sensitized PC-3 cells to CDDO-Me, whereas its overexpression rendered them resistant to CDDO-Me.	bardoxolone methyl	42-49	AKT serine/threonine kinase 1	Homo sapiens	13-16
22177954-4	2012	Evaluation of the effect of CDDO-Me on Akt which lies upstream of NF-kappaB and mTOR showed that CDDO-Me directly inhibits the Akt kinase activity in cell-free kinase activity assay and in vivo without modulating the activity of PDK1, the upstream kinase that phosphorylates and activates Akt.	bardoxolone methyl	28-35	AKT serine/threonine kinase 1	Homo sapiens	39-42
22177954-4	2012	Evaluation of the effect of CDDO-Me on Akt which lies upstream of NF-kappaB and mTOR showed that CDDO-Me directly inhibits the Akt kinase activity in cell-free kinase activity assay and in vivo without modulating the activity of PDK1, the upstream kinase that phosphorylates and activates Akt.	bardoxolone methyl	28-35	nuclear factor kappa B subunit 1	Homo sapiens	66-75
22177954-4	2012	Evaluation of the effect of CDDO-Me on Akt which lies upstream of NF-kappaB and mTOR showed that CDDO-Me directly inhibits the Akt kinase activity in cell-free kinase activity assay and in vivo without modulating the activity of PDK1, the upstream kinase that phosphorylates and activates Akt.	bardoxolone methyl	28-35	mechanistic target of rapamycin kinase	Homo sapiens	80-84
22177954-4	2012	Evaluation of the effect of CDDO-Me on Akt which lies upstream of NF-kappaB and mTOR showed that CDDO-Me directly inhibits the Akt kinase activity in cell-free kinase activity assay and in vivo without modulating the activity of PDK1, the upstream kinase that phosphorylates and activates Akt.	bardoxolone methyl	28-35	AKT serine/threonine kinase 1	Homo sapiens	127-130
22177954-4	2012	Evaluation of the effect of CDDO-Me on Akt which lies upstream of NF-kappaB and mTOR showed that CDDO-Me directly inhibits the Akt kinase activity in cell-free kinase activity assay and in vivo without modulating the activity of PDK1, the upstream kinase that phosphorylates and activates Akt.	bardoxolone methyl	28-35	AKT serine/threonine kinase 1	Homo sapiens	127-130
22177954-4	2012	Evaluation of the effect of CDDO-Me on Akt which lies upstream of NF-kappaB and mTOR showed that CDDO-Me directly inhibits the Akt kinase activity in cell-free kinase activity assay and in vivo without modulating the activity of PDK1, the upstream kinase that phosphorylates and activates Akt.	bardoxolone methyl	97-104	AKT serine/threonine kinase 1	Homo sapiens	39-42
22177954-4	2012	Evaluation of the effect of CDDO-Me on Akt which lies upstream of NF-kappaB and mTOR showed that CDDO-Me directly inhibits the Akt kinase activity in cell-free kinase activity assay and in vivo without modulating the activity of PDK1, the upstream kinase that phosphorylates and activates Akt.	bardoxolone methyl	97-104	nuclear factor kappa B subunit 1	Homo sapiens	66-75
22177954-4	2012	Evaluation of the effect of CDDO-Me on Akt which lies upstream of NF-kappaB and mTOR showed that CDDO-Me directly inhibits the Akt kinase activity in cell-free kinase activity assay and in vivo without modulating the activity of PDK1, the upstream kinase that phosphorylates and activates Akt.	bardoxolone methyl	97-104	mechanistic target of rapamycin kinase	Homo sapiens	80-84
22177954-4	2012	Evaluation of the effect of CDDO-Me on Akt which lies upstream of NF-kappaB and mTOR showed that CDDO-Me directly inhibits the Akt kinase activity in cell-free kinase activity assay and in vivo without modulating the activity of PDK1, the upstream kinase that phosphorylates and activates Akt.	bardoxolone methyl	97-104	AKT serine/threonine kinase 1	Homo sapiens	127-130
22177954-4	2012	Evaluation of the effect of CDDO-Me on Akt which lies upstream of NF-kappaB and mTOR showed that CDDO-Me directly inhibits the Akt kinase activity in cell-free kinase activity assay and in vivo without modulating the activity of PDK1, the upstream kinase that phosphorylates and activates Akt.	bardoxolone methyl	97-104	pyruvate dehydrogenase kinase 1	Homo sapiens	229-233
22177954-4	2012	Evaluation of the effect of CDDO-Me on Akt which lies upstream of NF-kappaB and mTOR showed that CDDO-Me directly inhibits the Akt kinase activity in cell-free kinase activity assay and in vivo without modulating the activity of PDK1, the upstream kinase that phosphorylates and activates Akt.	bardoxolone methyl	97-104	AKT serine/threonine kinase 1	Homo sapiens	127-130
22177954-6	2012	Further, inhibition of p-Akt by CDDO-Me was not attributable to an increase in the activity of protein phosphatase 2A (PP2A) or PH domain/leucine-rich repeat protein phosphatase1 (PHLPP1) both of which dephosphorylate p-Akt.	bardoxolone methyl	32-39	AKT serine/threonine kinase 1	Homo sapiens	25-28
22177954-7	2012	These findings show that Akt is a direct target of CDDO-Me in the Akt/NF-kappaB/mTOR prosurvival signaling axis.	bardoxolone methyl	51-58	AKT serine/threonine kinase 1	Homo sapiens	25-28
22177954-7	2012	These findings show that Akt is a direct target of CDDO-Me in the Akt/NF-kappaB/mTOR prosurvival signaling axis.	bardoxolone methyl	51-58	AKT serine/threonine kinase 1	Homo sapiens	66-69
22177954-7	2012	These findings show that Akt is a direct target of CDDO-Me in the Akt/NF-kappaB/mTOR prosurvival signaling axis.	bardoxolone methyl	51-58	nuclear factor kappa B subunit 1	Homo sapiens	70-79
22177954-7	2012	These findings show that Akt is a direct target of CDDO-Me in the Akt/NF-kappaB/mTOR prosurvival signaling axis.	bardoxolone methyl	51-58	mechanistic target of rapamycin kinase	Homo sapiens	80-84
22178289-3	2012	In this study, we tested the relative effectiveness and mechanisms of action of two electrophilic peroxisome proliferator-activated receptor gamma (PPARgamma) ligands: cyano-3,12-dioxolean-1,9-dien-28-oic acid-methyl ester (CDDO-Me) and 15-deoxy-Delta(-12,14)-prostaglandin J(2) (15d-PGJ(2)) for inhibiting TGFbeta-induced myofibroblast differentiation in vitro.	bardoxolone methyl	224-231	peroxisome proliferator activated receptor gamma	Homo sapiens	148-157
21933912-3	2012	Because the methyl ester of the synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oic acid (CDDO-Me) is a potent chemopreventive agent, we tested its efficacy in a highly relevant mouse model of BRCA1-mutated breast cancer.	bardoxolone methyl	106-113	breast cancer 1, early onset	Mus musculus	209-214
21933912-5	2012	CDDO-Me significantly (P < 0.05) delayed tumor development in the Brca1-mutated mice by an average of 5.2 weeks.	bardoxolone methyl	0-7	breast cancer 1, early onset	Mus musculus	69-74
21933912-6	2012	We also observed that levels of ErbB2, p-ErbB2, and cyclin D1 increased in a time-dependent manner in the mammary glands in Brca1-deficient mice, and CDDO-Me inhibited the constitutive phosphorylation of ErbB2 in tumor tissues from these mice.	bardoxolone methyl	150-157	erb-b2 receptor tyrosine kinase 2	Mus musculus	32-37
21933912-6	2012	We also observed that levels of ErbB2, p-ErbB2, and cyclin D1 increased in a time-dependent manner in the mammary glands in Brca1-deficient mice, and CDDO-Me inhibited the constitutive phosphorylation of ErbB2 in tumor tissues from these mice.	bardoxolone methyl	150-157	erb-b2 receptor tyrosine kinase 2	Mus musculus	41-46
21933912-6	2012	We also observed that levels of ErbB2, p-ErbB2, and cyclin D1 increased in a time-dependent manner in the mammary glands in Brca1-deficient mice, and CDDO-Me inhibited the constitutive phosphorylation of ErbB2 in tumor tissues from these mice.	bardoxolone methyl	150-157	erb-b2 receptor tyrosine kinase 2	Mus musculus	41-46
21933912-8	2012	These results suggest that CDDO-Me has the potential to prevent BRCA1-mutated breast cancer.	bardoxolone methyl	27-34	breast cancer 1, early onset	Mus musculus	64-69
22178289-9	2012	Both electrophilic PPARgamma ligands (CDDO-Me and 15d-PGJ(2)) potently inhibited TGFbeta-induced myofibroblast differentiation, but PPARgamma was only partially required for inhibition of myofibroblast differentiation by either agent.	bardoxolone methyl	38-45	peroxisome proliferator activated receptor gamma	Homo sapiens	19-28
22178289-9	2012	Both electrophilic PPARgamma ligands (CDDO-Me and 15d-PGJ(2)) potently inhibited TGFbeta-induced myofibroblast differentiation, but PPARgamma was only partially required for inhibition of myofibroblast differentiation by either agent.	bardoxolone methyl	38-45	transforming growth factor beta 1	Homo sapiens	81-88
22178289-11	2012	CDDO-Me and 15d-PGJ(2) are strong inhibitors of TGFbeta-induced corneal fibroblast to myofibroblast differentiation in vitro, suggesting this class of agents as potential novel therapies for corneal scarring warranting further study in pre-clinical animal models.	bardoxolone methyl	0-7	transforming growth factor beta 1	Homo sapiens	48-55
22946344-5	2012	Pretreatment with N-acetylcysteine (NAC) or overexpression of glutathione peroxidase (GPx) or superoxide dismutase-1 (SOD-1) blocked the antiproliferative effects of CDDO-Me.	bardoxolone methyl	166-173	superoxide dismutase 1	Homo sapiens	94-116
22946344-5	2012	Pretreatment with N-acetylcysteine (NAC) or overexpression of glutathione peroxidase (GPx) or superoxide dismutase-1 (SOD-1) blocked the antiproliferative effects of CDDO-Me.	bardoxolone methyl	166-173	superoxide dismutase 1	Homo sapiens	118-123
22946344-6	2012	Likewise, NAC prevented the induction of apoptosis (annexin V-FITC binding and cleavage of PARP-1 and procaspases-3,-8 and -9) and reversed the loss of mitochondrial membrane potential and release of cytochrome c from mitochondria by CDDO-Me.	bardoxolone methyl	234-241	cytochrome c, somatic	Homo sapiens	200-212
22946344-7	2012	CDDO-Me down-regulated p-Akt, p-mTOR and NF-kappaB (p65) but increased the activation of Erk1/2 and NAC blocked the modulation of these cell signaling proteins by CDDO-Me.	bardoxolone methyl	0-7	AKT serine/threonine kinase 1	Homo sapiens	25-28
22946344-7	2012	CDDO-Me down-regulated p-Akt, p-mTOR and NF-kappaB (p65) but increased the activation of Erk1/2 and NAC blocked the modulation of these cell signaling proteins by CDDO-Me.	bardoxolone methyl	0-7	mechanistic target of rapamycin kinase	Homo sapiens	32-36
22946344-7	2012	CDDO-Me down-regulated p-Akt, p-mTOR and NF-kappaB (p65) but increased the activation of Erk1/2 and NAC blocked the modulation of these cell signaling proteins by CDDO-Me.	bardoxolone methyl	0-7	RELA proto-oncogene, NF-kB subunit	Homo sapiens	52-55
22946344-7	2012	CDDO-Me down-regulated p-Akt, p-mTOR and NF-kappaB (p65) but increased the activation of Erk1/2 and NAC blocked the modulation of these cell signaling proteins by CDDO-Me.	bardoxolone methyl	0-7	mitogen-activated protein kinase 3	Homo sapiens	89-95
22946344-7	2012	CDDO-Me down-regulated p-Akt, p-mTOR and NF-kappaB (p65) but increased the activation of Erk1/2 and NAC blocked the modulation of these cell signaling proteins by CDDO-Me.	bardoxolone methyl	163-170	mitogen-activated protein kinase 3	Homo sapiens	89-95
22110186-0	2011	Synthetic oleanane triterpenoid, CDDO-Me, induces apoptosis in ovarian cancer cells by inhibiting prosurvival AKT/NF-kappaB/mTOR signaling.	bardoxolone methyl	33-40	AKT serine/threonine kinase 1	Homo sapiens	110-113
22110186-0	2011	Synthetic oleanane triterpenoid, CDDO-Me, induces apoptosis in ovarian cancer cells by inhibiting prosurvival AKT/NF-kappaB/mTOR signaling.	bardoxolone methyl	33-40	nuclear factor kappa B subunit 1	Homo sapiens	114-123
22110186-6	2011	Abrogation of AKT which regulates both NF-kappaB and mTOR increased the sensitivity of tumor cells to CDDO-Me.	bardoxolone methyl	102-109	AKT serine/threonine kinase 1	Homo sapiens	14-17
22110186-0	2011	Synthetic oleanane triterpenoid, CDDO-Me, induces apoptosis in ovarian cancer cells by inhibiting prosurvival AKT/NF-kappaB/mTOR signaling.	bardoxolone methyl	33-40	mechanistic target of rapamycin kinase	Homo sapiens	124-128
22110186-6	2011	Abrogation of AKT which regulates both NF-kappaB and mTOR increased the sensitivity of tumor cells to CDDO-Me.	bardoxolone methyl	102-109	nuclear factor kappa B subunit 1	Homo sapiens	39-48
22110186-6	2011	Abrogation of AKT which regulates both NF-kappaB and mTOR increased the sensitivity of tumor cells to CDDO-Me.	bardoxolone methyl	102-109	mechanistic target of rapamycin kinase	Homo sapiens	53-57
22110186-3	2011	CDDO-Me strongly inhibited the growth of ovarian cancer cells by inducing apoptosis characterized by increased annexin V binding, cleavage of poly (ADP-ribose) polymerase (PARP-1) and procaspases-3, -8 and -9.	bardoxolone methyl	0-7	poly(ADP-ribose) polymerase 1	Homo sapiens	142-170
22110186-7	2011	Thus, these data showing strong growth-inhibitory and apoptosis-inducing activity of CDDO-Me for ovarian cancer cells through the inhibition of AKT/ NF-kappaB/mTOR signaling pathway provide basis for evaluation of CDDO-Me for ovarian cancer.	bardoxolone methyl	85-92	AKT serine/threonine kinase 1	Homo sapiens	144-147
22110186-3	2011	CDDO-Me strongly inhibited the growth of ovarian cancer cells by inducing apoptosis characterized by increased annexin V binding, cleavage of poly (ADP-ribose) polymerase (PARP-1) and procaspases-3, -8 and -9.	bardoxolone methyl	0-7	caspase 3	Homo sapiens	172-208
22110186-7	2011	Thus, these data showing strong growth-inhibitory and apoptosis-inducing activity of CDDO-Me for ovarian cancer cells through the inhibition of AKT/ NF-kappaB/mTOR signaling pathway provide basis for evaluation of CDDO-Me for ovarian cancer.	bardoxolone methyl	85-92	nuclear factor kappa B subunit 1	Homo sapiens	149-158
22110186-7	2011	Thus, these data showing strong growth-inhibitory and apoptosis-inducing activity of CDDO-Me for ovarian cancer cells through the inhibition of AKT/ NF-kappaB/mTOR signaling pathway provide basis for evaluation of CDDO-Me for ovarian cancer.	bardoxolone methyl	85-92	mechanistic target of rapamycin kinase	Homo sapiens	159-163
21799944-5	2010	CDDO-Me inhibited the growth of both K-ras mutated (MiaPaca2, Panc1 and Capan2) and wild-type K-ras (BxPC3) pancreatic cancer cells at very low concentrations.	bardoxolone methyl	0-7	KRAS proto-oncogene, GTPase	Homo sapiens	37-42
21961053-0	2011	Prevention of Prostate Cancer with Oleanane Synthetic Triterpenoid CDDO-Me in the TRAMP Mouse Model of Prostate Cancer.	bardoxolone methyl	67-74	translocating chain-associating membrane protein 1	Mus musculus	82-87
21961053-3	2011	CDDO-Me inhibited the growth of murine TRAMPC-1 prostate cancer cells by inducing apoptosis through the inhibition of antiapoptotic p-Akt, p-mTOR and NF-kappaB.	bardoxolone methyl	0-7	thymoma viral proto-oncogene 1	Mus musculus	134-137
21961053-3	2011	CDDO-Me inhibited the growth of murine TRAMPC-1 prostate cancer cells by inducing apoptosis through the inhibition of antiapoptotic p-Akt, p-mTOR and NF-kappaB.	bardoxolone methyl	0-7	mechanistic target of rapamycin kinase	Mus musculus	141-145
21961053-4	2011	Early intervention with CDDO-Me (7.5 mg/kg) initiated at five weeks of age for 20 wk inhibited the progression of the preneoplastic lesions (low-grade PIN and high-grade-PIN) to adenocarcinoma in the dorsolateral prostate (DLP) and ventral prostate (VP) lobes of TRAMP mice.	bardoxolone methyl	24-31	translocating chain-associating membrane protein 1	Mus musculus	263-268
21961053-7	2011	Treatment with CDDO-Me inhibited the expression of prosurvival p-Akt and NF-kappaB in the prostate and knocking-down Akt in TRAMPC-1 tumor cells sensitized them to CDDO-Me.	bardoxolone methyl	15-22	thymoma viral proto-oncogene 1	Mus musculus	65-68
21961053-7	2011	Treatment with CDDO-Me inhibited the expression of prosurvival p-Akt and NF-kappaB in the prostate and knocking-down Akt in TRAMPC-1 tumor cells sensitized them to CDDO-Me.	bardoxolone methyl	15-22	thymoma viral proto-oncogene 1	Mus musculus	117-120
21961053-8	2011	These findings indicated that Akt is a target for apoptoxicity in TRAMPC-1 cells in vitro and potentially a target of CDDO-Me for inhibition of prostate cancer in vivo.	bardoxolone methyl	118-125	thymoma viral proto-oncogene 1	Mus musculus	30-33
21723306-7	2011	Using NCTC2544 human keratinocytes, we found that both sulforaphane and methyl-2-cyano-3,12-dioxooleana-1,9-dien-28-oate (CDDO-Me) stimulated nuclear localization of Nrf2 and induced expression of the GSH synthesis gene, GCLM.	bardoxolone methyl	122-129	NFE2 like bZIP transcription factor 2	Homo sapiens	166-170
21723306-7	2011	Using NCTC2544 human keratinocytes, we found that both sulforaphane and methyl-2-cyano-3,12-dioxooleana-1,9-dien-28-oate (CDDO-Me) stimulated nuclear localization of Nrf2 and induced expression of the GSH synthesis gene, GCLM.	bardoxolone methyl	122-129	glutamate-cysteine ligase modifier subunit	Homo sapiens	221-225
21545836-7	2011	Treatment with the Nrf2 activator CDDO-Me increased antioxidant gene expression and normalized I/R-induced superoxide in the retina in wild-type but not Nrf2(-/-) mice.	bardoxolone methyl	34-41	nuclear factor, erythroid derived 2, like 2	Mus musculus	19-23
21699019-5	2011	CDDO-Me induced apoptosis as demonstrated by the cleavage of PARP-1, activation of procaspases -3, -8, and -9 and mitochondrial depolarization and NAC blocked the activation of these apoptosis related processes.	bardoxolone methyl	0-7	poly(ADP-ribose) polymerase 1	Homo sapiens	61-109
21699019-6	2011	Furthermore, induction of apoptosis by CDDO-Me was associated with the inhibition of antiapoptotic/ prosurvival Akt, mTOR and NF-kappaB signaling proteins and the inhibition of these signaling molecules was blocked by NAG.	bardoxolone methyl	39-46	AKT serine/threonine kinase 1	Homo sapiens	112-115
21699019-6	2011	Furthermore, induction of apoptosis by CDDO-Me was associated with the inhibition of antiapoptotic/ prosurvival Akt, mTOR and NF-kappaB signaling proteins and the inhibition of these signaling molecules was blocked by NAG.	bardoxolone methyl	39-46	mechanistic target of rapamycin kinase	Homo sapiens	117-121
20956520-2	2010	Here we report that CDDO-Me ameliorates diabetes in high fat diet-fed type 2 diabetic mice and in Lepr(db/db) mice.	bardoxolone methyl	20-27	leptin receptor	Mus musculus	98-102
20956520-8	2010	CDDO-Me activates AMP-activated protein kinase (AMPK) and via LKB1 activation in muscle and liver in vivo.	bardoxolone methyl	0-7	serine/threonine kinase 11	Mus musculus	62-66
20956520-9	2010	Treatment of isolated hepatocytes with CDDO-Me directly stimulates AMPK activity and LKB1 phosphorylation and decreases acetyl-coA carboxylase activity; it also down-regulates lipogenic gene expression, suppresses gluconeogenesis, and increases glucose uptake.	bardoxolone methyl	39-46	serine/threonine kinase 11	Mus musculus	85-89
21799944-5	2010	CDDO-Me inhibited the growth of both K-ras mutated (MiaPaca2, Panc1 and Capan2) and wild-type K-ras (BxPC3) pancreatic cancer cells at very low concentrations.	bardoxolone methyl	0-7	KRAS proto-oncogene, GTPase	Homo sapiens	94-99
21799944-6	2010	The growth inhibitory activity of CDDO-Me was attributed to the induction of apoptosis characterized by increased annexin-V-FITC binding and cleavage of PARP-1 and procaspases-3, -8 and-9.	bardoxolone methyl	34-41	annexin A5	Homo sapiens	114-123
21799944-6	2010	The growth inhibitory activity of CDDO-Me was attributed to the induction of apoptosis characterized by increased annexin-V-FITC binding and cleavage of PARP-1 and procaspases-3, -8 and-9.	bardoxolone methyl	34-41	poly(ADP-ribose) polymerase 1	Homo sapiens	153-187
21799944-7	2010	In addition, CDDO-Me induced the loss of mitochondrial membrane potential and release of cytochrome C.	bardoxolone methyl	13-20	cytochrome c, somatic	Homo sapiens	89-101
21799944-8	2010	The antitumor activity of CDDO-Me was associated with the inhibition of prosurvival p-Akt, NF-kappaB and mammalian target of rapamycin (mTOR) signaling proteins and the downstream targets of Akt and mTOR, such as p-Foxo3a (Akt) and p-S6K1, p-eIF-4E and p-4E-BP1 (mTOR).	bardoxolone methyl	26-33	AKT serine/threonine kinase 1	Homo sapiens	86-89
21799944-8	2010	The antitumor activity of CDDO-Me was associated with the inhibition of prosurvival p-Akt, NF-kappaB and mammalian target of rapamycin (mTOR) signaling proteins and the downstream targets of Akt and mTOR, such as p-Foxo3a (Akt) and p-S6K1, p-eIF-4E and p-4E-BP1 (mTOR).	bardoxolone methyl	26-33	mechanistic target of rapamycin kinase	Homo sapiens	105-134
21799944-8	2010	The antitumor activity of CDDO-Me was associated with the inhibition of prosurvival p-Akt, NF-kappaB and mammalian target of rapamycin (mTOR) signaling proteins and the downstream targets of Akt and mTOR, such as p-Foxo3a (Akt) and p-S6K1, p-eIF-4E and p-4E-BP1 (mTOR).	bardoxolone methyl	26-33	mechanistic target of rapamycin kinase	Homo sapiens	136-140
21799944-8	2010	The antitumor activity of CDDO-Me was associated with the inhibition of prosurvival p-Akt, NF-kappaB and mammalian target of rapamycin (mTOR) signaling proteins and the downstream targets of Akt and mTOR, such as p-Foxo3a (Akt) and p-S6K1, p-eIF-4E and p-4E-BP1 (mTOR).	bardoxolone methyl	26-33	AKT serine/threonine kinase 1	Homo sapiens	191-194
21799944-8	2010	The antitumor activity of CDDO-Me was associated with the inhibition of prosurvival p-Akt, NF-kappaB and mammalian target of rapamycin (mTOR) signaling proteins and the downstream targets of Akt and mTOR, such as p-Foxo3a (Akt) and p-S6K1, p-eIF-4E and p-4E-BP1 (mTOR).	bardoxolone methyl	26-33	mechanistic target of rapamycin kinase	Homo sapiens	199-203
21799944-8	2010	The antitumor activity of CDDO-Me was associated with the inhibition of prosurvival p-Akt, NF-kappaB and mammalian target of rapamycin (mTOR) signaling proteins and the downstream targets of Akt and mTOR, such as p-Foxo3a (Akt) and p-S6K1, p-eIF-4E and p-4E-BP1 (mTOR).	bardoxolone methyl	26-33	forkhead box O3	Homo sapiens	215-221
21799944-8	2010	The antitumor activity of CDDO-Me was associated with the inhibition of prosurvival p-Akt, NF-kappaB and mammalian target of rapamycin (mTOR) signaling proteins and the downstream targets of Akt and mTOR, such as p-Foxo3a (Akt) and p-S6K1, p-eIF-4E and p-4E-BP1 (mTOR).	bardoxolone methyl	26-33	AKT serine/threonine kinase 1	Homo sapiens	191-194
21799944-8	2010	The antitumor activity of CDDO-Me was associated with the inhibition of prosurvival p-Akt, NF-kappaB and mammalian target of rapamycin (mTOR) signaling proteins and the downstream targets of Akt and mTOR, such as p-Foxo3a (Akt) and p-S6K1, p-eIF-4E and p-4E-BP1 (mTOR).	bardoxolone methyl	26-33	eukaryotic translation initiation factor 4E	Homo sapiens	242-248
21799944-8	2010	The antitumor activity of CDDO-Me was associated with the inhibition of prosurvival p-Akt, NF-kappaB and mammalian target of rapamycin (mTOR) signaling proteins and the downstream targets of Akt and mTOR, such as p-Foxo3a (Akt) and p-S6K1, p-eIF-4E and p-4E-BP1 (mTOR).	bardoxolone methyl	26-33	mechanistic target of rapamycin kinase	Homo sapiens	199-203
21799944-9	2010	Silencing of Akt or mTOR with gene specific-siRNA sensitized the pancreatic cancer cells to CDDO-Me, demonstrating Akt and mTOR as molecular targets of CDDO-Me for its growth inhibitory and apoptosis-inducing activity.	bardoxolone methyl	92-99	AKT serine/threonine kinase 1	Homo sapiens	13-16
21799944-9	2010	Silencing of Akt or mTOR with gene specific-siRNA sensitized the pancreatic cancer cells to CDDO-Me, demonstrating Akt and mTOR as molecular targets of CDDO-Me for its growth inhibitory and apoptosis-inducing activity.	bardoxolone methyl	92-99	mechanistic target of rapamycin kinase	Homo sapiens	20-24
21799944-9	2010	Silencing of Akt or mTOR with gene specific-siRNA sensitized the pancreatic cancer cells to CDDO-Me, demonstrating Akt and mTOR as molecular targets of CDDO-Me for its growth inhibitory and apoptosis-inducing activity.	bardoxolone methyl	152-159	AKT serine/threonine kinase 1	Homo sapiens	13-16
21799944-9	2010	Silencing of Akt or mTOR with gene specific-siRNA sensitized the pancreatic cancer cells to CDDO-Me, demonstrating Akt and mTOR as molecular targets of CDDO-Me for its growth inhibitory and apoptosis-inducing activity.	bardoxolone methyl	152-159	mechanistic target of rapamycin kinase	Homo sapiens	20-24
21799944-9	2010	Silencing of Akt or mTOR with gene specific-siRNA sensitized the pancreatic cancer cells to CDDO-Me, demonstrating Akt and mTOR as molecular targets of CDDO-Me for its growth inhibitory and apoptosis-inducing activity.	bardoxolone methyl	152-159	AKT serine/threonine kinase 1	Homo sapiens	115-118
21799944-9	2010	Silencing of Akt or mTOR with gene specific-siRNA sensitized the pancreatic cancer cells to CDDO-Me, demonstrating Akt and mTOR as molecular targets of CDDO-Me for its growth inhibitory and apoptosis-inducing activity.	bardoxolone methyl	152-159	mechanistic target of rapamycin kinase	Homo sapiens	123-127
20566646-4	2010	2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid (CDDO)-Im and CDDO-Me were observed to 1) inhibit the localization of Arp3 and actin at the leading edge of cells, 2) abrogate cell polarity, and 3) inhibit Arp2/3-dependent branched actin polymerization.	bardoxolone methyl	60-67	actin related protein 3	Rattus norvegicus	116-120
20488920-3	2010	RNA interference studies indicate that these repressed genes are regulated by specificity protein (Sp) transcription factors Sp1, Sp3, and Sp4, and Western blot analysis of lysates from pancreatic cancer cells treated with CDDO and CDDO-Me shows for the first time that both compounds decreased the expression of Sp1, Sp3, and Sp4.	bardoxolone methyl	232-239	Sp3 transcription factor	Homo sapiens	318-321
20230221-9	2010	Treatment with the anti-inflammatory agent CDDO-Me before and after MSC-IFN-beta injections resulted in reduction of MSC in the tumors and reversed the positive effect of tumor inhibition by MSC-IFN-beta alone (P=0.041).	bardoxolone methyl	43-50	interferon beta 1	Homo sapiens	72-80
20230221-9	2010	Treatment with the anti-inflammatory agent CDDO-Me before and after MSC-IFN-beta injections resulted in reduction of MSC in the tumors and reversed the positive effect of tumor inhibition by MSC-IFN-beta alone (P=0.041).	bardoxolone methyl	43-50	interferon beta 1	Homo sapiens	195-203
20386502-0	2010	Blockage of Stat3 with CDDO-Me inhibits tumor cell growth in chordoma.	bardoxolone methyl	23-30	signal transducer and activator of transcription 3	Homo sapiens	12-17
20386502-2	2010	OBJECTIVE: To investigate the activation of Src/Stat3 pathway in chordomas cells and to determine the efficiency of inhibiting this pathway by 2-cyano-3,12-dioxooleana-1,9 (11)-dien-28-oic acid-methyl ester (CDDO-Me) as a potential chemotherapeutic agent for chordoma treatment.	bardoxolone methyl	208-215	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	44-47
20386502-9	2010	The expression of key components of the Src/Stat3 signaling cascade and poly (ADP-ribose) polymerase cleavage in these CDDO-Me treated cells were analyzed by Western blot and immunofluorescence.	bardoxolone methyl	119-126	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	40-43
20386502-13	2010	Expression of the key components of the Src/Stat3 signaling cascade was inhibited in chordoma cells after treatment with CDDO-Me.	bardoxolone methyl	121-128	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	40-43
20386502-13	2010	Expression of the key components of the Src/Stat3 signaling cascade was inhibited in chordoma cells after treatment with CDDO-Me.	bardoxolone methyl	121-128	signal transducer and activator of transcription 3	Homo sapiens	44-49
20386502-18	2010	Blockage of Src/Stat3 pathway by CDDO-Me is a potential strategy for chordoma treatment and may be focus for future research.	bardoxolone methyl	33-40	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	12-15
20386502-18	2010	Blockage of Src/Stat3 pathway by CDDO-Me is a potential strategy for chordoma treatment and may be focus for future research.	bardoxolone methyl	33-40	signal transducer and activator of transcription 3	Homo sapiens	16-21
20488920-2	2010	Treatment of Panc1, Panc28, and L3.6pL pancreatic cancer cells with low micromolar concentrations of CDDO or CDDO-Me resulted in growth inhibition, induction of apoptosis, and down-regulation of cyclin D1, survivin, vascular endothelial growth factor (VEGF), and its receptor (VEGFR2).	bardoxolone methyl	109-116	cyclin D1	Homo sapiens	195-204
20488920-2	2010	Treatment of Panc1, Panc28, and L3.6pL pancreatic cancer cells with low micromolar concentrations of CDDO or CDDO-Me resulted in growth inhibition, induction of apoptosis, and down-regulation of cyclin D1, survivin, vascular endothelial growth factor (VEGF), and its receptor (VEGFR2).	bardoxolone methyl	109-116	vascular endothelial growth factor A	Homo sapiens	216-250
20488920-2	2010	Treatment of Panc1, Panc28, and L3.6pL pancreatic cancer cells with low micromolar concentrations of CDDO or CDDO-Me resulted in growth inhibition, induction of apoptosis, and down-regulation of cyclin D1, survivin, vascular endothelial growth factor (VEGF), and its receptor (VEGFR2).	bardoxolone methyl	109-116	vascular endothelial growth factor A	Homo sapiens	252-256
20488920-3	2010	RNA interference studies indicate that these repressed genes are regulated by specificity protein (Sp) transcription factors Sp1, Sp3, and Sp4, and Western blot analysis of lysates from pancreatic cancer cells treated with CDDO and CDDO-Me shows for the first time that both compounds decreased the expression of Sp1, Sp3, and Sp4.	bardoxolone methyl	232-239	Sp4 transcription factor	Homo sapiens	327-330
20488920-2	2010	Treatment of Panc1, Panc28, and L3.6pL pancreatic cancer cells with low micromolar concentrations of CDDO or CDDO-Me resulted in growth inhibition, induction of apoptosis, and down-regulation of cyclin D1, survivin, vascular endothelial growth factor (VEGF), and its receptor (VEGFR2).	bardoxolone methyl	109-116	kinase insert domain receptor	Homo sapiens	277-283
20488920-4	2010	Moreover, CDDO-Me (7.5 mg/kg/day) also inhibited pancreatic human L3.6pL tumor growth and down-regulated Sp1, Sp3, and Sp4 in tumors using an orthotopic pancreatic cancer model.	bardoxolone methyl	10-17	Sp3 transcription factor	Homo sapiens	110-113
20488920-4	2010	Moreover, CDDO-Me (7.5 mg/kg/day) also inhibited pancreatic human L3.6pL tumor growth and down-regulated Sp1, Sp3, and Sp4 in tumors using an orthotopic pancreatic cancer model.	bardoxolone methyl	10-17	Sp4 transcription factor	Homo sapiens	119-122
20488920-5	2010	CDDO-Me also induced reactive oxygen species (ROS) and decreased mitochondrial membrane potential (MMP) in Panc1 and L3.6pL cells, and cotreatment with antioxidants (glutathione and dithiothreitol) blocked the formation of ROS, reversed the loss of MMP, and inhibited down-regulation of Sp1, Sp3, and Sp4.	bardoxolone methyl	0-7	Sp3 transcription factor	Homo sapiens	292-295
20488920-5	2010	CDDO-Me also induced reactive oxygen species (ROS) and decreased mitochondrial membrane potential (MMP) in Panc1 and L3.6pL cells, and cotreatment with antioxidants (glutathione and dithiothreitol) blocked the formation of ROS, reversed the loss of MMP, and inhibited down-regulation of Sp1, Sp3, and Sp4.	bardoxolone methyl	0-7	Sp4 transcription factor	Homo sapiens	301-304
20488920-6	2010	Repression of Sp and Sp-dependent genes by CDDO-Me was due to the down-regulation of microRNA-27a and induction of zinc finger and BTB domain containing 10 (ZBTB10), an Sp repressor, and these responses were also reversed by antioxidants.	bardoxolone methyl	43-50	zinc finger and BTB domain containing 10	Homo sapiens	157-163
20488920-7	2010	Thus, the anticancer activity of CDDO-Me is due, in part, to activation of ROS, which in turn targets the microRNA-27a:ZBTB10-Sp transcription factor axis.	bardoxolone methyl	33-40	zinc finger and BTB domain containing 10	Homo sapiens	119-125
20063378-6	2010	Finally, we evaluated the effect of CDDO-Me on the inhibition of activated Stat3 pathway in osteosarcoma cell lines using MTT assay and Western blot analysis.	bardoxolone methyl	36-43	signal transducer and activator of transcription 3	Homo sapiens	75-80
20571062-4	2010	Here, we report that CDDO-Me blocks targeting of NFkappaB to the nucleus by inhibiting IkappaB kinase beta-mediated phosphorylation of IkappaBalpha.	bardoxolone methyl	21-28	nuclear factor kappa B subunit 1	Homo sapiens	49-57
20571062-4	2010	Here, we report that CDDO-Me blocks targeting of NFkappaB to the nucleus by inhibiting IkappaB kinase beta-mediated phosphorylation of IkappaBalpha.	bardoxolone methyl	21-28	NFKB inhibitor alpha	Homo sapiens	135-147
20571062-5	2010	Moreover, CDDO-Me blocked constitutive activation of the signal transducer and activator of transcription 3.	bardoxolone methyl	10-17	signal transducer and activator of transcription 3	Homo sapiens	57-107
20571062-6	2010	We report the potent and selective antiproliferative effects of CDDO-Me on FLT3/ITD-positive myeloid leukemia cell lines and primary AML cells.	bardoxolone methyl	64-71	fms related receptor tyrosine kinase 3	Homo sapiens	75-79
20571062-7	2010	The present studies show that CDDO-Me treatment results in caspase-3-mediated induction of apoptosis of FLT3/ITD-expressing cells and its antiproliferative effects are synergistic with PKC412, a FLT3-tyrosine kinase inhibitor currently in clinical trials.	bardoxolone methyl	30-37	caspase 3	Homo sapiens	59-68
20571062-7	2010	The present studies show that CDDO-Me treatment results in caspase-3-mediated induction of apoptosis of FLT3/ITD-expressing cells and its antiproliferative effects are synergistic with PKC412, a FLT3-tyrosine kinase inhibitor currently in clinical trials.	bardoxolone methyl	30-37	fms related receptor tyrosine kinase 3	Homo sapiens	104-108
20571062-7	2010	The present studies show that CDDO-Me treatment results in caspase-3-mediated induction of apoptosis of FLT3/ITD-expressing cells and its antiproliferative effects are synergistic with PKC412, a FLT3-tyrosine kinase inhibitor currently in clinical trials.	bardoxolone methyl	30-37	fms related receptor tyrosine kinase 3	Homo sapiens	195-199
20571062-8	2010	Taken together, our studies indicate that CDDO-Me greatly enhanced the efficacy of the FLT3 inhibitor PKC412, suggesting that combining two separate pathway inhibitors might be a viable therapeutic strategy for AML associated with a FLT3/ITD mutation.	bardoxolone methyl	42-49	fms related receptor tyrosine kinase 3	Homo sapiens	87-91
20571062-8	2010	Taken together, our studies indicate that CDDO-Me greatly enhanced the efficacy of the FLT3 inhibitor PKC412, suggesting that combining two separate pathway inhibitors might be a viable therapeutic strategy for AML associated with a FLT3/ITD mutation.	bardoxolone methyl	42-49	fms related receptor tyrosine kinase 3	Homo sapiens	233-237
20459702-0	2010	Oleanane triterpenoid CDDO-Me induces apoptosis in multidrug resistant osteosarcoma cells through inhibition of Stat3 pathway.	bardoxolone methyl	22-29	signal transducer and activator of transcription 3	Homo sapiens	112-117
20626291-7	2010	In contrast, CDDO-Me protection against LPS challenge had no impact on absolute numbers or distribution of splenocyte subsets, despite attenuating in vivo induction of proinflammatory cytokines in an IL-10-independent manner.	bardoxolone methyl	13-20	interleukin 10	Mus musculus	200-205
20459702-5	2010	The effect of CDDO-Me on osteosarcoma cell growth was evaluated by MTT and apoptosis by PARP cleavage assay and caspase-3/7 activity.	bardoxolone methyl	14-21	poly(ADP-ribose) polymerase 1	Homo sapiens	88-92
20459702-5	2010	The effect of CDDO-Me on osteosarcoma cell growth was evaluated by MTT and apoptosis by PARP cleavage assay and caspase-3/7 activity.	bardoxolone methyl	14-21	caspase 3	Homo sapiens	112-121
20459702-8	2010	Treatment with CDDO-Me significantly decreased the level of nuclear translocation and phosphorylation of Stat3.	bardoxolone methyl	15-22	signal transducer and activator of transcription 3	Homo sapiens	105-110
20459702-12	2010	CDDO-Me significantly inhibited Stat3 phosphorylation, Stat3 nuclear translocation and induced apoptosis in osteosarcoma.	bardoxolone methyl	0-7	signal transducer and activator of transcription 3	Homo sapiens	32-37
20459702-12	2010	CDDO-Me significantly inhibited Stat3 phosphorylation, Stat3 nuclear translocation and induced apoptosis in osteosarcoma.	bardoxolone methyl	0-7	signal transducer and activator of transcription 3	Homo sapiens	55-60
18757413-3	2008	CDDO-Me induced caspase-3, caspase-8, and caspase-9 activation; poly(ADP-ribose) polymerase cleavage; internucleosomal DNA fragmentation; and loss of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide reduction in PC3 and DU145 cells.	bardoxolone methyl	0-7	caspase 3	Homo sapiens	16-25
19782051-4	2010	Here, we show that CDDO-Me induces ROS generation from both nonmitochondrial and mitochondrial sources, which is associated with the induction of apoptosis as characterized by increased annexin V-binding, cleavage of PARP-1 and procaspases-3, -8, -9, loss of mitochondrial membrane potential and release of cytochrome c.	bardoxolone methyl	19-26	annexin A5	Homo sapiens	186-195
19782051-4	2010	Here, we show that CDDO-Me induces ROS generation from both nonmitochondrial and mitochondrial sources, which is associated with the induction of apoptosis as characterized by increased annexin V-binding, cleavage of PARP-1 and procaspases-3, -8, -9, loss of mitochondrial membrane potential and release of cytochrome c.	bardoxolone methyl	19-26	poly(ADP-ribose) polymerase 1	Homo sapiens	217-249
19782051-4	2010	Here, we show that CDDO-Me induces ROS generation from both nonmitochondrial and mitochondrial sources, which is associated with the induction of apoptosis as characterized by increased annexin V-binding, cleavage of PARP-1 and procaspases-3, -8, -9, loss of mitochondrial membrane potential and release of cytochrome c.	bardoxolone methyl	19-26	cytochrome c, somatic	Homo sapiens	307-319
19782051-5	2010	In addition, CDDO-Me inhibited cell survival Akt, NF-kappaB and mTOR signaling proteins.	bardoxolone methyl	13-20	AKT serine/threonine kinase 1	Homo sapiens	45-48
19782051-5	2010	In addition, CDDO-Me inhibited cell survival Akt, NF-kappaB and mTOR signaling proteins.	bardoxolone methyl	13-20	mechanistic target of rapamycin kinase	Homo sapiens	64-68
19782051-6	2010	The inhibition of ROS generation by N-acetylcysteine (NAC) or by overexpression of antioxidant enzymes glutathione peroxidase (GPx) and superoxide dismutase-1 (SOD-1) prevented CDDO-Me-induced apoptosis.	bardoxolone methyl	177-184	superoxide dismutase 1	Homo sapiens	136-158
19782051-6	2010	The inhibition of ROS generation by N-acetylcysteine (NAC) or by overexpression of antioxidant enzymes glutathione peroxidase (GPx) and superoxide dismutase-1 (SOD-1) prevented CDDO-Me-induced apoptosis.	bardoxolone methyl	177-184	superoxide dismutase 1	Homo sapiens	160-165
19782051-7	2010	Pretreatment with NAC blocked annexin V-binding, cleavage of PARP-1 and procaspases-3, -8, -9, loss of mitochondrial membrane potential and release of cytochrome c by CDDO-Me.	bardoxolone methyl	167-174	cytochrome c, somatic	Homo sapiens	151-163
19782051-8	2010	NAC also prevented the inhibition of constitutively active Akt, NF-kappaB and mTOR by CDDO-Me.	bardoxolone methyl	86-93	AKT serine/threonine kinase 1	Homo sapiens	59-62
18587580-0	2009	CDDO-Me, a synthetic triterpenoid, inhibits expression of IL-6 and Stat3 phosphorylation in multi-drug resistant ovarian cancer cells.	bardoxolone methyl	0-7	interleukin 6	Homo sapiens	58-62
18587580-0	2009	CDDO-Me, a synthetic triterpenoid, inhibits expression of IL-6 and Stat3 phosphorylation in multi-drug resistant ovarian cancer cells.	bardoxolone methyl	0-7	signal transducer and activator of transcription 3	Homo sapiens	67-72
18587580-3	2009	To explore potential therapeutic strategies for interrupting signaling through this pathway, we assessed the ability of CDDO-Me, a synthetic triterpenoid, to inhibit IL-6 secretion, Stat3 phosphorylation, Stat3 nuclear translocation and paclitaxel sensitivity in several cell line model systems.	bardoxolone methyl	120-127	interleukin 6	Homo sapiens	166-170
18587580-3	2009	To explore potential therapeutic strategies for interrupting signaling through this pathway, we assessed the ability of CDDO-Me, a synthetic triterpenoid, to inhibit IL-6 secretion, Stat3 phosphorylation, Stat3 nuclear translocation and paclitaxel sensitivity in several cell line model systems.	bardoxolone methyl	120-127	signal transducer and activator of transcription 3	Homo sapiens	182-187
18587580-4	2009	These studies demonstrated that CDDO-Me significantly inhibits IL-6 secretion in paclitaxel-resistant ovarian cancer cells and specifically suppresses IL-6- or oncostatin M-induced Stat3 nuclear translocation.	bardoxolone methyl	32-39	interleukin 6	Homo sapiens	63-67
18587580-4	2009	These studies demonstrated that CDDO-Me significantly inhibits IL-6 secretion in paclitaxel-resistant ovarian cancer cells and specifically suppresses IL-6- or oncostatin M-induced Stat3 nuclear translocation.	bardoxolone methyl	32-39	interleukin 6	Homo sapiens	151-156
18587580-4	2009	These studies demonstrated that CDDO-Me significantly inhibits IL-6 secretion in paclitaxel-resistant ovarian cancer cells and specifically suppresses IL-6- or oncostatin M-induced Stat3 nuclear translocation.	bardoxolone methyl	32-39	signal transducer and activator of transcription 3	Homo sapiens	181-186
18587580-5	2009	Treatment with CDDO-Me significantly decreases the levels of Stat3, Jak2, and Src phosphorylation in ovarian and breast cancer cell lines with constitutively activated Stat3.	bardoxolone methyl	15-22	signal transducer and activator of transcription 3	Homo sapiens	61-66
18587580-5	2009	Treatment with CDDO-Me significantly decreases the levels of Stat3, Jak2, and Src phosphorylation in ovarian and breast cancer cell lines with constitutively activated Stat3.	bardoxolone methyl	15-22	Janus kinase 2	Homo sapiens	68-72
18587580-5	2009	Treatment with CDDO-Me significantly decreases the levels of Stat3, Jak2, and Src phosphorylation in ovarian and breast cancer cell lines with constitutively activated Stat3.	bardoxolone methyl	15-22	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	78-81
18587580-5	2009	Treatment with CDDO-Me significantly decreases the levels of Stat3, Jak2, and Src phosphorylation in ovarian and breast cancer cell lines with constitutively activated Stat3.	bardoxolone methyl	15-22	signal transducer and activator of transcription 3	Homo sapiens	168-173
18587580-8	2009	Our data confirm that CDDO-Me interrupts the signaling of multiple kinases involved in the IL-6-Stat3 and Src signaling pathways.	bardoxolone methyl	22-29	interleukin 6	Homo sapiens	91-101
18587580-8	2009	Our data confirm that CDDO-Me interrupts the signaling of multiple kinases involved in the IL-6-Stat3 and Src signaling pathways.	bardoxolone methyl	22-29	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	106-109
18794136-0	2008	Coupling of endoplasmic reticulum stress to CDDO-Me-induced up-regulation of death receptor 5 via a CHOP-dependent mechanism involving JNK activation.	bardoxolone methyl	44-51	TNF receptor superfamily member 10b	Homo sapiens	77-93
18794136-0	2008	Coupling of endoplasmic reticulum stress to CDDO-Me-induced up-regulation of death receptor 5 via a CHOP-dependent mechanism involving JNK activation.	bardoxolone methyl	44-51	DNA damage inducible transcript 3	Homo sapiens	100-104
18794136-0	2008	Coupling of endoplasmic reticulum stress to CDDO-Me-induced up-regulation of death receptor 5 via a CHOP-dependent mechanism involving JNK activation.	bardoxolone methyl	44-51	mitogen-activated protein kinase 8	Homo sapiens	135-138
18794136-2	2008	We previously showed that CDDO-Me induces c-Jun NH(2)-terminal kinase (JNK)-dependent death receptor 5 (DR5) expression and augments death receptor-induced apoptosis.	bardoxolone methyl	26-33	mitogen-activated protein kinase 8	Homo sapiens	71-74
18794136-2	2008	We previously showed that CDDO-Me induces c-Jun NH(2)-terminal kinase (JNK)-dependent death receptor 5 (DR5) expression and augments death receptor-induced apoptosis.	bardoxolone methyl	26-33	TNF receptor superfamily member 10b	Homo sapiens	86-102
18794136-2	2008	We previously showed that CDDO-Me induces c-Jun NH(2)-terminal kinase (JNK)-dependent death receptor 5 (DR5) expression and augments death receptor-induced apoptosis.	bardoxolone methyl	26-33	TNF receptor superfamily member 10b	Homo sapiens	104-107
18794136-3	2008	The current study focused on addressing how CDDO-Me induces JNK-dependent DR5 expression.	bardoxolone methyl	44-51	mitogen-activated protein kinase 8	Homo sapiens	60-63
18794136-3	2008	The current study focused on addressing how CDDO-Me induces JNK-dependent DR5 expression.	bardoxolone methyl	44-51	TNF receptor superfamily member 10b	Homo sapiens	74-77
18794136-4	2008	Analysis of DR5 promoter regions defines that the CCAAT/enhancer binding protein homologous protein (CHOP) binding site is responsible for CDDO-Me-induced transactivation of the DR5 gene.	bardoxolone methyl	139-146	TNF receptor superfamily member 10b	Homo sapiens	12-15
18794136-4	2008	Analysis of DR5 promoter regions defines that the CCAAT/enhancer binding protein homologous protein (CHOP) binding site is responsible for CDDO-Me-induced transactivation of the DR5 gene.	bardoxolone methyl	139-146	DNA damage inducible transcript 3	Homo sapiens	50-99
18794136-4	2008	Analysis of DR5 promoter regions defines that the CCAAT/enhancer binding protein homologous protein (CHOP) binding site is responsible for CDDO-Me-induced transactivation of the DR5 gene.	bardoxolone methyl	139-146	DNA damage inducible transcript 3	Homo sapiens	101-105
18794136-4	2008	Analysis of DR5 promoter regions defines that the CCAAT/enhancer binding protein homologous protein (CHOP) binding site is responsible for CDDO-Me-induced transactivation of the DR5 gene.	bardoxolone methyl	139-146	TNF receptor superfamily member 10b	Homo sapiens	178-181
18794136-5	2008	Consistently, CDDO-Me induced DR5 expression and parallel CHOP up-regulation.	bardoxolone methyl	14-21	TNF receptor superfamily member 10b	Homo sapiens	30-33
18794136-5	2008	Consistently, CDDO-Me induced DR5 expression and parallel CHOP up-regulation.	bardoxolone methyl	14-21	DNA damage inducible transcript 3	Homo sapiens	58-62
18794136-6	2008	Blockade of CHOP up-regulation also abrogated CDDO-Me-induced DR5 expression.	bardoxolone methyl	46-53	DNA damage inducible transcript 3	Homo sapiens	12-16
18794136-6	2008	Blockade of CHOP up-regulation also abrogated CDDO-Me-induced DR5 expression.	bardoxolone methyl	46-53	TNF receptor superfamily member 10b	Homo sapiens	62-65
18794136-7	2008	These results indicate that CDDO-Me induces CHOP-dependent DR5 up-regulation.	bardoxolone methyl	28-35	DNA damage inducible transcript 3	Homo sapiens	44-48
18794136-7	2008	These results indicate that CDDO-Me induces CHOP-dependent DR5 up-regulation.	bardoxolone methyl	28-35	TNF receptor superfamily member 10b	Homo sapiens	59-62
20372807-5	2010	CDDO-Me, a synthetic triterpenoid, suppressed expression of Spot 14 and FASN genes and likewise inhibited LS cell growth.	bardoxolone methyl	0-7	thyroid hormone responsive	Homo sapiens	60-67
20372807-5	2010	CDDO-Me, a synthetic triterpenoid, suppressed expression of Spot 14 and FASN genes and likewise inhibited LS cell growth.	bardoxolone methyl	0-7	fatty acid synthase	Homo sapiens	72-76
20392997-7	2010	Induction of apoptosis by CDDO-Me was associated with the inhibition of pro-survival Akt, NF-kappaB and mTOR signaling proteins and NF-kappaB-regulated anti-apoptotic Bcl-2, Bcl-xL, Bad and survivin.	bardoxolone methyl	26-33	AKT serine/threonine kinase 1	Homo sapiens	85-88
20392997-7	2010	Induction of apoptosis by CDDO-Me was associated with the inhibition of pro-survival Akt, NF-kappaB and mTOR signaling proteins and NF-kappaB-regulated anti-apoptotic Bcl-2, Bcl-xL, Bad and survivin.	bardoxolone methyl	26-33	mechanistic target of rapamycin kinase	Homo sapiens	104-108
20392997-7	2010	Induction of apoptosis by CDDO-Me was associated with the inhibition of pro-survival Akt, NF-kappaB and mTOR signaling proteins and NF-kappaB-regulated anti-apoptotic Bcl-2, Bcl-xL, Bad and survivin.	bardoxolone methyl	26-33	BCL2 apoptosis regulator	Homo sapiens	167-172
20392997-7	2010	Induction of apoptosis by CDDO-Me was associated with the inhibition of pro-survival Akt, NF-kappaB and mTOR signaling proteins and NF-kappaB-regulated anti-apoptotic Bcl-2, Bcl-xL, Bad and survivin.	bardoxolone methyl	26-33	BCL2 like 1	Homo sapiens	174-180
19782051-8	2010	NAC also prevented the inhibition of constitutively active Akt, NF-kappaB and mTOR by CDDO-Me.	bardoxolone methyl	86-93	mechanistic target of rapamycin kinase	Homo sapiens	78-82
19189297-0	2009	Oleanane triterpenoid CDDO-Me inhibits growth and induces apoptosis in prostate cancer cells by independently targeting pro-survival Akt and mTOR.	bardoxolone methyl	22-29	AKT serine/threonine kinase 1	Homo sapiens	133-136
19189297-0	2009	Oleanane triterpenoid CDDO-Me inhibits growth and induces apoptosis in prostate cancer cells by independently targeting pro-survival Akt and mTOR.	bardoxolone methyl	22-29	mechanistic target of rapamycin kinase	Homo sapiens	141-145
19189297-3	2009	METHODS: The antitumor activity of CDDO-Me for hormone-refractory PC-3 (AR(-)) and C4-2 (AR(+)) prostate cancer cell lines was determined by effects on cell growth and induction of apoptosis, identification of molecular targets, and therapeutic efficacy in vivo in PC-3 xenograft model.	bardoxolone methyl	35-42	CDK5 regulatory subunit associated protein 1	Homo sapiens	83-87
19189297-4	2009	RESULTS: CDDO-Me inhibited the growth and induced apoptosis in PC-3 and C4-2 cells at extremely low concentrations.	bardoxolone methyl	9-16	CDK5 regulatory subunit associated protein 1	Homo sapiens	72-76
19189297-5	2009	The antitumor activity of CDDO-Me was associated with the inhibition of p-Akt, mammalian target of rapamycin (mTOR), and nuclear factor kappa B (NF-kappaB) signaling proteins and their downstream targets such as p-Bad and p-Foxo3a (Akt); p-S6K1, p-eIF-4E and p-4E-BP1 (mTOR); and COX-2, VEGF and cyclin D1(NF-kappaB).	bardoxolone methyl	26-33	AKT serine/threonine kinase 1	Homo sapiens	74-77
19189297-5	2009	The antitumor activity of CDDO-Me was associated with the inhibition of p-Akt, mammalian target of rapamycin (mTOR), and nuclear factor kappa B (NF-kappaB) signaling proteins and their downstream targets such as p-Bad and p-Foxo3a (Akt); p-S6K1, p-eIF-4E and p-4E-BP1 (mTOR); and COX-2, VEGF and cyclin D1(NF-kappaB).	bardoxolone methyl	26-33	mechanistic target of rapamycin kinase	Homo sapiens	79-108
19189297-5	2009	The antitumor activity of CDDO-Me was associated with the inhibition of p-Akt, mammalian target of rapamycin (mTOR), and nuclear factor kappa B (NF-kappaB) signaling proteins and their downstream targets such as p-Bad and p-Foxo3a (Akt); p-S6K1, p-eIF-4E and p-4E-BP1 (mTOR); and COX-2, VEGF and cyclin D1(NF-kappaB).	bardoxolone methyl	26-33	mechanistic target of rapamycin kinase	Homo sapiens	110-114
19189297-5	2009	The antitumor activity of CDDO-Me was associated with the inhibition of p-Akt, mammalian target of rapamycin (mTOR), and nuclear factor kappa B (NF-kappaB) signaling proteins and their downstream targets such as p-Bad and p-Foxo3a (Akt); p-S6K1, p-eIF-4E and p-4E-BP1 (mTOR); and COX-2, VEGF and cyclin D1(NF-kappaB).	bardoxolone methyl	26-33	nuclear factor kappa B subunit 1	Homo sapiens	121-143
19189297-5	2009	The antitumor activity of CDDO-Me was associated with the inhibition of p-Akt, mammalian target of rapamycin (mTOR), and nuclear factor kappa B (NF-kappaB) signaling proteins and their downstream targets such as p-Bad and p-Foxo3a (Akt); p-S6K1, p-eIF-4E and p-4E-BP1 (mTOR); and COX-2, VEGF and cyclin D1(NF-kappaB).	bardoxolone methyl	26-33	nuclear factor kappa B subunit 1	Homo sapiens	145-154
19189297-5	2009	The antitumor activity of CDDO-Me was associated with the inhibition of p-Akt, mammalian target of rapamycin (mTOR), and nuclear factor kappa B (NF-kappaB) signaling proteins and their downstream targets such as p-Bad and p-Foxo3a (Akt); p-S6K1, p-eIF-4E and p-4E-BP1 (mTOR); and COX-2, VEGF and cyclin D1(NF-kappaB).	bardoxolone methyl	26-33	AKT serine/threonine kinase 1	Homo sapiens	232-235
19189297-5	2009	The antitumor activity of CDDO-Me was associated with the inhibition of p-Akt, mammalian target of rapamycin (mTOR), and nuclear factor kappa B (NF-kappaB) signaling proteins and their downstream targets such as p-Bad and p-Foxo3a (Akt); p-S6K1, p-eIF-4E and p-4E-BP1 (mTOR); and COX-2, VEGF and cyclin D1(NF-kappaB).	bardoxolone methyl	26-33	eukaryotic translation initiation factor 4E	Homo sapiens	248-254
19189297-5	2009	The antitumor activity of CDDO-Me was associated with the inhibition of p-Akt, mammalian target of rapamycin (mTOR), and nuclear factor kappa B (NF-kappaB) signaling proteins and their downstream targets such as p-Bad and p-Foxo3a (Akt); p-S6K1, p-eIF-4E and p-4E-BP1 (mTOR); and COX-2, VEGF and cyclin D1(NF-kappaB).	bardoxolone methyl	26-33	mechanistic target of rapamycin kinase	Homo sapiens	269-273
19189297-5	2009	The antitumor activity of CDDO-Me was associated with the inhibition of p-Akt, mammalian target of rapamycin (mTOR), and nuclear factor kappa B (NF-kappaB) signaling proteins and their downstream targets such as p-Bad and p-Foxo3a (Akt); p-S6K1, p-eIF-4E and p-4E-BP1 (mTOR); and COX-2, VEGF and cyclin D1(NF-kappaB).	bardoxolone methyl	26-33	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	280-285
19189297-5	2009	The antitumor activity of CDDO-Me was associated with the inhibition of p-Akt, mammalian target of rapamycin (mTOR), and nuclear factor kappa B (NF-kappaB) signaling proteins and their downstream targets such as p-Bad and p-Foxo3a (Akt); p-S6K1, p-eIF-4E and p-4E-BP1 (mTOR); and COX-2, VEGF and cyclin D1(NF-kappaB).	bardoxolone methyl	26-33	vascular endothelial growth factor A	Homo sapiens	287-291
19189297-5	2009	The antitumor activity of CDDO-Me was associated with the inhibition of p-Akt, mammalian target of rapamycin (mTOR), and nuclear factor kappa B (NF-kappaB) signaling proteins and their downstream targets such as p-Bad and p-Foxo3a (Akt); p-S6K1, p-eIF-4E and p-4E-BP1 (mTOR); and COX-2, VEGF and cyclin D1(NF-kappaB).	bardoxolone methyl	26-33	cyclin D1	Homo sapiens	296-305
19189297-5	2009	The antitumor activity of CDDO-Me was associated with the inhibition of p-Akt, mammalian target of rapamycin (mTOR), and nuclear factor kappa B (NF-kappaB) signaling proteins and their downstream targets such as p-Bad and p-Foxo3a (Akt); p-S6K1, p-eIF-4E and p-4E-BP1 (mTOR); and COX-2, VEGF and cyclin D1(NF-kappaB).	bardoxolone methyl	26-33	nuclear factor kappa B subunit 1	Homo sapiens	306-315
19189297-6	2009	Silencing of Akt sensitized the PC-3 cells to CDDO-Me, whereas overexpression of Akt induced resistance to CDDO-Me.	bardoxolone methyl	46-53	AKT serine/threonine kinase 1	Homo sapiens	13-16
19189297-6	2009	Silencing of Akt sensitized the PC-3 cells to CDDO-Me, whereas overexpression of Akt induced resistance to CDDO-Me.	bardoxolone methyl	107-114	AKT serine/threonine kinase 1	Homo sapiens	81-84
19189297-7	2009	Targeted silencing of Akt showed that Akt does not regulate mTOR activation in PC-3 cells, but targeted silencing of mTOR sensitized PC-3 cells to CDDO-Me mediated growth inhibition.	bardoxolone methyl	147-154	mechanistic target of rapamycin kinase	Homo sapiens	117-121
19189297-10	2009	Data also identified Akt and mTOR as molecular targets of CDDO-Me in prostate cancer cells.	bardoxolone methyl	58-65	AKT serine/threonine kinase 1	Homo sapiens	21-24
19189297-10	2009	Data also identified Akt and mTOR as molecular targets of CDDO-Me in prostate cancer cells.	bardoxolone methyl	58-65	mechanistic target of rapamycin kinase	Homo sapiens	29-33
18794136-8	2008	Moreover, the JNK inhibitor SP600125 abrogated CHOP induction by CDDO-Me, suggesting a JNK-dependent CHOP up-regulation by CDDO-Me as well.	bardoxolone methyl	65-72	mitogen-activated protein kinase 8	Homo sapiens	14-17
18794136-8	2008	Moreover, the JNK inhibitor SP600125 abrogated CHOP induction by CDDO-Me, suggesting a JNK-dependent CHOP up-regulation by CDDO-Me as well.	bardoxolone methyl	65-72	DNA damage inducible transcript 3	Homo sapiens	47-51
18794136-8	2008	Moreover, the JNK inhibitor SP600125 abrogated CHOP induction by CDDO-Me, suggesting a JNK-dependent CHOP up-regulation by CDDO-Me as well.	bardoxolone methyl	65-72	mitogen-activated protein kinase 8	Homo sapiens	87-90
18794136-8	2008	Moreover, the JNK inhibitor SP600125 abrogated CHOP induction by CDDO-Me, suggesting a JNK-dependent CHOP up-regulation by CDDO-Me as well.	bardoxolone methyl	65-72	DNA damage inducible transcript 3	Homo sapiens	101-105
18794136-8	2008	Moreover, the JNK inhibitor SP600125 abrogated CHOP induction by CDDO-Me, suggesting a JNK-dependent CHOP up-regulation by CDDO-Me as well.	bardoxolone methyl	123-130	mitogen-activated protein kinase 8	Homo sapiens	14-17
18794136-8	2008	Moreover, the JNK inhibitor SP600125 abrogated CHOP induction by CDDO-Me, suggesting a JNK-dependent CHOP up-regulation by CDDO-Me as well.	bardoxolone methyl	123-130	DNA damage inducible transcript 3	Homo sapiens	47-51
18794136-8	2008	Moreover, the JNK inhibitor SP600125 abrogated CHOP induction by CDDO-Me, suggesting a JNK-dependent CHOP up-regulation by CDDO-Me as well.	bardoxolone methyl	123-130	mitogen-activated protein kinase 8	Homo sapiens	87-90
18794136-8	2008	Moreover, the JNK inhibitor SP600125 abrogated CHOP induction by CDDO-Me, suggesting a JNK-dependent CHOP up-regulation by CDDO-Me as well.	bardoxolone methyl	123-130	DNA damage inducible transcript 3	Homo sapiens	101-105
18794136-9	2008	Importantly, knockdown of CHOP attenuated CDDO-Me-induced apoptosis, showing that CHOP induction is involved in CDDO-Me-induced apoptosis.	bardoxolone methyl	42-49	DNA damage inducible transcript 3	Homo sapiens	26-30
18794136-9	2008	Importantly, knockdown of CHOP attenuated CDDO-Me-induced apoptosis, showing that CHOP induction is involved in CDDO-Me-induced apoptosis.	bardoxolone methyl	42-49	DNA damage inducible transcript 3	Homo sapiens	82-86
18794136-9	2008	Importantly, knockdown of CHOP attenuated CDDO-Me-induced apoptosis, showing that CHOP induction is involved in CDDO-Me-induced apoptosis.	bardoxolone methyl	112-119	DNA damage inducible transcript 3	Homo sapiens	26-30
18794136-9	2008	Importantly, knockdown of CHOP attenuated CDDO-Me-induced apoptosis, showing that CHOP induction is involved in CDDO-Me-induced apoptosis.	bardoxolone methyl	112-119	DNA damage inducible transcript 3	Homo sapiens	82-86
18794136-10	2008	Additionally, CDDO-Me increased the levels of Bip, phosphorylated eukaryotic translation initiation factor 2alpha, inositol requiring kinase 1alpha, and activating transcription factor 4, all of which are featured changes during endoplasmic reticulum (ER) stress.	bardoxolone methyl	14-21	growth differentiation factor 10	Homo sapiens	46-49
18794136-10	2008	Additionally, CDDO-Me increased the levels of Bip, phosphorylated eukaryotic translation initiation factor 2alpha, inositol requiring kinase 1alpha, and activating transcription factor 4, all of which are featured changes during endoplasmic reticulum (ER) stress.	bardoxolone methyl	14-21	activating transcription factor 4	Homo sapiens	107-186
18794136-11	2008	Furthermore, salubrinal, an inhibitor of ER stress-induced apoptosis, inhibited JNK activation and up-regulation of CHOP and DR5 by CDDO-Me and protected cells from CDDO-Me-induced apoptosis.	bardoxolone methyl	132-139	DNA damage inducible transcript 3	Homo sapiens	116-120
18794136-11	2008	Furthermore, salubrinal, an inhibitor of ER stress-induced apoptosis, inhibited JNK activation and up-regulation of CHOP and DR5 by CDDO-Me and protected cells from CDDO-Me-induced apoptosis.	bardoxolone methyl	132-139	TNF receptor superfamily member 10b	Homo sapiens	125-128
18794136-12	2008	Thus, ER stress seems to be important for CDDO-Me-induced JNK activation, CHOP and DR5 up-regulation, and apoptosis.	bardoxolone methyl	42-49	mitogen-activated protein kinase 8	Homo sapiens	58-61
18794136-12	2008	Thus, ER stress seems to be important for CDDO-Me-induced JNK activation, CHOP and DR5 up-regulation, and apoptosis.	bardoxolone methyl	42-49	DNA damage inducible transcript 3	Homo sapiens	74-78
18794136-12	2008	Thus, ER stress seems to be important for CDDO-Me-induced JNK activation, CHOP and DR5 up-regulation, and apoptosis.	bardoxolone methyl	42-49	TNF receptor superfamily member 10b	Homo sapiens	83-86
18794136-13	2008	Collectively, we conclude that CDDO-Me triggers ER stress, leading to JNK-dependent, CHOP-mediated DR5 up-regulation and apoptosis.	bardoxolone methyl	31-38	mitogen-activated protein kinase 8	Homo sapiens	70-73
18794136-13	2008	Collectively, we conclude that CDDO-Me triggers ER stress, leading to JNK-dependent, CHOP-mediated DR5 up-regulation and apoptosis.	bardoxolone methyl	31-38	DNA damage inducible transcript 3	Homo sapiens	85-89
18794136-13	2008	Collectively, we conclude that CDDO-Me triggers ER stress, leading to JNK-dependent, CHOP-mediated DR5 up-regulation and apoptosis.	bardoxolone methyl	31-38	TNF receptor superfamily member 10b	Homo sapiens	99-102
18757413-3	2008	CDDO-Me induced caspase-3, caspase-8, and caspase-9 activation; poly(ADP-ribose) polymerase cleavage; internucleosomal DNA fragmentation; and loss of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide reduction in PC3 and DU145 cells.	bardoxolone methyl	0-7	caspase 8	Homo sapiens	27-36
18757413-3	2008	CDDO-Me induced caspase-3, caspase-8, and caspase-9 activation; poly(ADP-ribose) polymerase cleavage; internucleosomal DNA fragmentation; and loss of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide reduction in PC3 and DU145 cells.	bardoxolone methyl	0-7	caspase 9	Homo sapiens	42-51
18757413-3	2008	CDDO-Me induced caspase-3, caspase-8, and caspase-9 activation; poly(ADP-ribose) polymerase cleavage; internucleosomal DNA fragmentation; and loss of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide reduction in PC3 and DU145 cells.	bardoxolone methyl	0-7	chromobox 8	Homo sapiens	224-227
18757413-5	2008	Interestingly, CDDO-Me induced inactivating phosphorylation at Ser(9) of glycogen synthase kinase 3beta (GSK3beta), a multifunctional kinase that mediates essential events promoting prostate cancer development and acquisition of androgen independence.	bardoxolone methyl	15-22	glycogen synthase kinase 3 beta	Homo sapiens	73-103
18757413-5	2008	Interestingly, CDDO-Me induced inactivating phosphorylation at Ser(9) of glycogen synthase kinase 3beta (GSK3beta), a multifunctional kinase that mediates essential events promoting prostate cancer development and acquisition of androgen independence.	bardoxolone methyl	15-22	glycogen synthase kinase 3 beta	Homo sapiens	105-113
18757413-6	2008	The GSK3 inhibitor lithium chloride and, more effectively, GSK3 gene silencing sensitized PC3 and DU145 prostate cancer cells to CDDO-Me cytotoxicity.	bardoxolone methyl	129-136	chromobox 8	Homo sapiens	90-93
18757413-7	2008	These data suggest that modulation of GSK3beta activation is involved in the cell death pathway engaged by CDDO-Me in prostate cancer cells.	bardoxolone methyl	107-114	glycogen synthase kinase 3 beta	Homo sapiens	38-46
18474101-0	2008	The synthetic triterpenoid CDDO-methyl ester modulates microglial activities, inhibits TNF production, and provides dopaminergic neuroprotection.	bardoxolone methyl	27-44	tumor necrosis factor	Mus musculus	87-90
18628471-0	2008	Prevention and treatment of experimental estrogen receptor-negative mammary carcinogenesis by the synthetic triterpenoid CDDO-methyl Ester and the rexinoid LG100268.	bardoxolone methyl	121-138	estrogen receptor 1 (alpha)	Mus musculus	41-58
18628471-4	2008	RESULTS: CDDO-Me and 268 significantly delayed the development of ER-negative tumors, with a 14- and 24-week delay, respectively, compared with the control group for the time required to reach 50% tumor incidence.	bardoxolone methyl	9-16	estrogen receptor 1 (alpha)	Mus musculus	66-68
18628471-8	2008	CDDO-Me inhibited constitutive STAT3 phosphorylation and the degradation of IKBalpha in ER-negative breast cancer cells, whereas 268 blocked IKBalpha degradation and the release of interleukin-6 in RAW264.7 macrophage-like cells, inhibited the ability of endothelial cells to organize into networks, and blocked angiogenesis in vivo.	bardoxolone methyl	0-7	signal transducer and activator of transcription 3	Mus musculus	31-36
18628471-8	2008	CDDO-Me inhibited constitutive STAT3 phosphorylation and the degradation of IKBalpha in ER-negative breast cancer cells, whereas 268 blocked IKBalpha degradation and the release of interleukin-6 in RAW264.7 macrophage-like cells, inhibited the ability of endothelial cells to organize into networks, and blocked angiogenesis in vivo.	bardoxolone methyl	0-7	nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha	Mus musculus	76-84
18474101-8	2008	RESULTS: We found that at low nanomolar concentrations, treatment of rat primary mesencephalon neuron/glia cultures with CDDO-Me resulted in attenuated LPS-, TNF- or fibrillar amyloid beta 1-42 (A beta 1-42) peptide-induced increases in reactive microglia and inflammatory gene expression without an overall effect on cell viability.	bardoxolone methyl	121-128	tumor necrosis factor	Mus musculus	158-161
18474101-9	2008	In functional assays CDDO-Me blocked death in the dopaminergic neuron-like cell line MN9D induced by conditioned media (CM) of LPS-stimulated BV2 microglia, but did not block cell death induced by addition of TNF to MN9D cells, suggesting that dopaminergic neuroprotection by CDDO-Me involved inhibition of microglial-derived cytokine production and not direct inhibition of TNF-dependent pro-apoptotic pathways.	bardoxolone methyl	21-28	tumor necrosis factor	Mus musculus	375-378
18474101-10	2008	Multiplexed immunoassays of CM from LPS-stimulated microglia confirmed that CDDO-Me-treated BV2 cells produced decreased levels of specific subsets of cytokines, in particular TNF.	bardoxolone methyl	76-83	tumor necrosis factor	Mus musculus	176-179
18253090-0	2007	c-FLIP downregulation contributes to apoptosis induction by the novel synthetic triterpenoid methyl-2-cyano-3, 12-dioxooleana-1, 9-dien-28-oate (CDDO-Me) in human lung cancer cells.	bardoxolone methyl	145-152	CASP8 and FADD like apoptosis regulator	Homo sapiens	0-6
18483301-4	2008	In addition, CDDO-Me rapidly decreased the viability of murine lymphoid Ba/F3 cells expressing wild-type p210 as well as the imatinib-resistant E255K and T315I mutations of bcr-abl.	bardoxolone methyl	13-20	envoplakin	Mus musculus	105-109
18413761-0	2008	Triterpenoid CDDO-methyl ester inhibits the Janus-activated kinase-1 (JAK1)-->signal transducer and activator of transcription-3 (STAT3) pathway by direct inhibition of JAK1 and STAT3.	bardoxolone methyl	13-30	signal transducer and activator of transcription 3	Homo sapiens	181-186
18413761-3	2008	The present studies show that CDDO-Me blocks interleukin-6 (IL-6)-induced and constitutive activation of the Janus-activated kinase 1 (JAK1) in cells.	bardoxolone methyl	30-37	interleukin 6	Homo sapiens	45-58
18413761-3	2008	The present studies show that CDDO-Me blocks interleukin-6 (IL-6)-induced and constitutive activation of the Janus-activated kinase 1 (JAK1) in cells.	bardoxolone methyl	30-37	interleukin 6	Homo sapiens	60-64
18413761-3	2008	The present studies show that CDDO-Me blocks interleukin-6 (IL-6)-induced and constitutive activation of the Janus-activated kinase 1 (JAK1) in cells.	bardoxolone methyl	30-37	Janus kinase 1	Homo sapiens	109-133
18413761-3	2008	The present studies show that CDDO-Me blocks interleukin-6 (IL-6)-induced and constitutive activation of the Janus-activated kinase 1 (JAK1) in cells.	bardoxolone methyl	30-37	Janus kinase 1	Homo sapiens	135-139
18413761-4	2008	In support of a direct mechanism, CDDO-Me forms adducts with JAK1 at Cys(1077) in the kinase domain and inhibits JAK1 activity.	bardoxolone methyl	34-41	Janus kinase 1	Homo sapiens	61-65
18413761-4	2008	In support of a direct mechanism, CDDO-Me forms adducts with JAK1 at Cys(1077) in the kinase domain and inhibits JAK1 activity.	bardoxolone methyl	34-41	Janus kinase 1	Homo sapiens	113-117
18413761-5	2008	In concert with these results, CDDO-Me blocked IL-6-induced and constitutive activation of signal transducer and activator of transcription 3 (STAT3).	bardoxolone methyl	31-38	interleukin 6	Homo sapiens	47-51
18413761-5	2008	In concert with these results, CDDO-Me blocked IL-6-induced and constitutive activation of signal transducer and activator of transcription 3 (STAT3).	bardoxolone methyl	31-38	signal transducer and activator of transcription 3	Homo sapiens	91-141
18413761-5	2008	In concert with these results, CDDO-Me blocked IL-6-induced and constitutive activation of signal transducer and activator of transcription 3 (STAT3).	bardoxolone methyl	31-38	signal transducer and activator of transcription 3	Homo sapiens	143-148
18413761-6	2008	Moreover, we show that CDDO-Me (a) binds directly to STAT3 by a mechanism dependent on the alkylation of Cys(259) and (b) inhibits the formation of STAT3 dimers.	bardoxolone methyl	23-30	signal transducer and activator of transcription 3	Homo sapiens	53-58
18413761-6	2008	Moreover, we show that CDDO-Me (a) binds directly to STAT3 by a mechanism dependent on the alkylation of Cys(259) and (b) inhibits the formation of STAT3 dimers.	bardoxolone methyl	23-30	signal transducer and activator of transcription 3	Homo sapiens	148-153
18413761-7	2008	These findings indicate that CDDO-Me inhibits activation of the JAK1-->STAT3 pathway by forming adducts with both JAK1 and STAT3.	bardoxolone methyl	29-36	Janus kinase 1	Homo sapiens	64-68
18413761-7	2008	These findings indicate that CDDO-Me inhibits activation of the JAK1-->STAT3 pathway by forming adducts with both JAK1 and STAT3.	bardoxolone methyl	29-36	signal transducer and activator of transcription 3	Homo sapiens	74-79
18413761-7	2008	These findings indicate that CDDO-Me inhibits activation of the JAK1-->STAT3 pathway by forming adducts with both JAK1 and STAT3.	bardoxolone methyl	29-36	Janus kinase 1	Homo sapiens	117-121
18413761-7	2008	These findings indicate that CDDO-Me inhibits activation of the JAK1-->STAT3 pathway by forming adducts with both JAK1 and STAT3.	bardoxolone methyl	29-36	signal transducer and activator of transcription 3	Homo sapiens	126-131
18472640-0	2008	CDDO-Me inhibits proliferation, induces apoptosis, down-regulates Akt, mTOR, NF-kappaB and NF-kappaB-regulated antiapoptotic and proangiogenic proteins in TRAMP prostate cancer cells.	bardoxolone methyl	0-7	thymoma viral proto-oncogene 1	Mus musculus	66-69
18472640-0	2008	CDDO-Me inhibits proliferation, induces apoptosis, down-regulates Akt, mTOR, NF-kappaB and NF-kappaB-regulated antiapoptotic and proangiogenic proteins in TRAMP prostate cancer cells.	bardoxolone methyl	0-7	mechanistic target of rapamycin kinase	Mus musculus	71-75
18472640-0	2008	CDDO-Me inhibits proliferation, induces apoptosis, down-regulates Akt, mTOR, NF-kappaB and NF-kappaB-regulated antiapoptotic and proangiogenic proteins in TRAMP prostate cancer cells.	bardoxolone methyl	0-7	tumor necrosis factor receptor superfamily, member 25	Mus musculus	155-160
18472640-7	2008	Further, CDDO-Me inhibited NF-kappaB-regulated antiapoptotic Bcl-2, Bcl-xL, and XIAP and proangiogenic VEGF.	bardoxolone methyl	9-16	B cell leukemia/lymphoma 2	Mus musculus	61-66
18472640-7	2008	Further, CDDO-Me inhibited NF-kappaB-regulated antiapoptotic Bcl-2, Bcl-xL, and XIAP and proangiogenic VEGF.	bardoxolone methyl	9-16	BCL2-like 1	Mus musculus	68-74
18472640-7	2008	Further, CDDO-Me inhibited NF-kappaB-regulated antiapoptotic Bcl-2, Bcl-xL, and XIAP and proangiogenic VEGF.	bardoxolone methyl	9-16	X-linked inhibitor of apoptosis	Mus musculus	80-84
18472640-7	2008	Further, CDDO-Me inhibited NF-kappaB-regulated antiapoptotic Bcl-2, Bcl-xL, and XIAP and proangiogenic VEGF.	bardoxolone methyl	9-16	vascular endothelial growth factor A	Mus musculus	103-107
18065492-6	2007	We also show antiangiogenic effects of CDDO-Me on xenografts of Kaposi"s sarcoma cells in immunocompromised mice, using CD31 as a marker.	bardoxolone methyl	39-46	platelet/endothelial cell adhesion molecule 1	Mus musculus	120-124
18065492-7	2007	Several known individual molecular targets of CDDO-Me and related triterpenoids that are relevant to all of these findings include nuclear factor-kappaB signaling, signal transducers and activators of transcription signaling, and transforming growth factor-beta signaling, as well as Keap1, the endogenous inhibitor of the transcription factor Nrf2.	bardoxolone methyl	46-53	nuclear factor, erythroid derived 2, like 2	Mus musculus	344-348
17822364-10	2007	In conclusion, these results demonstrate that activation of the Nrf2-dependent antioxidative pathway by CDDO-Im or CDDO-Me protects against the LPS-induced inflammatory response and suggest that they can be potential therapeutic candidates for intervening sepsis syndrome.	bardoxolone methyl	115-122	NFE2 like bZIP transcription factor 2	Homo sapiens	64-68
18277094-4	2008	After treatment of human neuroblastoma cells with CDDO-Me, cell cycle studies show depletion of the S-phase, while apoptosis studies show conformational activation and mitochondrial translocation of Bax protein, as well as activation of caspases -3 and -8.	bardoxolone methyl	50-57	BCL2 associated X, apoptosis regulator	Homo sapiens	199-202
18277094-4	2008	After treatment of human neuroblastoma cells with CDDO-Me, cell cycle studies show depletion of the S-phase, while apoptosis studies show conformational activation and mitochondrial translocation of Bax protein, as well as activation of caspases -3 and -8.	bardoxolone methyl	50-57	caspase 3	Homo sapiens	237-255
18413761-0	2008	Triterpenoid CDDO-methyl ester inhibits the Janus-activated kinase-1 (JAK1)-->signal transducer and activator of transcription-3 (STAT3) pathway by direct inhibition of JAK1 and STAT3.	bardoxolone methyl	13-30	Janus kinase 1	Homo sapiens	70-74
18413761-0	2008	Triterpenoid CDDO-methyl ester inhibits the Janus-activated kinase-1 (JAK1)-->signal transducer and activator of transcription-3 (STAT3) pathway by direct inhibition of JAK1 and STAT3.	bardoxolone methyl	13-30	signal transducer and activator of transcription 3	Homo sapiens	81-131
18413761-0	2008	Triterpenoid CDDO-methyl ester inhibits the Janus-activated kinase-1 (JAK1)-->signal transducer and activator of transcription-3 (STAT3) pathway by direct inhibition of JAK1 and STAT3.	bardoxolone methyl	13-30	signal transducer and activator of transcription 3	Homo sapiens	133-138
18413761-0	2008	Triterpenoid CDDO-methyl ester inhibits the Janus-activated kinase-1 (JAK1)-->signal transducer and activator of transcription-3 (STAT3) pathway by direct inhibition of JAK1 and STAT3.	bardoxolone methyl	13-30	Janus kinase 1	Homo sapiens	172-176
18608528-4	2008	The suppression of these cell-mediated immune responses by CDDO-Me was associated with the inhibition of NF-kappaB transcription factor.	bardoxolone methyl	59-66	nuclear factor kappa B subunit 1	Homo sapiens	105-114
17822364-0	2007	Preclinical evaluation of targeting the Nrf2 pathway by triterpenoids (CDDO-Im and CDDO-Me) for protection from LPS-induced inflammatory response and reactive oxygen species in human peripheral blood mononuclear cells and neutrophils.	bardoxolone methyl	83-90	NFE2 like bZIP transcription factor 2	Homo sapiens	40-44
18253090-1	2007	The novel synthetic triterpenoid methyl-2-cyano-3, 12-dioxooleana-1, 9-dien-28-oate (CDDO-Me) induces apoptosis of cancer cells, enhances tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis, and exhibits potent anticancer activity in animal models with a favorable pharmacokinetic profile.	bardoxolone methyl	85-92	TNF superfamily member 10	Homo sapiens	138-193
18253090-1	2007	The novel synthetic triterpenoid methyl-2-cyano-3, 12-dioxooleana-1, 9-dien-28-oate (CDDO-Me) induces apoptosis of cancer cells, enhances tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis, and exhibits potent anticancer activity in animal models with a favorable pharmacokinetic profile.	bardoxolone methyl	85-92	TNF superfamily member 10	Homo sapiens	195-200
18253090-3	2007	In an effort to understand the mechanism by which CDDO-Me induces apoptosis, particularly in human lung cancer cells, we previously demonstrated that CDDO-Me induces apoptosis involving c-Jun N-terminal kinase (JNK)-dependent upregulation of death receptor 5 (DR5) expression.	bardoxolone methyl	50-57	mitogen-activated protein kinase 8	Homo sapiens	186-209
18253090-3	2007	In an effort to understand the mechanism by which CDDO-Me induces apoptosis, particularly in human lung cancer cells, we previously demonstrated that CDDO-Me induces apoptosis involving c-Jun N-terminal kinase (JNK)-dependent upregulation of death receptor 5 (DR5) expression.	bardoxolone methyl	50-57	mitogen-activated protein kinase 8	Homo sapiens	211-214
18253090-3	2007	In an effort to understand the mechanism by which CDDO-Me induces apoptosis, particularly in human lung cancer cells, we previously demonstrated that CDDO-Me induces apoptosis involving c-Jun N-terminal kinase (JNK)-dependent upregulation of death receptor 5 (DR5) expression.	bardoxolone methyl	50-57	TNF receptor superfamily member 10b	Homo sapiens	242-258
18253090-3	2007	In an effort to understand the mechanism by which CDDO-Me induces apoptosis, particularly in human lung cancer cells, we previously demonstrated that CDDO-Me induces apoptosis involving c-Jun N-terminal kinase (JNK)-dependent upregulation of death receptor 5 (DR5) expression.	bardoxolone methyl	50-57	TNF receptor superfamily member 10b	Homo sapiens	260-263
18253090-3	2007	In an effort to understand the mechanism by which CDDO-Me induces apoptosis, particularly in human lung cancer cells, we previously demonstrated that CDDO-Me induces apoptosis involving c-Jun N-terminal kinase (JNK)-dependent upregulation of death receptor 5 (DR5) expression.	bardoxolone methyl	150-157	mitogen-activated protein kinase 8	Homo sapiens	186-209
18253090-3	2007	In an effort to understand the mechanism by which CDDO-Me induces apoptosis, particularly in human lung cancer cells, we previously demonstrated that CDDO-Me induces apoptosis involving c-Jun N-terminal kinase (JNK)-dependent upregulation of death receptor 5 (DR5) expression.	bardoxolone methyl	150-157	mitogen-activated protein kinase 8	Homo sapiens	211-214
18253090-3	2007	In an effort to understand the mechanism by which CDDO-Me induces apoptosis, particularly in human lung cancer cells, we previously demonstrated that CDDO-Me induces apoptosis involving c-Jun N-terminal kinase (JNK)-dependent upregulation of death receptor 5 (DR5) expression.	bardoxolone methyl	150-157	TNF receptor superfamily member 10b	Homo sapiens	242-258
18253090-3	2007	In an effort to understand the mechanism by which CDDO-Me induces apoptosis, particularly in human lung cancer cells, we previously demonstrated that CDDO-Me induces apoptosis involving c-Jun N-terminal kinase (JNK)-dependent upregulation of death receptor 5 (DR5) expression.	bardoxolone methyl	150-157	TNF receptor superfamily member 10b	Homo sapiens	260-263
18253090-4	2007	In the current work, we determined the modulatory effects of CDDO-Me on the levels of c-FLIP, a major inhibitor of death receptor-mediated caspase-8 activation, and its impact on CDDO-Me-induced apoptosis and enhancement of TRAIL-induced apoptosis in human lung cancer cells.	bardoxolone methyl	61-68	CASP8 and FADD like apoptosis regulator	Homo sapiens	86-92
18253090-4	2007	In the current work, we determined the modulatory effects of CDDO-Me on the levels of c-FLIP, a major inhibitor of death receptor-mediated caspase-8 activation, and its impact on CDDO-Me-induced apoptosis and enhancement of TRAIL-induced apoptosis in human lung cancer cells.	bardoxolone methyl	61-68	caspase 8	Homo sapiens	139-148
18253090-4	2007	In the current work, we determined the modulatory effects of CDDO-Me on the levels of c-FLIP, a major inhibitor of death receptor-mediated caspase-8 activation, and its impact on CDDO-Me-induced apoptosis and enhancement of TRAIL-induced apoptosis in human lung cancer cells.	bardoxolone methyl	61-68	TNF superfamily member 10	Homo sapiens	224-229
18253090-4	2007	In the current work, we determined the modulatory effects of CDDO-Me on the levels of c-FLIP, a major inhibitor of death receptor-mediated caspase-8 activation, and its impact on CDDO-Me-induced apoptosis and enhancement of TRAIL-induced apoptosis in human lung cancer cells.	bardoxolone methyl	179-186	TNF superfamily member 10	Homo sapiens	224-229
18253090-5	2007	CDDO-Me rapidly and potently decreased c-FLIP levels including both long (FLIP(L)) and short (FLIP(S)) forms of c-FLIP in multiple human lung cancer cell lines.	bardoxolone methyl	0-7	CASP8 and FADD like apoptosis regulator	Homo sapiens	39-45
18253090-5	2007	CDDO-Me rapidly and potently decreased c-FLIP levels including both long (FLIP(L)) and short (FLIP(S)) forms of c-FLIP in multiple human lung cancer cell lines.	bardoxolone methyl	0-7	CASP8 and FADD like apoptosis regulator	Homo sapiens	112-118
18253090-7	2007	Moreover, CDDO-Me increased ubiquitination of c-FLIP.	bardoxolone methyl	10-17	CASP8 and FADD like apoptosis regulator	Homo sapiens	46-52
18253090-8	2007	Thus, CDDO-Me induces ubiquitin/proteasome-dependent c-FLIP degradation independently of JNK activation.	bardoxolone methyl	6-13	CASP8 and FADD like apoptosis regulator	Homo sapiens	53-59
18253090-9	2007	Importantly, overexpression of c-FLIP (e.g., FLIP(L)) protected cells not only from CDDO-Me-induced apoptosis, but also from induction of apoptosis by the combination of CDDO-Me and TRAIL.	bardoxolone methyl	84-91	CASP8 and FADD like apoptosis regulator	Homo sapiens	31-37
18253090-9	2007	Importantly, overexpression of c-FLIP (e.g., FLIP(L)) protected cells not only from CDDO-Me-induced apoptosis, but also from induction of apoptosis by the combination of CDDO-Me and TRAIL.	bardoxolone methyl	170-177	CASP8 and FADD like apoptosis regulator	Homo sapiens	31-37
18253090-10	2007	Accordingly, silencing of c-FLIP with c-FLIP siRNA sensitized cancer cells to CDDO-Me.	bardoxolone methyl	78-85	CASP8 and FADD like apoptosis regulator	Homo sapiens	26-32
18253090-10	2007	Accordingly, silencing of c-FLIP with c-FLIP siRNA sensitized cancer cells to CDDO-Me.	bardoxolone methyl	78-85	CASP8 and FADD like apoptosis regulator	Homo sapiens	38-44
18253090-11	2007	Collectively, these results indicate that c-FLIP downregulation contributes to CDDO-Me-initiated apoptosis and also to enhancement of TRAIL-induced apoptosis by CDDO-Me.	bardoxolone methyl	79-86	CASP8 and FADD like apoptosis regulator	Homo sapiens	42-48
18253090-11	2007	Collectively, these results indicate that c-FLIP downregulation contributes to CDDO-Me-initiated apoptosis and also to enhancement of TRAIL-induced apoptosis by CDDO-Me.	bardoxolone methyl	161-168	CASP8 and FADD like apoptosis regulator	Homo sapiens	42-48
18253090-11	2007	Collectively, these results indicate that c-FLIP downregulation contributes to CDDO-Me-initiated apoptosis and also to enhancement of TRAIL-induced apoptosis by CDDO-Me.	bardoxolone methyl	161-168	TNF superfamily member 10	Homo sapiens	134-139
16998237-0	2006	Triterpenoid CDDO-Me blocks the NF-kappaB pathway by direct inhibition of IKKbeta on Cys-179.	bardoxolone methyl	13-20	inhibitor of nuclear factor kappa B kinase subunit beta	Homo sapiens	74-81
17970042-0	2007	CDDO-me induces apoptosis and inhibits Akt, mTOR and NF-kappaB signaling proteins in prostate cancer cells.	bardoxolone methyl	0-7	AKT serine/threonine kinase 1	Homo sapiens	39-42
17970042-0	2007	CDDO-me induces apoptosis and inhibits Akt, mTOR and NF-kappaB signaling proteins in prostate cancer cells.	bardoxolone methyl	0-7	mechanistic target of rapamycin kinase	Homo sapiens	44-48
17970042-0	2007	CDDO-me induces apoptosis and inhibits Akt, mTOR and NF-kappaB signaling proteins in prostate cancer cells.	bardoxolone methyl	0-7	nuclear factor kappa B subunit 1	Homo sapiens	53-62
17970042-6	2007	Furthermore, CDDO-Me inhibited the levels of anti-apoptotic Akt, mTOR and NF-kappaB (p65) signaling molecules.	bardoxolone methyl	13-20	AKT serine/threonine kinase 1	Homo sapiens	60-63
17970042-6	2007	Furthermore, CDDO-Me inhibited the levels of anti-apoptotic Akt, mTOR and NF-kappaB (p65) signaling molecules.	bardoxolone methyl	13-20	mechanistic target of rapamycin kinase	Homo sapiens	65-69
17970042-6	2007	Furthermore, CDDO-Me inhibited the levels of anti-apoptotic Akt, mTOR and NF-kappaB (p65) signaling molecules.	bardoxolone methyl	13-20	nuclear factor kappa B subunit 1	Homo sapiens	74-83
17970042-6	2007	Furthermore, CDDO-Me inhibited the levels of anti-apoptotic Akt, mTOR and NF-kappaB (p65) signaling molecules.	bardoxolone methyl	13-20	RELA proto-oncogene, NF-kB subunit	Homo sapiens	85-88
17483332-7	2007	In vitro, after treatment of 4T1 cells with 500 nmol/L CDDO-Me for 2 h, we found (a) inactivation of STAT3, (b) inactivation of Src and Akt, (c) 4-fold reduction of c-Myc mRNA levels, (d) accumulation of cells in G(2)-M cell cycle phase, (e) abrogation of invasive growth of 4T1 cells, and (f) lack of apoptosis induction.	bardoxolone methyl	55-62	signal transducer and activator of transcription 3	Mus musculus	101-106
17483332-7	2007	In vitro, after treatment of 4T1 cells with 500 nmol/L CDDO-Me for 2 h, we found (a) inactivation of STAT3, (b) inactivation of Src and Akt, (c) 4-fold reduction of c-Myc mRNA levels, (d) accumulation of cells in G(2)-M cell cycle phase, (e) abrogation of invasive growth of 4T1 cells, and (f) lack of apoptosis induction.	bardoxolone methyl	55-62	Rous sarcoma oncogene	Mus musculus	128-131
17483332-7	2007	In vitro, after treatment of 4T1 cells with 500 nmol/L CDDO-Me for 2 h, we found (a) inactivation of STAT3, (b) inactivation of Src and Akt, (c) 4-fold reduction of c-Myc mRNA levels, (d) accumulation of cells in G(2)-M cell cycle phase, (e) abrogation of invasive growth of 4T1 cells, and (f) lack of apoptosis induction.	bardoxolone methyl	55-62	thymoma viral proto-oncogene 1	Mus musculus	136-139
17483332-10	2007	In summary, these data suggest that CDDO-Me may have therapeutic potential in breast cancer therapy, in part, through inactivation of STAT3.	bardoxolone methyl	36-43	signal transducer and activator of transcription 3	Mus musculus	134-139
17361329-10	2007	Furthermore, CDDO-Me inhibited the levels of anti-apoptotic and prosurvival p-Akt, NF-kappaB (p65) and Notch1 signaling molecules.	bardoxolone methyl	13-20	AKT serine/threonine kinase 1	Homo sapiens	78-81
17361329-10	2007	Furthermore, CDDO-Me inhibited the levels of anti-apoptotic and prosurvival p-Akt, NF-kappaB (p65) and Notch1 signaling molecules.	bardoxolone methyl	13-20	RELA proto-oncogene, NF-kB subunit	Homo sapiens	94-97
17361329-10	2007	Furthermore, CDDO-Me inhibited the levels of anti-apoptotic and prosurvival p-Akt, NF-kappaB (p65) and Notch1 signaling molecules.	bardoxolone methyl	13-20	notch receptor 1	Homo sapiens	103-109
16998237-2	2006	The present studies show that CDDO and CDDO-Me block tumor necrosis factoralpha-induced targeting of NF-kappaB p65 to the nucleus.	bardoxolone methyl	39-46	RELA proto-oncogene, NF-kB subunit	Homo sapiens	111-114
16998237-3	2006	CDDO-Me also blocked tumor necrosis factor alpha-induced phosphorylation of IkappaBalpha.	bardoxolone methyl	0-7	tumor necrosis factor	Homo sapiens	21-48
16998237-3	2006	CDDO-Me also blocked tumor necrosis factor alpha-induced phosphorylation of IkappaBalpha.	bardoxolone methyl	0-7	NFKB inhibitor alpha	Homo sapiens	76-88
16998237-4	2006	In concert with these results, we found that CDDO-Me inhibits IkappaBalpha kinasebeta (IKKbeta) activity in cells.	bardoxolone methyl	45-52	NFKB inhibitor alpha	Homo sapiens	62-74
16998237-4	2006	In concert with these results, we found that CDDO-Me inhibits IkappaBalpha kinasebeta (IKKbeta) activity in cells.	bardoxolone methyl	45-52	inhibitor of nuclear factor kappa B kinase subunit beta	Homo sapiens	87-94
16998237-5	2006	In support of a direct mechanism, CDDO-Me inhibited recombinant IKKbeta activity in vitro.	bardoxolone methyl	34-41	inhibitor of nuclear factor kappa B kinase subunit beta	Homo sapiens	64-71
16998237-6	2006	The results also demonstrate that (i) CDDO and CDDO-Me form adducts with IKKbeta, but not IKKbeta with mutation of Cys-179 to Ala, and (ii) CDDO-Me inhibits IKKbeta by a mechanism dependent on oxidation of Cys-179.	bardoxolone methyl	47-54	inhibitor of nuclear factor kappa B kinase subunit beta	Homo sapiens	73-80
16998237-7	2006	These findings indicate that CDDO and CDDO-Me directly block IKKbeta activity and thereby the NF-kappaB pathway by interacting with Cys-179 in the IKKbeta activation loop.	bardoxolone methyl	38-45	inhibitor of nuclear factor kappa B kinase subunit beta	Homo sapiens	61-68
16998237-7	2006	These findings indicate that CDDO and CDDO-Me directly block IKKbeta activity and thereby the NF-kappaB pathway by interacting with Cys-179 in the IKKbeta activation loop.	bardoxolone methyl	38-45	inhibitor of nuclear factor kappa B kinase subunit beta	Homo sapiens	147-154
16582599-0	2006	Depletion of intracellular glutathione contributes to JNK-mediated death receptor 5 upregulation and apoptosis induction by the novel synthetic triterpenoid methyl-2-cyano-3, 12-dioxooleana-1, 9-dien-28-oate (CDDO-Me).	bardoxolone methyl	209-216	mitogen-activated protein kinase 8	Homo sapiens	54-57
16582599-5	2006	Thiol antioxidants, including N-acetyl-L-cycteine (NAC), glutathione (GSH) and dithiothrietol (DTT), abrogated CDDO-Me-induced apoptosis.	bardoxolone methyl	111-118	X-linked Kx blood group	Homo sapiens	30-49
16582599-2	2006	We previously demonstrated that CDDO-Me induces a c-Jun N-terminal kinase (JNK)-mediated DR5 expression and apoptosis.	bardoxolone methyl	32-39	mitogen-activated protein kinase 8	Homo sapiens	50-73
16582599-5	2006	Thiol antioxidants, including N-acetyl-L-cycteine (NAC), glutathione (GSH) and dithiothrietol (DTT), abrogated CDDO-Me-induced apoptosis.	bardoxolone methyl	111-118	X-linked Kx blood group	Homo sapiens	51-54
16582599-2	2006	We previously demonstrated that CDDO-Me induces a c-Jun N-terminal kinase (JNK)-mediated DR5 expression and apoptosis.	bardoxolone methyl	32-39	mitogen-activated protein kinase 8	Homo sapiens	75-78
16582599-2	2006	We previously demonstrated that CDDO-Me induces a c-Jun N-terminal kinase (JNK)-mediated DR5 expression and apoptosis.	bardoxolone methyl	32-39	TNF receptor superfamily member 10b	Homo sapiens	89-92
16582599-7	2006	Accordingly, only thiol antioxidants blocked JNK activation induced by CDDO-Me.	bardoxolone methyl	71-78	mitogen-activated protein kinase 8	Homo sapiens	45-48
16582599-3	2006	This study revealed the mechanism by which CDDO-Me induces JNK activation and subsequent DR5 upregulation and apoptosis.	bardoxolone methyl	43-50	mitogen-activated protein kinase 8	Homo sapiens	59-62
16582599-10	2006	These results suggest that depletion of intracellular GSH, but not ROS generation, contributes to CDDO-Me-induced JNK activation and apoptosis, at least in our systems.	bardoxolone methyl	98-105	mitogen-activated protein kinase 8	Homo sapiens	114-117
16582599-3	2006	This study revealed the mechanism by which CDDO-Me induces JNK activation and subsequent DR5 upregulation and apoptosis.	bardoxolone methyl	43-50	TNF receptor superfamily member 10b	Homo sapiens	89-92
16582599-4	2006	To determine whether CDDO-Me activates JNK and induces DR5 expression and apoptosis via oxidative stress by inducing the generation of reactive oxygen species (ROS), we examined the effects of various antioxidants on JNK activation, DR5 upregulation, and apoptosis induction by CDDO-Me.	bardoxolone methyl	21-28	mitogen-activated protein kinase 8	Homo sapiens	39-42
16582599-4	2006	To determine whether CDDO-Me activates JNK and induces DR5 expression and apoptosis via oxidative stress by inducing the generation of reactive oxygen species (ROS), we examined the effects of various antioxidants on JNK activation, DR5 upregulation, and apoptosis induction by CDDO-Me.	bardoxolone methyl	21-28	TNF receptor superfamily member 10b	Homo sapiens	55-58
16551868-0	2006	A synthetic triterpenoid, CDDO-Me, inhibits IkappaBalpha kinase and enhances apoptosis induced by TNF and chemotherapeutic agents through down-regulation of expression of nuclear factor kappaB-regulated gene products in human leukemic cells.	bardoxolone methyl	26-33	NFKB inhibitor alpha	Homo sapiens	44-56
16582599-11	2006	Furthermore, these thiol antioxidants abrogated CDDO-Me-induced DR5 expression, whereas the GSH-depleting agent diethylmaleate also upregulated DR5 expression at concentrations that deplete intracellular GSH, demonstrating that GSH depletion can cause DR5 upregulation.	bardoxolone methyl	48-55	TNF receptor superfamily member 10b	Homo sapiens	64-67
16582599-12	2006	Collectively, we conclude that CDDO-Me activates the JNK pathway via depletion of intracellular GSH, leading to DR5 upregulation and induction of apoptosis.	bardoxolone methyl	31-38	mitogen-activated protein kinase 8	Homo sapiens	53-56
16582599-12	2006	Collectively, we conclude that CDDO-Me activates the JNK pathway via depletion of intracellular GSH, leading to DR5 upregulation and induction of apoptosis.	bardoxolone methyl	31-38	TNF receptor superfamily member 10b	Homo sapiens	112-115
16410408-7	2006	Finally, transmission electron microscopy revealed that CDDO-Me rapidly induced caspase-independent mitochondrial swelling and loss of inner membrane structure before the release of cytochrome c.	bardoxolone methyl	56-63	cytochrome c, somatic	Homo sapiens	182-194
16551868-0	2006	A synthetic triterpenoid, CDDO-Me, inhibits IkappaBalpha kinase and enhances apoptosis induced by TNF and chemotherapeutic agents through down-regulation of expression of nuclear factor kappaB-regulated gene products in human leukemic cells.	bardoxolone methyl	26-33	tumor necrosis factor	Homo sapiens	98-101
16551868-2	2006	Because the nuclear transcription factor nuclear factor kappaB (NF-kappaB) has been shown to suppress apoptosis and promote proliferation and is linked with inflammation and differentiation, we postulated that CDDO-Me modulates NF-kappaB activity and NF-kappaB-regulated gene expression.	bardoxolone methyl	210-217	nuclear factor kappa B subunit 1	Homo sapiens	64-73
16551868-2	2006	Because the nuclear transcription factor nuclear factor kappaB (NF-kappaB) has been shown to suppress apoptosis and promote proliferation and is linked with inflammation and differentiation, we postulated that CDDO-Me modulates NF-kappaB activity and NF-kappaB-regulated gene expression.	bardoxolone methyl	210-217	nuclear factor kappa B subunit 1	Homo sapiens	228-237
16551868-2	2006	Because the nuclear transcription factor nuclear factor kappaB (NF-kappaB) has been shown to suppress apoptosis and promote proliferation and is linked with inflammation and differentiation, we postulated that CDDO-Me modulates NF-kappaB activity and NF-kappaB-regulated gene expression.	bardoxolone methyl	210-217	nuclear factor kappa B subunit 1	Homo sapiens	228-237
16551868-3	2006	Using human leukemia cell lines and patient samples, we show that CDDO-Me potently inhibits both constitutive and inducible NF-kappaB activated by tumor necrosis factor (TNF), interleukin (IL)-1beta, phorbol ester, okadaic acid, hydrogen peroxide, lipopolysaccharide, and cigarette smoke.	bardoxolone methyl	66-73	nuclear factor kappa B subunit 1	Homo sapiens	124-133
16551868-3	2006	Using human leukemia cell lines and patient samples, we show that CDDO-Me potently inhibits both constitutive and inducible NF-kappaB activated by tumor necrosis factor (TNF), interleukin (IL)-1beta, phorbol ester, okadaic acid, hydrogen peroxide, lipopolysaccharide, and cigarette smoke.	bardoxolone methyl	66-73	tumor necrosis factor	Homo sapiens	147-168
16551868-3	2006	Using human leukemia cell lines and patient samples, we show that CDDO-Me potently inhibits both constitutive and inducible NF-kappaB activated by tumor necrosis factor (TNF), interleukin (IL)-1beta, phorbol ester, okadaic acid, hydrogen peroxide, lipopolysaccharide, and cigarette smoke.	bardoxolone methyl	66-73	tumor necrosis factor	Homo sapiens	170-173
16551868-3	2006	Using human leukemia cell lines and patient samples, we show that CDDO-Me potently inhibits both constitutive and inducible NF-kappaB activated by tumor necrosis factor (TNF), interleukin (IL)-1beta, phorbol ester, okadaic acid, hydrogen peroxide, lipopolysaccharide, and cigarette smoke.	bardoxolone methyl	66-73	interleukin 1 beta	Homo sapiens	176-198
16551868-7	2006	CDDO-Me also potentiated the cytotoxic effects of TNF and chemotherapeutic agents.	bardoxolone methyl	0-7	tumor necrosis factor	Homo sapiens	50-53
16551868-8	2006	Overall, our results suggest that CDDO-Me inhibits NF-kappaB through inhibition of IkappaBalpha kinase, leading to the suppression of expression of NF-kappaB-regulated gene products and enhancement of apoptosis induced by TNF and chemotherapeutic agents.	bardoxolone methyl	34-41	nuclear factor kappa B subunit 1	Homo sapiens	51-60
16551868-8	2006	Overall, our results suggest that CDDO-Me inhibits NF-kappaB through inhibition of IkappaBalpha kinase, leading to the suppression of expression of NF-kappaB-regulated gene products and enhancement of apoptosis induced by TNF and chemotherapeutic agents.	bardoxolone methyl	34-41	NFKB inhibitor alpha	Homo sapiens	83-95
16551868-8	2006	Overall, our results suggest that CDDO-Me inhibits NF-kappaB through inhibition of IkappaBalpha kinase, leading to the suppression of expression of NF-kappaB-regulated gene products and enhancement of apoptosis induced by TNF and chemotherapeutic agents.	bardoxolone methyl	34-41	nuclear factor kappa B subunit 1	Homo sapiens	148-157
16551868-8	2006	Overall, our results suggest that CDDO-Me inhibits NF-kappaB through inhibition of IkappaBalpha kinase, leading to the suppression of expression of NF-kappaB-regulated gene products and enhancement of apoptosis induced by TNF and chemotherapeutic agents.	bardoxolone methyl	34-41	tumor necrosis factor	Homo sapiens	222-225
12467212-11	2002	In addition, no correlation was found between cell sensitivity to CDDO-Me and p53 status, suggesting that CDDO-Me induce a p53-independent apoptosis.	bardoxolone methyl	106-113	tumor protein p53	Homo sapiens	123-126
15931262-0	2005	The novel triterpenoid CDDO-Me suppresses MAPK pathways and promotes p38 activation in acute myeloid leukemia cells.	bardoxolone methyl	23-30	mitogen-activated protein kinase 3	Homo sapiens	42-46
15931262-0	2005	The novel triterpenoid CDDO-Me suppresses MAPK pathways and promotes p38 activation in acute myeloid leukemia cells.	bardoxolone methyl	23-30	mitogen-activated protein kinase 1	Homo sapiens	69-72
15931262-3	2005	In this report, the effects of CDDO-Me on CD34(+) AML progenitor cells in vitro were examined.	bardoxolone methyl	31-38	CD34 molecule	Homo sapiens	42-46
15931262-5	2005	CDDO-Me is known to inhibit the activation of ERK1/2.	bardoxolone methyl	0-7	mitogen-activated protein kinase 3	Homo sapiens	46-52
15931262-6	2005	In this series of primary AML samples, ERK was expressed and phosphorylated in all patient samples studied and CDDO-Me inhibited ERK phosphorylation in five of 10 samples.	bardoxolone methyl	111-118	mitogen-activated protein kinase 1	Homo sapiens	129-132
15931262-8	2005	CDDO-Me induced phosphorylation of p38 in AML-derived U937 cells.	bardoxolone methyl	0-7	mitogen-activated protein kinase 1	Homo sapiens	35-38
15931262-9	2005	Pretreatment of U937 cells with a p38 inhibitor protected cells from the cyto-toxic effects of CDDO-Me.	bardoxolone methyl	95-102	mitogen-activated protein kinase 1	Homo sapiens	34-37
15931262-10	2005	These findings suggest a role for p38 in CDDO-Me-induced apoptosis.	bardoxolone methyl	41-48	mitogen-activated protein kinase 1	Homo sapiens	34-37
15931262-11	2005	In preliminary studies, CDDO-Me induced p38 phosphorylation in seven of eight primary AML samples.	bardoxolone methyl	24-31	mitogen-activated protein kinase 1	Homo sapiens	40-43
15798084-1	2005	2-Cyano-3,12-dioxoolean-1,9-dien-28-oic acid (CDDO) and the corresponding methyl (CDDO-Me) and imidazole (CDDO-Im) esters induce peroxisome proliferator-activated receptor gamma (PPARgamma)-dependent transactivation in SW-480 colon cancer cells, and these responses were inhibited by small inhibitory RNA for PPARgamma.	bardoxolone methyl	82-89	peroxisome proliferator activated receptor gamma	Homo sapiens	129-177
15798084-1	2005	2-Cyano-3,12-dioxoolean-1,9-dien-28-oic acid (CDDO) and the corresponding methyl (CDDO-Me) and imidazole (CDDO-Im) esters induce peroxisome proliferator-activated receptor gamma (PPARgamma)-dependent transactivation in SW-480 colon cancer cells, and these responses were inhibited by small inhibitory RNA for PPARgamma.	bardoxolone methyl	82-89	peroxisome proliferator activated receptor gamma	Homo sapiens	179-188
15798084-1	2005	2-Cyano-3,12-dioxoolean-1,9-dien-28-oic acid (CDDO) and the corresponding methyl (CDDO-Me) and imidazole (CDDO-Im) esters induce peroxisome proliferator-activated receptor gamma (PPARgamma)-dependent transactivation in SW-480 colon cancer cells, and these responses were inhibited by small inhibitory RNA for PPARgamma.	bardoxolone methyl	82-89	peroxisome proliferator activated receptor gamma	Homo sapiens	309-318
15798084-6	2005	Induction of caveolin-1 by CDDO, CDDO-Me, and CDDO-Im was inhibited by the PPARgamma antagonist N-(4"-aminopyridyl-2-chloro-5-nitrobenzamide (T007), whereas higher doses induced apoptosis [poly(ADP-ribose) polymerase cleavage], which was not inhibited by T007.	bardoxolone methyl	33-40	caveolin 1	Homo sapiens	13-23
15798084-6	2005	Induction of caveolin-1 by CDDO, CDDO-Me, and CDDO-Im was inhibited by the PPARgamma antagonist N-(4"-aminopyridyl-2-chloro-5-nitrobenzamide (T007), whereas higher doses induced apoptosis [poly(ADP-ribose) polymerase cleavage], which was not inhibited by T007.	bardoxolone methyl	33-40	peroxisome proliferator activated receptor gamma	Homo sapiens	75-84
15798084-7	2005	These results illustrate that CDDO-, CDDO-Me, and CDDO-Im induce both PPARgamma-dependent and -independent responses in colon cancer cells, and activation of these pathways are separable and concentration-dependent for all three compounds.	bardoxolone methyl	37-44	peroxisome proliferator activated receptor gamma	Homo sapiens	70-79
15492284-8	2004	Moreover, application of the JNK-specific inhibitor SP600125 blocked CDDO-Me-induced increases in JNK activation, DR up-regulation, caspase-8 activation, and DNA fragmentation.	bardoxolone methyl	69-76	caspase 8	Homo sapiens	132-141
15492284-9	2004	These results show that activation of JNK pathway results in CDDO-Me-induced DR up-regulation, caspase-8 activation, and apoptosis.	bardoxolone methyl	61-68	mitogen-activated protein kinase 8	Homo sapiens	38-41
15492284-10	2004	Collectively, we conclude that CDDO-Me induces apoptosis via the JNK-mediated DR up-regulation in human lung cancer cells.	bardoxolone methyl	31-38	mitogen-activated protein kinase 8	Homo sapiens	65-68
15492284-4	2004	We found that CDDO-Me not only activated caspase-8 but also induced expression of DRs, particularly DR5, in a p53-independent mechanism.	bardoxolone methyl	14-21	caspase 8	Homo sapiens	41-50
15492284-4	2004	We found that CDDO-Me not only activated caspase-8 but also induced expression of DRs, particularly DR5, in a p53-independent mechanism.	bardoxolone methyl	14-21	TNF receptor superfamily member 10b	Homo sapiens	100-103
15492284-4	2004	We found that CDDO-Me not only activated caspase-8 but also induced expression of DRs, particularly DR5, in a p53-independent mechanism.	bardoxolone methyl	14-21	tumor protein p53	Homo sapiens	110-113
15492284-5	2004	Correspondingly, CDDO-Me augmented TRAIL-induced apoptosis in these cells regardless of p53 status as evidenced by enhanced DNA fragmentation and activation of caspase cascades, suggesting that CDDO-Me-induced DRs are functionally active.	bardoxolone methyl	17-24	TNF superfamily member 10	Homo sapiens	35-40
15492284-5	2004	Correspondingly, CDDO-Me augmented TRAIL-induced apoptosis in these cells regardless of p53 status as evidenced by enhanced DNA fragmentation and activation of caspase cascades, suggesting that CDDO-Me-induced DRs are functionally active.	bardoxolone methyl	194-201	TNF superfamily member 10	Homo sapiens	35-40
15492284-6	2004	Moreover, silencing of DR5 expression using small interfering RNA suppressed apoptosis induced by CDDO-Me alone or by combination of CDDO-Me and TRAIL, indicating that DR5 up-regulation is required for induction of apoptosis by CDDO-Me and for enhancement of TRAIL-induced apoptosis by CDDO-Me.	bardoxolone methyl	98-105	TNF receptor superfamily member 10b	Homo sapiens	23-26
15492284-6	2004	Moreover, silencing of DR5 expression using small interfering RNA suppressed apoptosis induced by CDDO-Me alone or by combination of CDDO-Me and TRAIL, indicating that DR5 up-regulation is required for induction of apoptosis by CDDO-Me and for enhancement of TRAIL-induced apoptosis by CDDO-Me.	bardoxolone methyl	98-105	TNF superfamily member 10	Homo sapiens	145-150
15492284-6	2004	Moreover, silencing of DR5 expression using small interfering RNA suppressed apoptosis induced by CDDO-Me alone or by combination of CDDO-Me and TRAIL, indicating that DR5 up-regulation is required for induction of apoptosis by CDDO-Me and for enhancement of TRAIL-induced apoptosis by CDDO-Me.	bardoxolone methyl	98-105	TNF superfamily member 10	Homo sapiens	259-264
15492284-6	2004	Moreover, silencing of DR5 expression using small interfering RNA suppressed apoptosis induced by CDDO-Me alone or by combination of CDDO-Me and TRAIL, indicating that DR5 up-regulation is required for induction of apoptosis by CDDO-Me and for enhancement of TRAIL-induced apoptosis by CDDO-Me.	bardoxolone methyl	133-140	TNF receptor superfamily member 10b	Homo sapiens	23-26
15492284-6	2004	Moreover, silencing of DR5 expression using small interfering RNA suppressed apoptosis induced by CDDO-Me alone or by combination of CDDO-Me and TRAIL, indicating that DR5 up-regulation is required for induction of apoptosis by CDDO-Me and for enhancement of TRAIL-induced apoptosis by CDDO-Me.	bardoxolone methyl	133-140	TNF superfamily member 10	Homo sapiens	259-264
15492284-6	2004	Moreover, silencing of DR5 expression using small interfering RNA suppressed apoptosis induced by CDDO-Me alone or by combination of CDDO-Me and TRAIL, indicating that DR5 up-regulation is required for induction of apoptosis by CDDO-Me and for enhancement of TRAIL-induced apoptosis by CDDO-Me.	bardoxolone methyl	133-140	TNF receptor superfamily member 10b	Homo sapiens	23-26
15492284-6	2004	Moreover, silencing of DR5 expression using small interfering RNA suppressed apoptosis induced by CDDO-Me alone or by combination of CDDO-Me and TRAIL, indicating that DR5 up-regulation is required for induction of apoptosis by CDDO-Me and for enhancement of TRAIL-induced apoptosis by CDDO-Me.	bardoxolone methyl	133-140	TNF superfamily member 10	Homo sapiens	259-264
15492284-6	2004	Moreover, silencing of DR5 expression using small interfering RNA suppressed apoptosis induced by CDDO-Me alone or by combination of CDDO-Me and TRAIL, indicating that DR5 up-regulation is required for induction of apoptosis by CDDO-Me and for enhancement of TRAIL-induced apoptosis by CDDO-Me.	bardoxolone methyl	133-140	TNF receptor superfamily member 10b	Homo sapiens	23-26
15492284-6	2004	Moreover, silencing of DR5 expression using small interfering RNA suppressed apoptosis induced by CDDO-Me alone or by combination of CDDO-Me and TRAIL, indicating that DR5 up-regulation is required for induction of apoptosis by CDDO-Me and for enhancement of TRAIL-induced apoptosis by CDDO-Me.	bardoxolone methyl	133-140	TNF superfamily member 10	Homo sapiens	259-264
15492284-7	2004	CDDO-Me rapidly activated c-Jun NH(2)-terminal kinase (JNK) before DR up-regulation and caspase-8 activation.	bardoxolone methyl	0-7	mitogen-activated protein kinase 8	Homo sapiens	55-58
15492284-7	2004	CDDO-Me rapidly activated c-Jun NH(2)-terminal kinase (JNK) before DR up-regulation and caspase-8 activation.	bardoxolone methyl	0-7	caspase 8	Homo sapiens	88-97
15492284-8	2004	Moreover, application of the JNK-specific inhibitor SP600125 blocked CDDO-Me-induced increases in JNK activation, DR up-regulation, caspase-8 activation, and DNA fragmentation.	bardoxolone methyl	69-76	mitogen-activated protein kinase 8	Homo sapiens	29-32
15492284-8	2004	Moreover, application of the JNK-specific inhibitor SP600125 blocked CDDO-Me-induced increases in JNK activation, DR up-regulation, caspase-8 activation, and DNA fragmentation.	bardoxolone methyl	69-76	mitogen-activated protein kinase 8	Homo sapiens	98-101
11756188-3	2002	CDDO-Me decreased the viability of leukemic cell lines, including multidrug resistant (MDR)-1-overexpressing, p53(null) HL-60-Dox and of primary AML cells, and it was 3- to 5-fold more active than CDDO.	bardoxolone methyl	0-7	tumor protein p53	Homo sapiens	110-113
11756188-4	2002	CDDO-Me induced a loss of mitochondrial membrane potential, induction of caspase-3 cleavage, increase in annexin V binding and DNA fragmentation, suggesting the induction of apoptosis.	bardoxolone methyl	0-7	caspase 3	Homo sapiens	73-82
11756188-4	2002	CDDO-Me induced a loss of mitochondrial membrane potential, induction of caspase-3 cleavage, increase in annexin V binding and DNA fragmentation, suggesting the induction of apoptosis.	bardoxolone methyl	0-7	annexin A5	Homo sapiens	105-114
11756188-5	2002	CDDO-Me induced pro-apoptotic Bax protein that preceded caspase activation.	bardoxolone methyl	0-7	BCL2 associated X, apoptosis regulator	Homo sapiens	30-33
11756188-6	2002	Furthermore, CDDO-Me inhibited the activation of ERK1/2, as determined by the inhibition of mitochondrial ERK1/2 phosphorylation, and it blocked Bcl-2 phosphorylation, rendering Bcl-2 less anti-apoptotic.	bardoxolone methyl	13-20	mitogen-activated protein kinase 3	Homo sapiens	49-55
11756188-6	2002	Furthermore, CDDO-Me inhibited the activation of ERK1/2, as determined by the inhibition of mitochondrial ERK1/2 phosphorylation, and it blocked Bcl-2 phosphorylation, rendering Bcl-2 less anti-apoptotic.	bardoxolone methyl	13-20	mitogen-activated protein kinase 3	Homo sapiens	106-112
11756188-6	2002	Furthermore, CDDO-Me inhibited the activation of ERK1/2, as determined by the inhibition of mitochondrial ERK1/2 phosphorylation, and it blocked Bcl-2 phosphorylation, rendering Bcl-2 less anti-apoptotic.	bardoxolone methyl	13-20	BCL2 apoptosis regulator	Homo sapiens	145-150
11756188-6	2002	Furthermore, CDDO-Me inhibited the activation of ERK1/2, as determined by the inhibition of mitochondrial ERK1/2 phosphorylation, and it blocked Bcl-2 phosphorylation, rendering Bcl-2 less anti-apoptotic.	bardoxolone methyl	13-20	BCL2 apoptosis regulator	Homo sapiens	178-183
11756188-9	2002	Combinations with ATRA or the RXR-specific ligand LG100268 enhanced the effects of CDDO-Me on cell viability and terminal differentiation of myeloid leukemic cell lines.	bardoxolone methyl	83-90	retinoid X receptor alpha	Homo sapiens	30-33
11756188-10	2002	In conclusion, CDDO-Me is an MDR-1- and a p53-independent compound that exerts strong antiproliferative, apoptotic, and differentiating effects in myeloid leukemic cell lines and in primary AML samples when given in submicromolar concentrations.	bardoxolone methyl	15-22	ATP binding cassette subfamily B member 1	Homo sapiens	29-34
11756188-10	2002	In conclusion, CDDO-Me is an MDR-1- and a p53-independent compound that exerts strong antiproliferative, apoptotic, and differentiating effects in myeloid leukemic cell lines and in primary AML samples when given in submicromolar concentrations.	bardoxolone methyl	15-22	tumor protein p53	Homo sapiens	42-45
12467212-7	2002	These results indicate that CDDO-Me induced apoptosis in human NSCLC cells via a cytochrome c-triggered caspase activation pathway.	bardoxolone methyl	28-35	cytochrome c, somatic	Homo sapiens	81-93
35512420-2	2022	Herein, we reported a novel strategy to prepare Cathepsin B (CTSB) cleavable and improved water-soluble prodrugs of CDDO-Me.	bardoxolone methyl	116-123	cathepsin B	Homo sapiens	48-59
11043571-4	2000	The methyl ester of CDDO, CDDO-Me, binds to PPARgamma with similar affinity, but is an antagonist.	bardoxolone methyl	26-33	peroxisome proliferator activated receptor gamma	Mus musculus	44-53
11043571-6	2000	The partial agonism of CDDO and the antagonism of CDDO-Me reflect the differences in their capacity to recruit or displace cofactors of transcriptional regulation; CDDO and rosiglitazone both release the nuclear receptor corepressor, NCoR, from PPARgamma, while CDDO-Me does not.	bardoxolone methyl	50-57	nuclear receptor co-repressor 1	Mus musculus	234-238
34573098-3	2021	Bardoxolone methyl (methyl 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oate; CDDO-Me; RTA 402) is a semisynthetic triterpenoid with effects against antioxidative stress and inflammation in neurodegeneration and kidney disease that activates the nuclear factor erythroid 2-related factor 2 (Nrf2) signaling pathway.	bardoxolone methyl	74-81	NFE2 like bZIP transcription factor 2	Homo sapiens	242-285
34573098-3	2021	Bardoxolone methyl (methyl 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oate; CDDO-Me; RTA 402) is a semisynthetic triterpenoid with effects against antioxidative stress and inflammation in neurodegeneration and kidney disease that activates the nuclear factor erythroid 2-related factor 2 (Nrf2) signaling pathway.	bardoxolone methyl	74-81	NFE2 like bZIP transcription factor 2	Homo sapiens	287-291
34573098-3	2021	Bardoxolone methyl (methyl 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oate; CDDO-Me; RTA 402) is a semisynthetic triterpenoid with effects against antioxidative stress and inflammation in neurodegeneration and kidney disease that activates the nuclear factor erythroid 2-related factor 2 (Nrf2) signaling pathway.	bardoxolone methyl	83-90	NFE2 like bZIP transcription factor 2	Homo sapiens	242-285
34573098-3	2021	Bardoxolone methyl (methyl 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oate; CDDO-Me; RTA 402) is a semisynthetic triterpenoid with effects against antioxidative stress and inflammation in neurodegeneration and kidney disease that activates the nuclear factor erythroid 2-related factor 2 (Nrf2) signaling pathway.	bardoxolone methyl	83-90	NFE2 like bZIP transcription factor 2	Homo sapiens	287-291
34573098-8	2021	Treatment with RTA402 results in antiapoptotic, antioxidative stress, anti-inflammatory, and myelin-preserving effects on retinal ganglion cell (RGC) survival and visual function via regulation of NQO1 and HO-1, reduced IL-6 and Iba1 expression in macrophages, and promoted microglial expression of TGF-beta and Ym1 + 2 in the retina and optic nerve.	bardoxolone methyl	15-21	NAD(P)H quinone dehydrogenase 1	Homo sapiens	197-201
34573098-8	2021	Treatment with RTA402 results in antiapoptotic, antioxidative stress, anti-inflammatory, and myelin-preserving effects on retinal ganglion cell (RGC) survival and visual function via regulation of NQO1 and HO-1, reduced IL-6 and Iba1 expression in macrophages, and promoted microglial expression of TGF-beta and Ym1 + 2 in the retina and optic nerve.	bardoxolone methyl	15-21	heme oxygenase 1	Homo sapiens	206-210
34573098-8	2021	Treatment with RTA402 results in antiapoptotic, antioxidative stress, anti-inflammatory, and myelin-preserving effects on retinal ganglion cell (RGC) survival and visual function via regulation of NQO1 and HO-1, reduced IL-6 and Iba1 expression in macrophages, and promoted microglial expression of TGF-beta and Ym1 + 2 in the retina and optic nerve.	bardoxolone methyl	15-21	interleukin 6	Homo sapiens	220-224
34573098-8	2021	Treatment with RTA402 results in antiapoptotic, antioxidative stress, anti-inflammatory, and myelin-preserving effects on retinal ganglion cell (RGC) survival and visual function via regulation of NQO1 and HO-1, reduced IL-6 and Iba1 expression in macrophages, and promoted microglial expression of TGF-beta and Ym1 + 2 in the retina and optic nerve.	bardoxolone methyl	15-21	allograft inflammatory factor 1	Homo sapiens	229-233
34573098-8	2021	Treatment with RTA402 results in antiapoptotic, antioxidative stress, anti-inflammatory, and myelin-preserving effects on retinal ganglion cell (RGC) survival and visual function via regulation of NQO1 and HO-1, reduced IL-6 and Iba1 expression in macrophages, and promoted microglial expression of TGF-beta and Ym1 + 2 in the retina and optic nerve.	bardoxolone methyl	15-21	transforming growth factor alpha	Homo sapiens	299-307
34573098-10	2021	Our results provide explicit evidence that RTA 402 modulates the Nrf2 and NFkappaB signaling pathways to protect RGCs from apoptosis and maintain the visual function in an rAION model.	bardoxolone methyl	43-50	NFE2 like bZIP transcription factor 2	Homo sapiens	65-69
34440619-4	2021	CDDO-Me (CDDO methyl ester, an Nrf2 inducer) administration attenuated PD-like neurodegeneration mainly through Nrf2 activation in astrocytes by activating the antioxidant signaling pathway and enhancing autophagy in the substantia nigra and striatum.	bardoxolone methyl	0-7	NFE2 like bZIP transcription factor 2	Rattus norvegicus	31-35
34440619-4	2021	CDDO-Me (CDDO methyl ester, an Nrf2 inducer) administration attenuated PD-like neurodegeneration mainly through Nrf2 activation in astrocytes by activating the antioxidant signaling pathway and enhancing autophagy in the substantia nigra and striatum.	bardoxolone methyl	0-7	NFE2 like bZIP transcription factor 2	Rattus norvegicus	112-116
34440619-4	2021	CDDO-Me (CDDO methyl ester, an Nrf2 inducer) administration attenuated PD-like neurodegeneration mainly through Nrf2 activation in astrocytes by activating the antioxidant signaling pathway and enhancing autophagy in the substantia nigra and striatum.	bardoxolone methyl	9-26	NFE2 like bZIP transcription factor 2	Rattus norvegicus	31-35
34440619-4	2021	CDDO-Me (CDDO methyl ester, an Nrf2 inducer) administration attenuated PD-like neurodegeneration mainly through Nrf2 activation in astrocytes by activating the antioxidant signaling pathway and enhancing autophagy in the substantia nigra and striatum.	bardoxolone methyl	9-26	NFE2 like bZIP transcription factor 2	Rattus norvegicus	112-116
34440619-10	2021	Treatment with CDDO-Me attenuated the Nrf2-knockdown-induced degeneration in the flies through the activation of the antioxidant signaling pathway and increased autophagy.	bardoxolone methyl	15-22	Keap1	Drosophila melanogaster	38-42
11043571-6	2000	The partial agonism of CDDO and the antagonism of CDDO-Me reflect the differences in their capacity to recruit or displace cofactors of transcriptional regulation; CDDO and rosiglitazone both release the nuclear receptor corepressor, NCoR, from PPARgamma, while CDDO-Me does not.	bardoxolone methyl	262-269	nuclear receptor co-repressor 1	Mus musculus	234-238
34480604-5	2021	Bardoxolone-methyl (CDDO-Me) induced oxidative stress caused similarly increased expression of both the wild-type and eGFP-tagged HMOX1 at the mRNA and protein level.	bardoxolone methyl	0-18	heme oxygenase 1	Homo sapiens	130-135
34480604-5	2021	Bardoxolone-methyl (CDDO-Me) induced oxidative stress caused similarly increased expression of both the wild-type and eGFP-tagged HMOX1 at the mRNA and protein level.	bardoxolone methyl	20-27	heme oxygenase 1	Homo sapiens	130-135
35512420-2	2022	Herein, we reported a novel strategy to prepare Cathepsin B (CTSB) cleavable and improved water-soluble prodrugs of CDDO-Me.	bardoxolone methyl	116-123	cathepsin B	Homo sapiens	61-65
35512420-3	2022	CTSB linkers connection to the highly active alpha-cyano-alpha, beta-unsaturated ketone (CUK) part of CDDO-Me with the incorporation of polyethylene glycol (PEG) moieties, provided a series of prodrugs of CDDO-Me without CUK part exposure.	bardoxolone methyl	102-109	cathepsin B	Homo sapiens	0-4
35512420-3	2022	CTSB linkers connection to the highly active alpha-cyano-alpha, beta-unsaturated ketone (CUK) part of CDDO-Me with the incorporation of polyethylene glycol (PEG) moieties, provided a series of prodrugs of CDDO-Me without CUK part exposure.	bardoxolone methyl	205-212	cathepsin B	Homo sapiens	0-4
35512420-4	2022	Theoretically, these prodrugs shielding CUK part can be stably circulated and finally cleaved by CTSB in lysosomes to release CDDO-Me.	bardoxolone methyl	126-133	cathepsin B	Homo sapiens	97-101
35512420-7	2022	More importantly, prodrug 20 showed relatively lower human ether-a-go-go-related gene (hERG) inhibitory activity compared with CDDO-Me, which demonstrated prodrug 20 might be safer than CDDO-Me.	bardoxolone methyl	127-134	ETS transcription factor ERG	Homo sapiens	87-91
35512420-7	2022	More importantly, prodrug 20 showed relatively lower human ether-a-go-go-related gene (hERG) inhibitory activity compared with CDDO-Me, which demonstrated prodrug 20 might be safer than CDDO-Me.	bardoxolone methyl	186-193	ETS transcription factor ERG	Homo sapiens	87-91
35512420-8	2022	In conclusion, the novel strategy of shielding CUK part with CTSB linkers provided a new idea for solving the limitations of CDDO-Me in clinical application.	bardoxolone methyl	125-132	cathepsin B	Homo sapiens	61-65
35395074-6	2022	Targeting the Rab13-mediated BCSC niche with bardoxolone-methyl (CDDO-Me) prevented BCSC stemness in vitro and in vivo.	bardoxolone methyl	45-63	RAB13, member RAS oncogene family	Homo sapiens	14-19
35395074-6	2022	Targeting the Rab13-mediated BCSC niche with bardoxolone-methyl (CDDO-Me) prevented BCSC stemness in vitro and in vivo.	bardoxolone methyl	65-72	RAB13, member RAS oncogene family	Homo sapiens	14-19
35626147-5	2022	The siRNA-mediated knockdown of NFE2L2, the gene encoding for NRF2, or activation of the NRF2 pathway through siRNA-mediated knockdown of KEAP1 or via chemical induction with the NRF2-activator CDDO-Me confirmed that NRF2 is a regulator of KYNU expression in LUAD.	bardoxolone methyl	194-201	NFE2 like bZIP transcription factor 2	Homo sapiens	32-38
35626147-5	2022	The siRNA-mediated knockdown of NFE2L2, the gene encoding for NRF2, or activation of the NRF2 pathway through siRNA-mediated knockdown of KEAP1 or via chemical induction with the NRF2-activator CDDO-Me confirmed that NRF2 is a regulator of KYNU expression in LUAD.	bardoxolone methyl	194-201	NFE2 like bZIP transcription factor 2	Homo sapiens	62-66
35626147-5	2022	The siRNA-mediated knockdown of NFE2L2, the gene encoding for NRF2, or activation of the NRF2 pathway through siRNA-mediated knockdown of KEAP1 or via chemical induction with the NRF2-activator CDDO-Me confirmed that NRF2 is a regulator of KYNU expression in LUAD.	bardoxolone methyl	194-201	NFE2 like bZIP transcription factor 2	Homo sapiens	89-93
35626147-5	2022	The siRNA-mediated knockdown of NFE2L2, the gene encoding for NRF2, or activation of the NRF2 pathway through siRNA-mediated knockdown of KEAP1 or via chemical induction with the NRF2-activator CDDO-Me confirmed that NRF2 is a regulator of KYNU expression in LUAD.	bardoxolone methyl	194-201	kelch like ECH associated protein 1	Homo sapiens	138-143
35624848-0	2022	CDDO-Me Attenuates CA1 Neuronal Death by Facilitating RalBP1-Mediated Mitochondrial Fission and 4-HNE Efflux in the Rat Hippocampus Following Status Epilepticus.	bardoxolone methyl	0-7	carbonic anhydrase 1	Rattus norvegicus	19-22
35624848-0	2022	CDDO-Me Attenuates CA1 Neuronal Death by Facilitating RalBP1-Mediated Mitochondrial Fission and 4-HNE Efflux in the Rat Hippocampus Following Status Epilepticus.	bardoxolone methyl	0-7	ralA binding protein 1	Rattus norvegicus	54-60
35624848-2	2022	In the present study, we found that 2-cyano-3,12-dioxo-oleana-1,9(11)-dien-28-oic acid methyl ester (CDDO-Me) attenuated CA1 neuronal death and aberrant mitochondrial elongations in these neurons coupled with enhanced RalBP1 expression and reduced 4-HNE levels following status epilepticus (SE).	bardoxolone methyl	101-108	carbonic anhydrase 1	Rattus norvegicus	121-124
35624848-2	2022	In the present study, we found that 2-cyano-3,12-dioxo-oleana-1,9(11)-dien-28-oic acid methyl ester (CDDO-Me) attenuated CA1 neuronal death and aberrant mitochondrial elongations in these neurons coupled with enhanced RalBP1 expression and reduced 4-HNE levels following status epilepticus (SE).	bardoxolone methyl	101-108	ralA binding protein 1	Rattus norvegicus	218-224
35624848-4	2022	Following SE, however, cotreatment of RalBP1 siRNA diminished the effect of CDDO-Me on 4-HNE levels, mitochondrial hyperfusion in CA1 neurons, and CA1 neuronal death.	bardoxolone methyl	76-83	ralA binding protein 1	Rattus norvegicus	38-44
35624848-4	2022	Following SE, however, cotreatment of RalBP1 siRNA diminished the effect of CDDO-Me on 4-HNE levels, mitochondrial hyperfusion in CA1 neurons, and CA1 neuronal death.	bardoxolone methyl	76-83	carbonic anhydrase 1	Rattus norvegicus	130-133
35624848-5	2022	These findings indicate that CDDO-Me may ameliorate CA1 neuronal death by facilitating RalBP1-mediated 4-HNE efflux and mitochondrial fission following SE.	bardoxolone methyl	29-36	carbonic anhydrase 1	Rattus norvegicus	52-55
35624848-5	2022	These findings indicate that CDDO-Me may ameliorate CA1 neuronal death by facilitating RalBP1-mediated 4-HNE efflux and mitochondrial fission following SE.	bardoxolone methyl	29-36	ralA binding protein 1	Rattus norvegicus	87-93
35562960-0	2022	CDDO-Me Attenuates Clasmatodendrosis in CA1 Astrocyte by Inhibiting HSP25-AKT Mediated DRP1-S637 Phosphorylation in Chronic Epilepsy Rats.	bardoxolone methyl	0-7	heat shock protein family B (small) member 1	Rattus norvegicus	68-73
35620281-2	2022	In this study, transgenic Sickle Cell Anemia mice (SS mice) treated with CDDO-Methyl (CDDO-Me), a potent Nrf2 activator, showed reduced progression of hemolytic anemia with aging, but surprisingly also showed reduced endothelial function.	bardoxolone methyl	86-93	nuclear factor, erythroid derived 2, like 2	Mus musculus	105-109
35620281-4	2022	It is unclear what molecular mechanism underly the vascular impairment, however, our in vitro assays revealed that CDDO-Me induced the expression of the endothelin receptor (ETA and ETB) in vascular smooth muscle cells.	bardoxolone methyl	115-122	endothelin receptor type B	Mus musculus	182-185
35192689-7	2022	Human islets transplanted under the kidney capsule of immunocompromised mice and treated systemically with CDDO-Me, an Nrf2 activator, display increased beta-cell proliferation.	bardoxolone methyl	107-114	nuclear factor, erythroid derived 2, like 2	Mus musculus	119-123
35562960-5	2022	2-Cyano-3,12-dioxo-oleana-1,9(11)-dien-28-oic acid methyl ester (CDDO-Me; bardoxolone methyl or RTA 402) abrogated abnormal mitochondrial elongation by reducing HSP25 upregulation, AKT S473- and DRP1 S637 phosphorylations.	bardoxolone methyl	65-72	heat shock protein family B (small) member 1	Rattus norvegicus	161-166
35562960-5	2022	2-Cyano-3,12-dioxo-oleana-1,9(11)-dien-28-oic acid methyl ester (CDDO-Me; bardoxolone methyl or RTA 402) abrogated abnormal mitochondrial elongation by reducing HSP25 upregulation, AKT S473- and DRP1 S637 phosphorylations.	bardoxolone methyl	65-72	AKT serine/threonine kinase 1	Rattus norvegicus	181-184
35562960-0	2022	CDDO-Me Attenuates Clasmatodendrosis in CA1 Astrocyte by Inhibiting HSP25-AKT Mediated DRP1-S637 Phosphorylation in Chronic Epilepsy Rats.	bardoxolone methyl	0-7	AKT serine/threonine kinase 1	Rattus norvegicus	74-77
35562960-5	2022	2-Cyano-3,12-dioxo-oleana-1,9(11)-dien-28-oic acid methyl ester (CDDO-Me; bardoxolone methyl or RTA 402) abrogated abnormal mitochondrial elongation by reducing HSP25 upregulation, AKT S473- and DRP1 S637 phosphorylations.	bardoxolone methyl	65-72	dynamin 1-like	Rattus norvegicus	195-199
35562960-0	2022	CDDO-Me Attenuates Clasmatodendrosis in CA1 Astrocyte by Inhibiting HSP25-AKT Mediated DRP1-S637 Phosphorylation in Chronic Epilepsy Rats.	bardoxolone methyl	0-7	dynamin 1-like	Rattus norvegicus	87-91
34973124-11	2022	The antioxidant enzymes, HO1, NQO1, GPX1, and CAT were upregulated by CDDO-Me treatment.	bardoxolone methyl	70-77	heme oxygenase 1	Homo sapiens	25-28
35456042-6	2022	Exposure of worms to triterpenoid CDDO-Me, an inhibitor of human LonP1, stimulated only UPRcyt responses.	bardoxolone methyl	34-41	lon peptidase 1, mitochondrial	Homo sapiens	65-70
34973124-11	2022	The antioxidant enzymes, HO1, NQO1, GPX1, and CAT were upregulated by CDDO-Me treatment.	bardoxolone methyl	70-77	NAD(P)H quinone dehydrogenase 1	Homo sapiens	30-34
34973124-11	2022	The antioxidant enzymes, HO1, NQO1, GPX1, and CAT were upregulated by CDDO-Me treatment.	bardoxolone methyl	70-77	glutathione peroxidase 1	Homo sapiens	36-40
34973124-11	2022	The antioxidant enzymes, HO1, NQO1, GPX1, and CAT were upregulated by CDDO-Me treatment.	bardoxolone methyl	70-77	catalase	Homo sapiens	46-49
35265066-5	2022	We also demonstrated that addition of CDDO-Me to tri-cultures enhanced T cell-mediated reductions in CCL2, VEGF and IL-6 production in a contact-independent manner.	bardoxolone methyl	38-45	C-C motif chemokine ligand 2	Homo sapiens	101-105
35265066-5	2022	We also demonstrated that addition of CDDO-Me to tri-cultures enhanced T cell-mediated reductions in CCL2, VEGF and IL-6 production in a contact-independent manner.	bardoxolone methyl	38-45	vascular endothelial growth factor A	Homo sapiens	107-111
35265066-5	2022	We also demonstrated that addition of CDDO-Me to tri-cultures enhanced T cell-mediated reductions in CCL2, VEGF and IL-6 production in a contact-independent manner.	bardoxolone methyl	38-45	interleukin 6	Homo sapiens	116-120
35265066-7	2022	Our results indicated that CDDO-Me inhibited phosphorylation of STAT3, a known inducer of TAM activation.	bardoxolone methyl	27-34	signal transducer and activator of transcription 3	Homo sapiens	64-69
35204223-8	2022	Furthermore, although activated in cells that survived standalone FUS, pre-sensitization with CDDO-me and/or nelfinavir suppressed both total and activated (phosphorylated) NF-kappaB and Akt protein levels.	bardoxolone methyl	94-101	nuclear factor kappa B subunit 1	Homo sapiens	173-182
35204223-8	2022	Furthermore, although activated in cells that survived standalone FUS, pre-sensitization with CDDO-me and/or nelfinavir suppressed both total and activated (phosphorylated) NF-kappaB and Akt protein levels.	bardoxolone methyl	94-101	AKT serine/threonine kinase 1	Homo sapiens	187-190
33872408-3	2021	APPROACH & RESULTS: Wild type and Nrf2 null mice were administered bardoxolone methyl (CDDO-Me), a potent activator of Nrf2 that has entered clinical development, and then subjected to two-thirds partial hepatectomy.	bardoxolone methyl	67-85	nuclear factor, erythroid derived 2, like 2	Mus musculus	34-38
33922531-0	2021	CDDO-Me Attenuates Astroglial Autophagy via Nrf2-, ERK1/2-SP1- and Src-CK2-PTEN-PI3K/AKT-Mediated Signaling Pathways in the Hippocampus of Chronic Epilepsy Rats.	bardoxolone methyl	0-7	NFE2 like bZIP transcription factor 2	Rattus norvegicus	44-48
33922531-0	2021	CDDO-Me Attenuates Astroglial Autophagy via Nrf2-, ERK1/2-SP1- and Src-CK2-PTEN-PI3K/AKT-Mediated Signaling Pathways in the Hippocampus of Chronic Epilepsy Rats.	bardoxolone methyl	0-7	mitogen activated protein kinase 3	Rattus norvegicus	51-57
33922531-0	2021	CDDO-Me Attenuates Astroglial Autophagy via Nrf2-, ERK1/2-SP1- and Src-CK2-PTEN-PI3K/AKT-Mediated Signaling Pathways in the Hippocampus of Chronic Epilepsy Rats.	bardoxolone methyl	0-7	SRC proto-oncogene, non-receptor tyrosine kinase	Rattus norvegicus	67-70
33922531-0	2021	CDDO-Me Attenuates Astroglial Autophagy via Nrf2-, ERK1/2-SP1- and Src-CK2-PTEN-PI3K/AKT-Mediated Signaling Pathways in the Hippocampus of Chronic Epilepsy Rats.	bardoxolone methyl	0-7	casein kinase 2 beta	Rattus norvegicus	71-74
33922531-0	2021	CDDO-Me Attenuates Astroglial Autophagy via Nrf2-, ERK1/2-SP1- and Src-CK2-PTEN-PI3K/AKT-Mediated Signaling Pathways in the Hippocampus of Chronic Epilepsy Rats.	bardoxolone methyl	0-7	phosphatase and tensin homolog	Rattus norvegicus	75-79
33922531-0	2021	CDDO-Me Attenuates Astroglial Autophagy via Nrf2-, ERK1/2-SP1- and Src-CK2-PTEN-PI3K/AKT-Mediated Signaling Pathways in the Hippocampus of Chronic Epilepsy Rats.	bardoxolone methyl	0-7	AKT serine/threonine kinase 1	Rattus norvegicus	85-88
33922531-4	2021	The 2-cyano-3,12-dioxo-oleana-1,9(11)-dien-28-oic acid methyl ester (CDDO-Me; RTA 402) is one of the activators for nuclear factor-erythroid 2-related factor 2 (Nrf2) that is a redox-sensitive transcription factor.	bardoxolone methyl	69-76	NFE2 like bZIP transcription factor 2	Rattus norvegicus	116-159
33922531-4	2021	The 2-cyano-3,12-dioxo-oleana-1,9(11)-dien-28-oic acid methyl ester (CDDO-Me; RTA 402) is one of the activators for nuclear factor-erythroid 2-related factor 2 (Nrf2) that is a redox-sensitive transcription factor.	bardoxolone methyl	69-76	NFE2 like bZIP transcription factor 2	Rattus norvegicus	161-165
33922531-4	2021	The 2-cyano-3,12-dioxo-oleana-1,9(11)-dien-28-oic acid methyl ester (CDDO-Me; RTA 402) is one of the activators for nuclear factor-erythroid 2-related factor 2 (Nrf2) that is a redox-sensitive transcription factor.	bardoxolone methyl	78-85	NFE2 like bZIP transcription factor 2	Rattus norvegicus	116-159
33922531-4	2021	The 2-cyano-3,12-dioxo-oleana-1,9(11)-dien-28-oic acid methyl ester (CDDO-Me; RTA 402) is one of the activators for nuclear factor-erythroid 2-related factor 2 (Nrf2) that is a redox-sensitive transcription factor.	bardoxolone methyl	78-85	NFE2 like bZIP transcription factor 2	Rattus norvegicus	161-165
33922531-6	2021	In the present study, clasmatodendritic astrocytes showed reduced Nrf2 expression and its nuclear accumulation, which were restored by CDDO-Me.	bardoxolone methyl	135-142	NFE2 like bZIP transcription factor 2	Rattus norvegicus	66-70
35073378-3	2022	In this study, we aimed to disentangle the effects of these factors and clarify whether bardoxolone methyl (CDDO-Me), a novel nuclear factor erythroid 2-related factor 2 (Nrf2) activator, protects against glucose spike-induced endothelial dysfunction.	bardoxolone methyl	108-115	NFE2 like bZIP transcription factor 2	Rattus norvegicus	126-169
35073378-3	2022	In this study, we aimed to disentangle the effects of these factors and clarify whether bardoxolone methyl (CDDO-Me), a novel nuclear factor erythroid 2-related factor 2 (Nrf2) activator, protects against glucose spike-induced endothelial dysfunction.	bardoxolone methyl	108-115	NFE2 like bZIP transcription factor 2	Rattus norvegicus	171-175
33714136-4	2021	CDDO Methyl Ester (CDDO-ME) or ML385 treatment aggravated or alleviated rPT cells injury induced by Cd respectively, indicating that Nrf2 nucleus translocation played a negative role during Cd-induced rPT cells injury.	bardoxolone methyl	0-17	NFE2 like bZIP transcription factor 2	Rattus norvegicus	133-137
33714136-4	2021	CDDO Methyl Ester (CDDO-ME) or ML385 treatment aggravated or alleviated rPT cells injury induced by Cd respectively, indicating that Nrf2 nucleus translocation played a negative role during Cd-induced rPT cells injury.	bardoxolone methyl	19-26	NFE2 like bZIP transcription factor 2	Rattus norvegicus	133-137
33714136-6	2021	Dephosphorylation of AMPK induced by Cd were facilitated or restored by CDDO-ME or ML385 treatment, which confirmed AMPK is a downstream factor of Nrf2.	bardoxolone methyl	72-79	protein kinase AMP-activated catalytic subunit alpha 2	Rattus norvegicus	21-25
33714136-6	2021	Dephosphorylation of AMPK induced by Cd were facilitated or restored by CDDO-ME or ML385 treatment, which confirmed AMPK is a downstream factor of Nrf2.	bardoxolone methyl	72-79	protein kinase AMP-activated catalytic subunit alpha 2	Rattus norvegicus	116-120
33714136-6	2021	Dephosphorylation of AMPK induced by Cd were facilitated or restored by CDDO-ME or ML385 treatment, which confirmed AMPK is a downstream factor of Nrf2.	bardoxolone methyl	72-79	NFE2 like bZIP transcription factor 2	Rattus norvegicus	147-151
33714136-7	2021	Simultaneously, CDDO-ME further enhanced Phosphorylation of mTOR and AKT which increased during Cd exposure.	bardoxolone methyl	16-23	mechanistic target of rapamycin kinase	Rattus norvegicus	60-64
33714136-7	2021	Simultaneously, CDDO-ME further enhanced Phosphorylation of mTOR and AKT which increased during Cd exposure.	bardoxolone methyl	16-23	AKT serine/threonine kinase 1	Rattus norvegicus	69-72
33872408-3	2021	APPROACH & RESULTS: Wild type and Nrf2 null mice were administered bardoxolone methyl (CDDO-Me), a potent activator of Nrf2 that has entered clinical development, and then subjected to two-thirds partial hepatectomy.	bardoxolone methyl	67-85	nuclear factor, erythroid derived 2, like 2	Mus musculus	119-123
33872408-3	2021	APPROACH & RESULTS: Wild type and Nrf2 null mice were administered bardoxolone methyl (CDDO-Me), a potent activator of Nrf2 that has entered clinical development, and then subjected to two-thirds partial hepatectomy.	bardoxolone methyl	87-94	nuclear factor, erythroid derived 2, like 2	Mus musculus	34-38
33872408-3	2021	APPROACH & RESULTS: Wild type and Nrf2 null mice were administered bardoxolone methyl (CDDO-Me), a potent activator of Nrf2 that has entered clinical development, and then subjected to two-thirds partial hepatectomy.	bardoxolone methyl	87-94	nuclear factor, erythroid derived 2, like 2	Mus musculus	119-123
31471671-0	2021	Beneficial effects of bardoxolone methyl, an Nrf2 activator, on crush-related acute kidney injury in rats.	bardoxolone methyl	22-40	NFE2 like bZIP transcription factor 2	Rattus norvegicus	45-49
33924360-12	2021	In particular, CDDO-Me administration reduced the histopathological signs of endometriosis and inflammatory cells recruitment into the lesions, as shown by toluidine blue staining and myeloperoxidase (MPO) activity.	bardoxolone methyl	15-22	myeloperoxidase	Rattus norvegicus	184-199
33924360-12	2021	In particular, CDDO-Me administration reduced the histopathological signs of endometriosis and inflammatory cells recruitment into the lesions, as shown by toluidine blue staining and myeloperoxidase (MPO) activity.	bardoxolone methyl	15-22	myeloperoxidase	Rattus norvegicus	201-204
33924360-13	2021	CDDO-Me strongly suppressed alpha-SMA and fibronectin expression and collagen deposition, reducing endometriosis-associated fibrosis.	bardoxolone methyl	0-7	fibronectin 1	Rattus norvegicus	42-53
33924360-14	2021	In conclusion, CDDO-Me treatment resulted in a coordinated and effective suppression of endometriosis by modulating the Nrf2 and NFkB pathways.	bardoxolone methyl	15-22	NFE2 like bZIP transcription factor 2	Rattus norvegicus	120-124
33924360-14	2021	In conclusion, CDDO-Me treatment resulted in a coordinated and effective suppression of endometriosis by modulating the Nrf2 and NFkB pathways.	bardoxolone methyl	15-22	nuclear factor kappa B subunit 1	Rattus norvegicus	129-133
33924360-7	2021	CDDO-Me displayed antioxidant activity by activating the Nfr2 pathway and the expression of antioxidant mediators such as NQO-1 and HO-1.	bardoxolone methyl	0-7	NAD(P)H quinone dehydrogenase 1	Rattus norvegicus	122-127
33924360-7	2021	CDDO-Me displayed antioxidant activity by activating the Nfr2 pathway and the expression of antioxidant mediators such as NQO-1 and HO-1.	bardoxolone methyl	0-7	heme oxygenase 1	Rattus norvegicus	132-136
33924360-9	2021	CDDO-Me also showed anti-inflammatory activity by decreasing the expression of pro-inflammatory cytokines in peritoneal fluids and NFkB activation.	bardoxolone methyl	0-7	nuclear factor kappa B subunit 1	Rattus norvegicus	131-135
31471671-1	2021	PURPOSE: The purpose of this study was to investigate the effects of bardoxolone methyl (BM), a nuclear factor erythroid 2-related factor 2 (Nrf2) activator, on acute kidney injury in a rat model of crush syndrome model.	bardoxolone methyl	69-87	NFE2 like bZIP transcription factor 2	Rattus norvegicus	96-139
31471671-1	2021	PURPOSE: The purpose of this study was to investigate the effects of bardoxolone methyl (BM), a nuclear factor erythroid 2-related factor 2 (Nrf2) activator, on acute kidney injury in a rat model of crush syndrome model.	bardoxolone methyl	69-87	NFE2 like bZIP transcription factor 2	Rattus norvegicus	141-145
31471671-1	2021	PURPOSE: The purpose of this study was to investigate the effects of bardoxolone methyl (BM), a nuclear factor erythroid 2-related factor 2 (Nrf2) activator, on acute kidney injury in a rat model of crush syndrome model.	bardoxolone methyl	89-91	NFE2 like bZIP transcription factor 2	Rattus norvegicus	96-139
31471671-1	2021	PURPOSE: The purpose of this study was to investigate the effects of bardoxolone methyl (BM), a nuclear factor erythroid 2-related factor 2 (Nrf2) activator, on acute kidney injury in a rat model of crush syndrome model.	bardoxolone methyl	89-91	NFE2 like bZIP transcription factor 2	Rattus norvegicus	141-145
33096818-0	2020	CDDO-Me Distinctly Regulates Regional Specific Astroglial Responses to Status Epilepticus via ERK1/2-Nrf2, PTEN-PI3K-AKT and NFkappaB Signaling Pathways.	bardoxolone methyl	0-7	mitogen activated protein kinase 3	Rattus norvegicus	94-100
33096818-0	2020	CDDO-Me Distinctly Regulates Regional Specific Astroglial Responses to Status Epilepticus via ERK1/2-Nrf2, PTEN-PI3K-AKT and NFkappaB Signaling Pathways.	bardoxolone methyl	0-7	NFE2 like bZIP transcription factor 2	Rattus norvegicus	101-105
33096818-0	2020	CDDO-Me Distinctly Regulates Regional Specific Astroglial Responses to Status Epilepticus via ERK1/2-Nrf2, PTEN-PI3K-AKT and NFkappaB Signaling Pathways.	bardoxolone methyl	0-7	phosphatase and tensin homolog	Rattus norvegicus	107-111
33096818-0	2020	CDDO-Me Distinctly Regulates Regional Specific Astroglial Responses to Status Epilepticus via ERK1/2-Nrf2, PTEN-PI3K-AKT and NFkappaB Signaling Pathways.	bardoxolone methyl	0-7	AKT serine/threonine kinase 1	Rattus norvegicus	117-120
33096818-3	2020	Furthermore, CDDO-Me has antioxidant properties, since it activates nuclear factor-erythroid 2-related factor 2 (Nrf2), which is a key player of redox homeostasis.	bardoxolone methyl	13-20	NFE2 like bZIP transcription factor 2	Rattus norvegicus	68-111
33096818-3	2020	Furthermore, CDDO-Me has antioxidant properties, since it activates nuclear factor-erythroid 2-related factor 2 (Nrf2), which is a key player of redox homeostasis.	bardoxolone methyl	13-20	NFE2 like bZIP transcription factor 2	Rattus norvegicus	113-117
33096818-5	2020	Under physiological conditions, CDDO-Me increased Nrf2 expression in the hippocampus without altering activities (phosphorylations) of phosphatase and tensin homolog deleted on chromosome 10 (PTEN), phosphatidylinositol-3-kinase (PI3K), and AKT.	bardoxolone methyl	32-39	NFE2 like bZIP transcription factor 2	Rattus norvegicus	50-54
33096818-5	2020	Under physiological conditions, CDDO-Me increased Nrf2 expression in the hippocampus without altering activities (phosphorylations) of phosphatase and tensin homolog deleted on chromosome 10 (PTEN), phosphatidylinositol-3-kinase (PI3K), and AKT.	bardoxolone methyl	32-39	AKT serine/threonine kinase 1	Rattus norvegicus	241-244
33096818-7	2020	However, CDDO-Me ameliorated reduced astroglial Nrf2 expression in the CA1 region and the molecular layer of the dentate gyrus (ML), and attenuated reactive astrogliosis and ML astroglial apoptosis following SE.	bardoxolone methyl	9-16	NFE2 like bZIP transcription factor 2	Rattus norvegicus	48-52
33096818-7	2020	However, CDDO-Me ameliorated reduced astroglial Nrf2 expression in the CA1 region and the molecular layer of the dentate gyrus (ML), and attenuated reactive astrogliosis and ML astroglial apoptosis following SE.	bardoxolone methyl	9-16	carbonic anhydrase 1	Rattus norvegicus	71-74
33096818-8	2020	In CA1 astrocytes, CDDO-Me inhibited the PI3K/AKT pathway by activating PTEN.	bardoxolone methyl	19-26	carbonic anhydrase 1	Rattus norvegicus	3-6
33096818-8	2020	In CA1 astrocytes, CDDO-Me inhibited the PI3K/AKT pathway by activating PTEN.	bardoxolone methyl	19-26	AKT serine/threonine kinase 1	Rattus norvegicus	46-49
33096818-8	2020	In CA1 astrocytes, CDDO-Me inhibited the PI3K/AKT pathway by activating PTEN.	bardoxolone methyl	19-26	phosphatase and tensin homolog	Rattus norvegicus	72-76
33096818-9	2020	In contrast, CDDO-ME resulted in extracellular signal-related kinases 1/2 (ERK1/2)-mediated Nrf2 upregulation in ML astrocytes.	bardoxolone methyl	13-20	mitogen activated protein kinase 3	Rattus norvegicus	75-81
33096818-9	2020	In contrast, CDDO-ME resulted in extracellular signal-related kinases 1/2 (ERK1/2)-mediated Nrf2 upregulation in ML astrocytes.	bardoxolone methyl	13-20	NFE2 like bZIP transcription factor 2	Rattus norvegicus	92-96
33096818-10	2020	Furthermore, CDDO-Me decreased nuclear factor-kappaB (NFkappaB) phosphorylation in both CA1 and ML astrocytes.	bardoxolone methyl	13-20	carbonic anhydrase 1	Rattus norvegicus	88-91
33096818-11	2020	Therefore, our findings suggest that CDDO-Me may attenuate SE-induced reactive astrogliosis and astroglial apoptosis via regulation of ERK1/2-Nrf2, PTEN-PI3K-AKT, and NFkappaB signaling pathways.	bardoxolone methyl	37-44	mitogen activated protein kinase 3	Rattus norvegicus	135-141
33096818-11	2020	Therefore, our findings suggest that CDDO-Me may attenuate SE-induced reactive astrogliosis and astroglial apoptosis via regulation of ERK1/2-Nrf2, PTEN-PI3K-AKT, and NFkappaB signaling pathways.	bardoxolone methyl	37-44	NFE2 like bZIP transcription factor 2	Rattus norvegicus	142-146
33096818-11	2020	Therefore, our findings suggest that CDDO-Me may attenuate SE-induced reactive astrogliosis and astroglial apoptosis via regulation of ERK1/2-Nrf2, PTEN-PI3K-AKT, and NFkappaB signaling pathways.	bardoxolone methyl	37-44	phosphatase and tensin homolog	Rattus norvegicus	148-152
33096818-11	2020	Therefore, our findings suggest that CDDO-Me may attenuate SE-induced reactive astrogliosis and astroglial apoptosis via regulation of ERK1/2-Nrf2, PTEN-PI3K-AKT, and NFkappaB signaling pathways.	bardoxolone methyl	37-44	AKT serine/threonine kinase 1	Rattus norvegicus	158-161
32300202-0	2020	CDDO-Me Alters the Tumor Microenvironment in Estrogen Receptor Negative Breast Cancer.	bardoxolone methyl	0-7	estrogen receptor 1 (alpha)	Mus musculus	45-62
32802194-20	2020	Quantitative evaluation of the anti-inflammatory effect of CDDO-Me on neuroinflammation was successfully monitored with TSPO-targeting [18F]CB251-PET/MR and BLI.	bardoxolone methyl	59-66	translocator protein	Mus musculus	120-124
32766432-6	2020	Protein levels of multidrug resistance-associated protein 2, multidrug resistance-associated protein 3, and sodium-taurocholate cotransporter were higher in the IR90 group relative to those in the sham or IR60 groups, wherein the difference was notable only when BARD was administered.	bardoxolone methyl	263-267	ATP binding cassette subfamily C member 2	Rattus norvegicus	18-59
32484788-2	2020	Bardoxolone-methyl (BARD) is a NF-E2 p45-related factor 2 (Nrf2) agonist.	bardoxolone methyl	0-18	NFE2 like bZIP transcription factor 2	Homo sapiens	31-57
32484788-2	2020	Bardoxolone-methyl (BARD) is a NF-E2 p45-related factor 2 (Nrf2) agonist.	bardoxolone methyl	0-18	NFE2 like bZIP transcription factor 2	Homo sapiens	59-63
32484788-2	2020	Bardoxolone-methyl (BARD) is a NF-E2 p45-related factor 2 (Nrf2) agonist.	bardoxolone methyl	20-24	NFE2 like bZIP transcription factor 2	Homo sapiens	31-57
32484788-2	2020	Bardoxolone-methyl (BARD) is a NF-E2 p45-related factor 2 (Nrf2) agonist.	bardoxolone methyl	20-24	NFE2 like bZIP transcription factor 2	Homo sapiens	59-63
32370011-0	2020	CDDO-Me Inhibits Microglial Activation and Monocyte Infiltration by Abrogating NFkappaB- and p38 MAPK-Mediated Signaling Pathways Following Status Epilepticus.	bardoxolone methyl	0-7	nuclear factor kappa B subunit 1	Homo sapiens	79-87
32370011-0	2020	CDDO-Me Inhibits Microglial Activation and Monocyte Infiltration by Abrogating NFkappaB- and p38 MAPK-Mediated Signaling Pathways Following Status Epilepticus.	bardoxolone methyl	0-7	mitogen-activated protein kinase 14	Homo sapiens	93-101
32370011-3	2020	2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid methyl ester (CDDO-Me; RTA 402) is an activator of nuclear factor-erythroid 2-related factor 2 (Nrf2), which regulates intracellular redox homeostasis.	bardoxolone methyl	0-58	NFE2 like bZIP transcription factor 2	Homo sapiens	97-140
32370011-3	2020	2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid methyl ester (CDDO-Me; RTA 402) is an activator of nuclear factor-erythroid 2-related factor 2 (Nrf2), which regulates intracellular redox homeostasis.	bardoxolone methyl	0-58	NFE2 like bZIP transcription factor 2	Homo sapiens	142-146
32370011-3	2020	2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid methyl ester (CDDO-Me; RTA 402) is an activator of nuclear factor-erythroid 2-related factor 2 (Nrf2), which regulates intracellular redox homeostasis.	bardoxolone methyl	60-67	NFE2 like bZIP transcription factor 2	Homo sapiens	97-140
32370011-3	2020	2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid methyl ester (CDDO-Me; RTA 402) is an activator of nuclear factor-erythroid 2-related factor 2 (Nrf2), which regulates intracellular redox homeostasis.	bardoxolone methyl	60-67	NFE2 like bZIP transcription factor 2	Homo sapiens	142-146
32370011-3	2020	2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid methyl ester (CDDO-Me; RTA 402) is an activator of nuclear factor-erythroid 2-related factor 2 (Nrf2), which regulates intracellular redox homeostasis.	bardoxolone methyl	69-76	NFE2 like bZIP transcription factor 2	Homo sapiens	97-140
32370011-3	2020	2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid methyl ester (CDDO-Me; RTA 402) is an activator of nuclear factor-erythroid 2-related factor 2 (Nrf2), which regulates intracellular redox homeostasis.	bardoxolone methyl	69-76	NFE2 like bZIP transcription factor 2	Homo sapiens	142-146
32370011-5	2020	In the present study, CDDO-Me ameliorated monocyte infiltration without vasogenic edema formation in the frontoparietal cortex (FPC) following SE, accompanied by abrogating monocyte chemotactic protein-1 (MCP-1)/tumor necrosis factor-alpha (TNF-alpha) expressions and p38 mitogen-activated protein kinase (p38 MAPK) phosphorylation.	bardoxolone methyl	22-29	C-C motif chemokine ligand 2	Homo sapiens	173-203
32370011-5	2020	In the present study, CDDO-Me ameliorated monocyte infiltration without vasogenic edema formation in the frontoparietal cortex (FPC) following SE, accompanied by abrogating monocyte chemotactic protein-1 (MCP-1)/tumor necrosis factor-alpha (TNF-alpha) expressions and p38 mitogen-activated protein kinase (p38 MAPK) phosphorylation.	bardoxolone methyl	22-29	C-C motif chemokine ligand 2	Homo sapiens	205-210
32370011-5	2020	In the present study, CDDO-Me ameliorated monocyte infiltration without vasogenic edema formation in the frontoparietal cortex (FPC) following SE, accompanied by abrogating monocyte chemotactic protein-1 (MCP-1)/tumor necrosis factor-alpha (TNF-alpha) expressions and p38 mitogen-activated protein kinase (p38 MAPK) phosphorylation.	bardoxolone methyl	22-29	tumor necrosis factor	Homo sapiens	212-239
32370011-5	2020	In the present study, CDDO-Me ameliorated monocyte infiltration without vasogenic edema formation in the frontoparietal cortex (FPC) following SE, accompanied by abrogating monocyte chemotactic protein-1 (MCP-1)/tumor necrosis factor-alpha (TNF-alpha) expressions and p38 mitogen-activated protein kinase (p38 MAPK) phosphorylation.	bardoxolone methyl	22-29	tumor necrosis factor	Homo sapiens	241-250
32370011-5	2020	In the present study, CDDO-Me ameliorated monocyte infiltration without vasogenic edema formation in the frontoparietal cortex (FPC) following SE, accompanied by abrogating monocyte chemotactic protein-1 (MCP-1)/tumor necrosis factor-alpha (TNF-alpha) expressions and p38 mitogen-activated protein kinase (p38 MAPK) phosphorylation.	bardoxolone methyl	22-29	mitogen-activated protein kinase 14	Homo sapiens	268-304
32370011-5	2020	In the present study, CDDO-Me ameliorated monocyte infiltration without vasogenic edema formation in the frontoparietal cortex (FPC) following SE, accompanied by abrogating monocyte chemotactic protein-1 (MCP-1)/tumor necrosis factor-alpha (TNF-alpha) expressions and p38 mitogen-activated protein kinase (p38 MAPK) phosphorylation.	bardoxolone methyl	22-29	mitogen-activated protein kinase 14	Homo sapiens	306-314
32370011-6	2020	Furthermore, CDDO-Me inhibited nuclear factor-kappaB (NFkappaB)-S276 phosphorylation and microglial transformation, independent of Nrf2 expression.	bardoxolone methyl	13-20	nuclear factor kappa B subunit 1	Homo sapiens	54-62
32370011-8	2020	Therefore, these findings suggest, for the first time, that CDDO-Me may attenuate microglia/monocyte-mediated neuroinflammation via modulating NFkappaB- and p38 MAPK-MCP-1 signaling pathways following SE.	bardoxolone methyl	60-67	nuclear factor kappa B subunit 1	Homo sapiens	143-151
32370011-8	2020	Therefore, these findings suggest, for the first time, that CDDO-Me may attenuate microglia/monocyte-mediated neuroinflammation via modulating NFkappaB- and p38 MAPK-MCP-1 signaling pathways following SE.	bardoxolone methyl	60-67	mitogen-activated protein kinase 14	Homo sapiens	157-165
32370011-8	2020	Therefore, these findings suggest, for the first time, that CDDO-Me may attenuate microglia/monocyte-mediated neuroinflammation via modulating NFkappaB- and p38 MAPK-MCP-1 signaling pathways following SE.	bardoxolone methyl	60-67	C-C motif chemokine ligand 2	Homo sapiens	166-171
32787104-1	2020	Synthetic triterpenoids including CDDO, its methyl ester (CDDO-Me, bardoxolone methyl), and its imidazolide (CDDO-Im) enhance Nrf2-mediated anti-oxidant and anti-inflammatory activity in many diseases by reacting with thiols on the adaptor protein, Keap1.	bardoxolone methyl	58-65	NFE2 like bZIP transcription factor 2	Homo sapiens	126-130
32556916-1	2020	Bardoxolone methyl (Bard), a nuclear factor erythroid 2-related factor 2 (Nrf2) activator regulates multiple oxidative and inflammatory diseases.	bardoxolone methyl	0-18	NFE2 like bZIP transcription factor 2	Rattus norvegicus	29-72
32556916-1	2020	Bardoxolone methyl (Bard), a nuclear factor erythroid 2-related factor 2 (Nrf2) activator regulates multiple oxidative and inflammatory diseases.	bardoxolone methyl	0-18	NFE2 like bZIP transcription factor 2	Rattus norvegicus	74-78
32556916-1	2020	Bardoxolone methyl (Bard), a nuclear factor erythroid 2-related factor 2 (Nrf2) activator regulates multiple oxidative and inflammatory diseases.	bardoxolone methyl	0-4	NFE2 like bZIP transcription factor 2	Rattus norvegicus	29-72
32556916-1	2020	Bardoxolone methyl (Bard), a nuclear factor erythroid 2-related factor 2 (Nrf2) activator regulates multiple oxidative and inflammatory diseases.	bardoxolone methyl	0-4	NFE2 like bZIP transcription factor 2	Rattus norvegicus	74-78
32040844-4	2020	Direct binding and inhibition of PKM2 activity by CDDO-Me was demonstrated by pull-down and activity assays.	bardoxolone methyl	50-57	pyruvate kinase M1/2	Homo sapiens	33-37
32040844-8	2020	CDDO-Me binds directly and specifically to recombinant PKM2, leading to a reduction of its catalytic activity.	bardoxolone methyl	0-13	pyruvate kinase M1/2	Homo sapiens	55-59
32300202-5	2020	We demonstrate that CDDO-Me significantly attenuates IL-10 and VEGF expression but stimulates TNF production, and reduces surface expression of CD206 and CD115, markers of immunosuppressive TAMs.	bardoxolone methyl	20-27	interleukin 10	Mus musculus	53-58
32300202-5	2020	We demonstrate that CDDO-Me significantly attenuates IL-10 and VEGF expression but stimulates TNF production, and reduces surface expression of CD206 and CD115, markers of immunosuppressive TAMs.	bardoxolone methyl	20-27	vascular endothelial growth factor A	Mus musculus	63-67
32300202-5	2020	We demonstrate that CDDO-Me significantly attenuates IL-10 and VEGF expression but stimulates TNF production, and reduces surface expression of CD206 and CD115, markers of immunosuppressive TAMs.	bardoxolone methyl	20-27	tumor necrosis factor	Mus musculus	94-97
32300202-5	2020	We demonstrate that CDDO-Me significantly attenuates IL-10 and VEGF expression but stimulates TNF production, and reduces surface expression of CD206 and CD115, markers of immunosuppressive TAMs.	bardoxolone methyl	20-27	mannose receptor, C type 1	Mus musculus	144-149
32300202-5	2020	We demonstrate that CDDO-Me significantly attenuates IL-10 and VEGF expression but stimulates TNF production, and reduces surface expression of CD206 and CD115, markers of immunosuppressive TAMs.	bardoxolone methyl	20-27	colony stimulating factor 1 receptor	Mus musculus	154-159
32300202-6	2020	CDDO-Me treatment redirects the TAM transcriptional profile, inducing signaling pathways associated with immune stimulation, and inhibits TAM tumor infiltration, consistent with decreased expression of CCL2.	bardoxolone methyl	0-7	chemokine (C-C motif) ligand 2	Mus musculus	202-206
32300202-7	2020	In CDDO-Me-treated mice, both the absolute number and proportion of splenic CD4+ T cells were reduced, while the proportion of CD8+ T cells was significantly increased in both tumors and spleen.	bardoxolone methyl	3-10	CD4 antigen	Mus musculus	76-79
32300202-8	2020	Moreover, mice fed CDDO-Me demonstrated significant reductions in numbers of CD4+ Foxp3+ regulatory T cells within tumors.	bardoxolone methyl	19-26	CD4 antigen	Mus musculus	77-80
32300202-8	2020	Moreover, mice fed CDDO-Me demonstrated significant reductions in numbers of CD4+ Foxp3+ regulatory T cells within tumors.	bardoxolone methyl	19-26	forkhead box P3	Mus musculus	82-87
31541463-6	2020	As a downstream gene of Nrf2, heme oxygenase-1 expression decreased significantly with the cotreatment of erastin and APAP, which could be rescued by BM.	bardoxolone methyl	150-152	NFE2 like bZIP transcription factor 2	Homo sapiens	24-28
32032580-13	2020	Moreover, bardoxolone methyl (CDDO-Me), a potent Nrf2 activator, ameliorated BLM-induced skin fibrosis after topical administration.	bardoxolone methyl	10-28	nuclear factor, erythroid derived 2, like 2	Mus musculus	49-53
32032580-13	2020	Moreover, bardoxolone methyl (CDDO-Me), a potent Nrf2 activator, ameliorated BLM-induced skin fibrosis after topical administration.	bardoxolone methyl	30-37	nuclear factor, erythroid derived 2, like 2	Mus musculus	49-53
31541463-6	2020	As a downstream gene of Nrf2, heme oxygenase-1 expression decreased significantly with the cotreatment of erastin and APAP, which could be rescued by BM.	bardoxolone methyl	150-152	heme oxygenase 1	Homo sapiens	30-46
31421166-3	2019	Here we report the identification of the compound Bardoxolone methyl (CDDO-me) as a potent inhibitor of the Hrd1 ubiquitin ligase-mediated ERAD, which possesses a broad-spectrum activity against both DENV and ZIKV.	bardoxolone methyl	50-68	synoviolin 1	Homo sapiens	108-112
32015160-0	2020	CDDO-Me elicits anti-breast cancer activity by targeting LRP6 and FZD7 receptor complex.	bardoxolone methyl	0-15	LDL receptor related protein 6	Homo sapiens	57-61
32015160-0	2020	CDDO-Me elicits anti-breast cancer activity by targeting LRP6 and FZD7 receptor complex.	bardoxolone methyl	0-15	frizzled class receptor 7	Homo sapiens	66-70
32015160-3	2020	In this study, we found that CDDO-Me could inhibit Wnt/beta-catenin signaling mainly through targeting the LRP6 and FZD7 receptor complex.	bardoxolone methyl	29-42	catenin beta 1	Homo sapiens	55-67
32015160-3	2020	In this study, we found that CDDO-Me could inhibit Wnt/beta-catenin signaling mainly through targeting the LRP6 and FZD7 receptor complex.	bardoxolone methyl	29-42	LDL receptor related protein 6	Homo sapiens	107-111
32015160-3	2020	In this study, we found that CDDO-Me could inhibit Wnt/beta-catenin signaling mainly through targeting the LRP6 and FZD7 receptor complex.	bardoxolone methyl	29-42	frizzled class receptor 7	Homo sapiens	116-120
32015160-5	2020	We further showed CDDO-Me mediated degradation of FZD7 in a LRP6 ectodomain-dependent manner.	bardoxolone methyl	18-25	frizzled class receptor 7	Homo sapiens	50-54
32015160-5	2020	We further showed CDDO-Me mediated degradation of FZD7 in a LRP6 ectodomain-dependent manner.	bardoxolone methyl	18-25	LDL receptor related protein 6	Homo sapiens	60-64
32015160-6	2020	In breast cancer cells, treatment with CDDO-Me increased the degradation of LRP6 and Fzd7, reduced the levels of phosphorylated DVL2 and active beta-catenin, resulting in downregulation of Wnt target genes and some cancer stem cell (CSC) marker genes.	bardoxolone methyl	39-46	LDL receptor related protein 6	Homo sapiens	76-80
32015160-6	2020	In breast cancer cells, treatment with CDDO-Me increased the degradation of LRP6 and Fzd7, reduced the levels of phosphorylated DVL2 and active beta-catenin, resulting in downregulation of Wnt target genes and some cancer stem cell (CSC) marker genes.	bardoxolone methyl	39-46	frizzled class receptor 7	Homo sapiens	85-89
32015160-6	2020	In breast cancer cells, treatment with CDDO-Me increased the degradation of LRP6 and Fzd7, reduced the levels of phosphorylated DVL2 and active beta-catenin, resulting in downregulation of Wnt target genes and some cancer stem cell (CSC) marker genes.	bardoxolone methyl	39-46	dishevelled segment polarity protein 2	Homo sapiens	128-132
32015160-6	2020	In breast cancer cells, treatment with CDDO-Me increased the degradation of LRP6 and Fzd7, reduced the levels of phosphorylated DVL2 and active beta-catenin, resulting in downregulation of Wnt target genes and some cancer stem cell (CSC) marker genes.	bardoxolone methyl	39-46	catenin beta 1	Homo sapiens	144-156
32015160-7	2020	In a murine xenograft bearing MMTV-Wnt1-driven mammary tumor, administration of CDDO-Me significantly inhibited tumor growth, accompanied by reduced expression of phosphorylated and total LRP6, phosphorylated and unphosphorylated DVL2, active beta-catenin, several Wnt target genes and CSC marker genes.	bardoxolone methyl	80-87	LDL receptor related protein 6	Homo sapiens	188-192
32015160-7	2020	In a murine xenograft bearing MMTV-Wnt1-driven mammary tumor, administration of CDDO-Me significantly inhibited tumor growth, accompanied by reduced expression of phosphorylated and total LRP6, phosphorylated and unphosphorylated DVL2, active beta-catenin, several Wnt target genes and CSC marker genes.	bardoxolone methyl	80-87	dishevelled segment polarity protein 2	Homo sapiens	230-234
32015160-7	2020	In a murine xenograft bearing MMTV-Wnt1-driven mammary tumor, administration of CDDO-Me significantly inhibited tumor growth, accompanied by reduced expression of phosphorylated and total LRP6, phosphorylated and unphosphorylated DVL2, active beta-catenin, several Wnt target genes and CSC marker genes.	bardoxolone methyl	80-87	catenin beta 1	Homo sapiens	243-255
32015160-8	2020	Collectively, our results demonstrated that CDDO-Me is a potent Wnt/beta-catenin signaling inhibitor and so may be a promising therapeutic agent against breast cancer.	bardoxolone methyl	44-51	catenin beta 1	Homo sapiens	68-80
31940946-9	2020	The anti-oxidant N-acetyl cysteine (NAC) could overcome this AR-suppressive effect of CDDO-Me. Co-exposure of PC cells to CDDO-Me enhanced the efficacy of a clinically approved anti-androgen, enzalutamide (ENZ), as evident by decreased cell-viability along with migration and colony forming ability of PC cells.	bardoxolone methyl	86-93	androgen receptor	Homo sapiens	61-63
31940946-0	2020	Bardoxolone-Methyl (CDDO-Me) Suppresses Androgen Receptor and Its Splice-Variant AR-V7 and Enhances Efficacy of Enzalutamide in Prostate Cancer Cells.	bardoxolone methyl	0-28	androgen receptor	Homo sapiens	40-57
31940946-4	2020	We examined whether a triterpenoid antioxidant drug, Bardoxolone-methyl, known as CDDO-Me or RTA 402, can decrease AR-FL and AR-V7 expression in PC cells.	bardoxolone methyl	53-71	androgen receptor	Homo sapiens	115-120
31940946-4	2020	We examined whether a triterpenoid antioxidant drug, Bardoxolone-methyl, known as CDDO-Me or RTA 402, can decrease AR-FL and AR-V7 expression in PC cells.	bardoxolone methyl	53-71	androgen receptor	Homo sapiens	115-117
31940946-4	2020	We examined whether a triterpenoid antioxidant drug, Bardoxolone-methyl, known as CDDO-Me or RTA 402, can decrease AR-FL and AR-V7 expression in PC cells.	bardoxolone methyl	82-96	androgen receptor	Homo sapiens	115-120
31940946-4	2020	We examined whether a triterpenoid antioxidant drug, Bardoxolone-methyl, known as CDDO-Me or RTA 402, can decrease AR-FL and AR-V7 expression in PC cells.	bardoxolone methyl	82-96	androgen receptor	Homo sapiens	115-117
31940946-5	2020	Nanomolar (nM) concentrations of CDDO-Me rapidly downregulated AR-FL in LNCaP and C4-2B cells, and both AR-FL and AR-V7 in CWR22Rv1 (22Rv1) cells.	bardoxolone methyl	33-48	androgen receptor	Homo sapiens	63-68
31940946-5	2020	Nanomolar (nM) concentrations of CDDO-Me rapidly downregulated AR-FL in LNCaP and C4-2B cells, and both AR-FL and AR-V7 in CWR22Rv1 (22Rv1) cells.	bardoxolone methyl	33-48	androgen receptor	Homo sapiens	63-65
31940946-6	2020	The AR-suppressive effect of CDDO-Me was evident at both the mRNA and protein levels.	bardoxolone methyl	29-36	androgen receptor	Homo sapiens	4-6
31940946-9	2020	The anti-oxidant N-acetyl cysteine (NAC) could overcome this AR-suppressive effect of CDDO-Me. Co-exposure of PC cells to CDDO-Me enhanced the efficacy of a clinically approved anti-androgen, enzalutamide (ENZ), as evident by decreased cell-viability along with migration and colony forming ability of PC cells.	bardoxolone methyl	86-94	androgen receptor	Homo sapiens	61-63
31601682-4	2019	Here, we investigated the beneficial hemodynamic effects of bardoxolone methyl (2-Cyano-3,12-dioxooleana-1,9(11)-dien-28-oic acid methyl ester, CDDO-Me), a pharmacological activator of Nrf2, in a rodent model of CHF.	bardoxolone methyl	80-142	NFE2 like bZIP transcription factor 2	Rattus norvegicus	185-189
31601682-9	2019	Molecular studies revealed that CDDO-Me-induced cardiac functional improvement was attributed to an increase of both Nrf2 transcription and translation, and a decrease of oxidative stress in the noninfarcted areas of the heart.	bardoxolone methyl	32-39	NFE2 like bZIP transcription factor 2	Rattus norvegicus	117-121
31601682-10	2019	Furthermore, CDDO-Me reduced NF-kappaB binding and increased Nrf2 binding to the CREB-binding protein, which may contribute to the selective increase of Nrf2 downstream targets, including NADPH Oxidase Quinone 1, Heme Oxygenase 1, Catalase, and Glutamate-Cysteine Ligase Catalytic Subunit, and the attenuation of myocardial inflammation in CHF rats.	bardoxolone methyl	13-20	NFE2 like bZIP transcription factor 2	Rattus norvegicus	61-65
31601682-10	2019	Furthermore, CDDO-Me reduced NF-kappaB binding and increased Nrf2 binding to the CREB-binding protein, which may contribute to the selective increase of Nrf2 downstream targets, including NADPH Oxidase Quinone 1, Heme Oxygenase 1, Catalase, and Glutamate-Cysteine Ligase Catalytic Subunit, and the attenuation of myocardial inflammation in CHF rats.	bardoxolone methyl	13-20	CREB binding protein	Rattus norvegicus	81-101
31601682-10	2019	Furthermore, CDDO-Me reduced NF-kappaB binding and increased Nrf2 binding to the CREB-binding protein, which may contribute to the selective increase of Nrf2 downstream targets, including NADPH Oxidase Quinone 1, Heme Oxygenase 1, Catalase, and Glutamate-Cysteine Ligase Catalytic Subunit, and the attenuation of myocardial inflammation in CHF rats.	bardoxolone methyl	13-20	NFE2 like bZIP transcription factor 2	Rattus norvegicus	153-157
31601682-10	2019	Furthermore, CDDO-Me reduced NF-kappaB binding and increased Nrf2 binding to the CREB-binding protein, which may contribute to the selective increase of Nrf2 downstream targets, including NADPH Oxidase Quinone 1, Heme Oxygenase 1, Catalase, and Glutamate-Cysteine Ligase Catalytic Subunit, and the attenuation of myocardial inflammation in CHF rats.	bardoxolone methyl	13-20	heme oxygenase 1	Rattus norvegicus	213-229
31601682-10	2019	Furthermore, CDDO-Me reduced NF-kappaB binding and increased Nrf2 binding to the CREB-binding protein, which may contribute to the selective increase of Nrf2 downstream targets, including NADPH Oxidase Quinone 1, Heme Oxygenase 1, Catalase, and Glutamate-Cysteine Ligase Catalytic Subunit, and the attenuation of myocardial inflammation in CHF rats.	bardoxolone methyl	13-20	catalase	Rattus norvegicus	231-239
31601682-10	2019	Furthermore, CDDO-Me reduced NF-kappaB binding and increased Nrf2 binding to the CREB-binding protein, which may contribute to the selective increase of Nrf2 downstream targets, including NADPH Oxidase Quinone 1, Heme Oxygenase 1, Catalase, and Glutamate-Cysteine Ligase Catalytic Subunit, and the attenuation of myocardial inflammation in CHF rats.	bardoxolone methyl	13-20	glutamate-cysteine ligase, catalytic subunit	Rattus norvegicus	245-288
31421166-8	2019	Inhibition of grp94 may contribute to the antiviral activity of CDDO-me.	bardoxolone methyl	64-71	heat shock protein 90 beta family member 1	Homo sapiens	14-19
31421166-3	2019	Here we report the identification of the compound Bardoxolone methyl (CDDO-me) as a potent inhibitor of the Hrd1 ubiquitin ligase-mediated ERAD, which possesses a broad-spectrum activity against both DENV and ZIKV.	bardoxolone methyl	70-77	synoviolin 1	Homo sapiens	108-112
31421166-4	2019	Cellular thermal shift assay (CETSA) suggested that CDDO-me binds to grp94, a key component of the Hrd1 pathway, at a low nanomolar concentration, whereas interaction was not detected with its paralog Hsp90.	bardoxolone methyl	52-59	heat shock protein 90 beta family member 1	Homo sapiens	69-74
31421166-4	2019	Cellular thermal shift assay (CETSA) suggested that CDDO-me binds to grp94, a key component of the Hrd1 pathway, at a low nanomolar concentration, whereas interaction was not detected with its paralog Hsp90.	bardoxolone methyl	52-59	synoviolin 1	Homo sapiens	99-103
31543152-0	2019	Increased albuminuria in bardoxolone methyl-treated type 2 diabetes patients: mere reflection of eGFR improvement?	bardoxolone methyl	25-43	epidermal growth factor receptor	Homo sapiens	97-101
31543152-2	2019	Because bardoxolone methyl also increases albuminuria, Rossing and colleagues performed a retrospective analysis of the Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes (BEACON) study and attributed increased albuminuria to increased estimated glomerular filtration rate.	bardoxolone methyl	8-26	ubiquitin like 5	Homo sapiens	211-217
31543152-2	2019	Because bardoxolone methyl also increases albuminuria, Rossing and colleagues performed a retrospective analysis of the Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes (BEACON) study and attributed increased albuminuria to increased estimated glomerular filtration rate.	bardoxolone methyl	120-138	ubiquitin like 5	Homo sapiens	211-217
31574956-5	2019	CDDO-Me also abolished NF-kappaB threonine 435 phosphorylation in endothelial cells and TNF-alpha-mediated-phosphatidylinositol-3-kinase (PI3K)/AKT/endothelial nitric oxide synthase (eNOS) signaling cascades, which trigger vasogenic edema following SE.	bardoxolone methyl	0-7	tumor necrosis factor	Rattus norvegicus	88-97
31356822-4	2019	In this study, cell viability, reactive oxygen species (ROS) production, and several proteins" expressions of human embryonic kidney 293T (HEK293T) cells in response to UA, OTA, and/or Lonp1 inhibitor CDDO-me treatment were detected to reveal the protective mechanism of UA against OTA-induced renal cytotoxicity.	bardoxolone methyl	201-208	lon peptidase 1, mitochondrial	Homo sapiens	185-190
31356822-7	2019	The protein expressions of Lonp1, Aco2 and Hsp75 were inhibited by the addition of CDDO-me.	bardoxolone methyl	83-90	lon peptidase 1, mitochondrial	Homo sapiens	27-32
31356822-7	2019	The protein expressions of Lonp1, Aco2 and Hsp75 were inhibited by the addition of CDDO-me.	bardoxolone methyl	83-90	aconitase 2	Homo sapiens	34-38
31356822-7	2019	The protein expressions of Lonp1, Aco2 and Hsp75 were inhibited by the addition of CDDO-me.	bardoxolone methyl	83-90	TNF receptor associated protein 1	Homo sapiens	43-48
31574956-0	2019	CDDO-Me Attenuates Vasogenic Edema and Astroglial Death by Regulating NF-kappaB p65 Phosphorylations and Nrf2 Expression Following Status Epilepticus.	bardoxolone methyl	0-7	NFE2 like bZIP transcription factor 2	Rattus norvegicus	105-109
31574956-4	2019	CDDO-Me abrogated tumor necrosis factor-alpha (TNF-alpha) synthesis in activated microglia by inhibiting nuclear factor-kappaB (NF-kappaB) p65 serine 276 phosphorylation.	bardoxolone methyl	0-7	tumor necrosis factor	Rattus norvegicus	47-56
31574956-5	2019	CDDO-Me also abolished NF-kappaB threonine 435 phosphorylation in endothelial cells and TNF-alpha-mediated-phosphatidylinositol-3-kinase (PI3K)/AKT/endothelial nitric oxide synthase (eNOS) signaling cascades, which trigger vasogenic edema following SE.	bardoxolone methyl	0-7	AKT serine/threonine kinase 1	Rattus norvegicus	144-147
31574956-5	2019	CDDO-Me also abolished NF-kappaB threonine 435 phosphorylation in endothelial cells and TNF-alpha-mediated-phosphatidylinositol-3-kinase (PI3K)/AKT/endothelial nitric oxide synthase (eNOS) signaling cascades, which trigger vasogenic edema following SE.	bardoxolone methyl	0-7	nitric oxide synthase 3	Rattus norvegicus	183-187
31574956-4	2019	CDDO-Me abrogated tumor necrosis factor-alpha (TNF-alpha) synthesis in activated microglia by inhibiting nuclear factor-kappaB (NF-kappaB) p65 serine 276 phosphorylation.	bardoxolone methyl	0-7	synaptotagmin 1	Rattus norvegicus	139-142
31574956-6	2019	Furthermore, CDDO-Me increased astroglial viability via the up-regulation of nuclear factor-erythroid 2-related factor 2 (Nrf2) expression.	bardoxolone methyl	13-20	NFE2 like bZIP transcription factor 2	Rattus norvegicus	77-120
31574956-6	2019	Furthermore, CDDO-Me increased astroglial viability via the up-regulation of nuclear factor-erythroid 2-related factor 2 (Nrf2) expression.	bardoxolone methyl	13-20	NFE2 like bZIP transcription factor 2	Rattus norvegicus	122-126
31574956-7	2019	Therefore, our findings suggest that CDDO-Me may ameliorate SE-induced vasogenic edema formation by regulating NF-kappaB p65 phosphorylations in microglia as well as endothelial cells and enhancing Nrf2 expression in astrocytes, respectively.	bardoxolone methyl	37-44	NFE2 like bZIP transcription factor 2	Rattus norvegicus	198-202
31580543-6	2019	Bardoxolone exerts antioxidant activity by promoting the activation of Nrf2 (Nuclear factor erythroid2-derivative - 2) and the downregulation of the proinflammatory NF-kB (Nuclear factor kappa-light-chain-enhancer of activated B cells) signaling.	bardoxolone methyl	0-11	NFE2 like bZIP transcription factor 2	Homo sapiens	71-75
30079536-4	2019	OA derivatives, such as CDDO-Im and CDDO-Me, are even more potent Nrf2 activators.	bardoxolone methyl	36-43	NFE2 like bZIP transcription factor 2	Homo sapiens	66-70
31387295-0	2019	CDDO-Me Selectively Attenuates CA1 Neuronal Death Induced by Status Epilepticus via Facilitating Mitochondrial Fission Independent of LONP1.	bardoxolone methyl	0-7	carbonic anhydrase 1	Homo sapiens	31-34
31387295-0	2019	CDDO-Me Selectively Attenuates CA1 Neuronal Death Induced by Status Epilepticus via Facilitating Mitochondrial Fission Independent of LONP1.	bardoxolone methyl	0-7	lon peptidase 1, mitochondrial	Homo sapiens	134-139
30826055-0	2019	CDDO-Me, Sulforaphane and tBHQ attenuate the RANKL-induced osteoclast differentiation via activating the NRF2-mediated antioxidant response.	bardoxolone methyl	0-7	TNF superfamily member 11	Homo sapiens	45-50
30826055-0	2019	CDDO-Me, Sulforaphane and tBHQ attenuate the RANKL-induced osteoclast differentiation via activating the NRF2-mediated antioxidant response.	bardoxolone methyl	0-7	NFE2 like bZIP transcription factor 2	Homo sapiens	105-109
30826055-8	2019	Taken together, these results suggest that CDDO-Me, SFN and tBHQ attenuate RANKL-induced osteoclastogenesis via activation of NRF2-mediated antioxidant response.	bardoxolone methyl	43-50	TNF superfamily member 11	Homo sapiens	75-80
30826055-8	2019	Taken together, these results suggest that CDDO-Me, SFN and tBHQ attenuate RANKL-induced osteoclastogenesis via activation of NRF2-mediated antioxidant response.	bardoxolone methyl	43-50	NFE2 like bZIP transcription factor 2	Homo sapiens	126-130
31387295-2	2019	In addition, CDDO-Me affects cellular differentiation and cell cycle arrest, and irreversibly inhibits Lon protease-1 (LONP1).	bardoxolone methyl	13-20	lon peptidase 1, mitochondrial	Homo sapiens	103-117
31387295-2	2019	In addition, CDDO-Me affects cellular differentiation and cell cycle arrest, and irreversibly inhibits Lon protease-1 (LONP1).	bardoxolone methyl	13-20	lon peptidase 1, mitochondrial	Homo sapiens	119-124
31387295-4	2019	CDDO-Me increased dynamin-related proteins 1 (DRP1)-serine 616 phosphorylation via activating extracellular-signal-regulated kinase 1/2 (ERK1/2) and c-Jun N-terminal kinase (JNK), but not protein kinase A (PKA) or protein phosphatases (PPs).	bardoxolone methyl	0-7	dynamin 1 like	Homo sapiens	18-44
31387295-4	2019	CDDO-Me increased dynamin-related proteins 1 (DRP1)-serine 616 phosphorylation via activating extracellular-signal-regulated kinase 1/2 (ERK1/2) and c-Jun N-terminal kinase (JNK), but not protein kinase A (PKA) or protein phosphatases (PPs).	bardoxolone methyl	0-7	dynamin 1 like	Homo sapiens	46-50
31387295-4	2019	CDDO-Me increased dynamin-related proteins 1 (DRP1)-serine 616 phosphorylation via activating extracellular-signal-regulated kinase 1/2 (ERK1/2) and c-Jun N-terminal kinase (JNK), but not protein kinase A (PKA) or protein phosphatases (PPs).	bardoxolone methyl	0-7	mitogen-activated protein kinase 1	Homo sapiens	94-135
31387295-4	2019	CDDO-Me increased dynamin-related proteins 1 (DRP1)-serine 616 phosphorylation via activating extracellular-signal-regulated kinase 1/2 (ERK1/2) and c-Jun N-terminal kinase (JNK), but not protein kinase A (PKA) or protein phosphatases (PPs).	bardoxolone methyl	0-7	mitogen-activated protein kinase 3	Homo sapiens	137-143
31387295-4	2019	CDDO-Me increased dynamin-related proteins 1 (DRP1)-serine 616 phosphorylation via activating extracellular-signal-regulated kinase 1/2 (ERK1/2) and c-Jun N-terminal kinase (JNK), but not protein kinase A (PKA) or protein phosphatases (PPs).	bardoxolone methyl	0-7	mitogen-activated protein kinase 8	Homo sapiens	149-172
31387295-4	2019	CDDO-Me increased dynamin-related proteins 1 (DRP1)-serine 616 phosphorylation via activating extracellular-signal-regulated kinase 1/2 (ERK1/2) and c-Jun N-terminal kinase (JNK), but not protein kinase A (PKA) or protein phosphatases (PPs).	bardoxolone methyl	0-7	mitogen-activated protein kinase 8	Homo sapiens	174-177
31387295-5	2019	In addition, CDDO-Me facilitated DRP1-mediated mitochondrial fissions, which selectively attenuated SE-induced CA1 neuronal death.	bardoxolone methyl	13-20	dynamin 1 like	Homo sapiens	33-37
31387295-5	2019	In addition, CDDO-Me facilitated DRP1-mediated mitochondrial fissions, which selectively attenuated SE-induced CA1 neuronal death.	bardoxolone methyl	13-20	carbonic anhydrase 1	Homo sapiens	111-114
31387295-8	2019	Co-treatment of CDDO-Me with LONP1 siRNA ameliorated only CA1 neuronal death, concomitant with abrogation of mitochondrial elongation induced by SE.	bardoxolone methyl	16-23	lon peptidase 1, mitochondrial	Homo sapiens	29-34
31387295-8	2019	Co-treatment of CDDO-Me with LONP1 siRNA ameliorated only CA1 neuronal death, concomitant with abrogation of mitochondrial elongation induced by SE.	bardoxolone methyl	16-23	carbonic anhydrase 1	Homo sapiens	58-61
31387295-9	2019	Thus, our findings suggest that CDDO-Me may selectively attenuate SE-induced CA1 neuronal death by rescuing the abnormal mitochondrial machinery, independent of LONP1 activity.	bardoxolone methyl	32-39	carbonic anhydrase 1	Homo sapiens	77-80
31170712-3	2019	METHODS: BEACON randomized patients (n = 2,185) with type 2 diabetes (T2DM) and stage 4 chronic kidney disease (CKD) 1:1 to receive Bard (20 mg) or placebo once daily.	bardoxolone methyl	132-136	ubiquitin like 5	Homo sapiens	9-15
30456486-11	2019	Several other, clinically relevant, compounds (i.e., sulphorophane, nitrofurantoin and CDDO-Me) also enhanced the induction of Srxn1-GFP upon two consecutive repeated exposure.	bardoxolone methyl	87-94	sulfiredoxin 1	Homo sapiens	127-132
30465784-8	2019	Interestingly, anti-rotaviral effects of RA-839 were also mimicked by 2-Cyano-3, 12-dioxo-oleana-1, 9(11)-dien-28-oic acid methyl ester (CDDO-Me) and Hemin, two classical pharmacological activators of Nrf2/ARE pathway.	bardoxolone methyl	137-144	NFE2 like bZIP transcription factor 2	Homo sapiens	201-205
30279437-9	2018	The pre-clinically tested inhibitors of PI3K (PX-866) and NFkappaB (CDDO-Me) suppressed MSC-mediated HIV-1 reactivation.	bardoxolone methyl	68-75	nuclear factor kappa B subunit 1	Homo sapiens	58-66
29118925-0	2017	Bardoxolone methyl (CDDO-Me or RTA402) induces cell cycle arrest, apoptosis and autophagy via PI3K/Akt/mTOR and p38 MAPK/Erk1/2 signaling pathways in K562 cells.	bardoxolone methyl	0-18	AKT serine/threonine kinase 1	Homo sapiens	99-102
28978980-8	2018	The increase in reactive oxygen species (ROS) and upregulation of angiotensinogen expression in the kidneys of the Ald group was significantly prevented in the Ald-BM group.	bardoxolone methyl	164-166	angiotensinogen	Homo sapiens	66-81
28978980-9	2018	The upregulation of human L-FABP expression induced in the kidneys and increase in urinary L-FABP in the Ald group were significantly suppressed by BM administration.	bardoxolone methyl	148-150	fatty acid binding protein 1	Homo sapiens	26-32
28978980-9	2018	The upregulation of human L-FABP expression induced in the kidneys and increase in urinary L-FABP in the Ald group were significantly suppressed by BM administration.	bardoxolone methyl	148-150	fatty acid binding protein 1	Homo sapiens	91-97
29953997-5	2018	CDDO-me exerted cytotoxic activity against W4P-LHB-expressing NIH3T3 cells, HepG2 cells, and Huh7 cells, and induced apoptotic cell death in a dose-dependent manner, demonstrating its anti-cancer activity against HCC.	bardoxolone methyl	0-7	luteinizing hormone beta	Mus musculus	47-50
29953997-5	2018	CDDO-me exerted cytotoxic activity against W4P-LHB-expressing NIH3T3 cells, HepG2 cells, and Huh7 cells, and induced apoptotic cell death in a dose-dependent manner, demonstrating its anti-cancer activity against HCC.	bardoxolone methyl	0-7	MIR7-3 host gene	Homo sapiens	93-97
29953997-6	2018	Sublethal concentrations of CDDO-me suppressed STAT3 activation by W4P-LHB ectopic expression and interleukin-6 treatment in W4P-LHB-NIH3T3 and Huh7 cells respectively.	bardoxolone methyl	28-35	signal transducer and activator of transcription 3	Homo sapiens	47-52
29953997-6	2018	Sublethal concentrations of CDDO-me suppressed STAT3 activation by W4P-LHB ectopic expression and interleukin-6 treatment in W4P-LHB-NIH3T3 and Huh7 cells respectively.	bardoxolone methyl	28-35	luteinizing hormone beta	Mus musculus	71-74
29953997-6	2018	Sublethal concentrations of CDDO-me suppressed STAT3 activation by W4P-LHB ectopic expression and interleukin-6 treatment in W4P-LHB-NIH3T3 and Huh7 cells respectively.	bardoxolone methyl	28-35	interleukin 6	Homo sapiens	98-111
29953997-6	2018	Sublethal concentrations of CDDO-me suppressed STAT3 activation by W4P-LHB ectopic expression and interleukin-6 treatment in W4P-LHB-NIH3T3 and Huh7 cells respectively.	bardoxolone methyl	28-35	luteinizing hormone subunit beta	Homo sapiens	129-132
29953997-6	2018	Sublethal concentrations of CDDO-me suppressed STAT3 activation by W4P-LHB ectopic expression and interleukin-6 treatment in W4P-LHB-NIH3T3 and Huh7 cells respectively.	bardoxolone methyl	28-35	MIR7-3 host gene	Homo sapiens	144-148
29953997-7	2018	The suppression of STAT3 activation by CDDO-me in W4P-LHB-NIH3T3 cells was further confirmed by decreased cyclin D1 protein levels and increased p21 and p53 mRNA synthesis.	bardoxolone methyl	39-46	signal transducer and activator of transcription 3	Homo sapiens	19-24
29953997-7	2018	The suppression of STAT3 activation by CDDO-me in W4P-LHB-NIH3T3 cells was further confirmed by decreased cyclin D1 protein levels and increased p21 and p53 mRNA synthesis.	bardoxolone methyl	39-46	luteinizing hormone subunit beta	Homo sapiens	54-57
29953997-7	2018	The suppression of STAT3 activation by CDDO-me in W4P-LHB-NIH3T3 cells was further confirmed by decreased cyclin D1 protein levels and increased p21 and p53 mRNA synthesis.	bardoxolone methyl	39-46	cyclin D1	Homo sapiens	106-115
29953997-7	2018	The suppression of STAT3 activation by CDDO-me in W4P-LHB-NIH3T3 cells was further confirmed by decreased cyclin D1 protein levels and increased p21 and p53 mRNA synthesis.	bardoxolone methyl	39-46	H3 histone pseudogene 16	Homo sapiens	145-148
29953997-7	2018	The suppression of STAT3 activation by CDDO-me in W4P-LHB-NIH3T3 cells was further confirmed by decreased cyclin D1 protein levels and increased p21 and p53 mRNA synthesis.	bardoxolone methyl	39-46	tumor protein p53	Homo sapiens	153-156
29953997-8	2018	In addition, CDDO-me treatment resulted in decreased cell migration and colony formation in in vitro assays using W4P-LHB-NIH3T3, HepG2, or Huh7 cell lines, supporting its anti-cancer activity through STAT3 inhibition.	bardoxolone methyl	13-20	luteinizing hormone subunit beta	Homo sapiens	118-121
29953997-8	2018	In addition, CDDO-me treatment resulted in decreased cell migration and colony formation in in vitro assays using W4P-LHB-NIH3T3, HepG2, or Huh7 cell lines, supporting its anti-cancer activity through STAT3 inhibition.	bardoxolone methyl	13-20	MIR7-3 host gene	Homo sapiens	140-144
29953997-8	2018	In addition, CDDO-me treatment resulted in decreased cell migration and colony formation in in vitro assays using W4P-LHB-NIH3T3, HepG2, or Huh7 cell lines, supporting its anti-cancer activity through STAT3 inhibition.	bardoxolone methyl	13-20	signal transducer and activator of transcription 3	Homo sapiens	201-206
29953997-9	2018	Furthermore, -CDDO-me administration significantly suppressed tumor growth induced by W4P-LHB-expressing NIH3T3 cells in nude mice, confirming its anti-cancer activity.	bardoxolone methyl	14-21	luteinizing hormone beta	Mus musculus	90-93
29953997-10	2018	Collectively, our findings demonstrated that CDDO-me is capable of suppressing STAT3 activation in HCC cells and cells transformed by the natural variant of HBV protein.	bardoxolone methyl	45-52	signal transducer and activator of transcription 3	Homo sapiens	79-84
28978980-1	2018	The aim of this study was to investigate the renoprotective effect of bardoxolone methyl (BM), a nuclear factor erythroid 2-related factor 2 (Nrf2) activator with an antioxidant effect, in a salt-sensitive hypertension model induced by aldosterone (Ald) and salt.	bardoxolone methyl	70-88	NFE2 like bZIP transcription factor 2	Homo sapiens	97-140
28978980-1	2018	The aim of this study was to investigate the renoprotective effect of bardoxolone methyl (BM), a nuclear factor erythroid 2-related factor 2 (Nrf2) activator with an antioxidant effect, in a salt-sensitive hypertension model induced by aldosterone (Ald) and salt.	bardoxolone methyl	70-88	NFE2 like bZIP transcription factor 2	Homo sapiens	142-146
28978980-1	2018	The aim of this study was to investigate the renoprotective effect of bardoxolone methyl (BM), a nuclear factor erythroid 2-related factor 2 (Nrf2) activator with an antioxidant effect, in a salt-sensitive hypertension model induced by aldosterone (Ald) and salt.	bardoxolone methyl	90-92	NFE2 like bZIP transcription factor 2	Homo sapiens	97-140
28978980-1	2018	The aim of this study was to investigate the renoprotective effect of bardoxolone methyl (BM), a nuclear factor erythroid 2-related factor 2 (Nrf2) activator with an antioxidant effect, in a salt-sensitive hypertension model induced by aldosterone (Ald) and salt.	bardoxolone methyl	90-92	NFE2 like bZIP transcription factor 2	Homo sapiens	142-146
29118925-0	2017	Bardoxolone methyl (CDDO-Me or RTA402) induces cell cycle arrest, apoptosis and autophagy via PI3K/Akt/mTOR and p38 MAPK/Erk1/2 signaling pathways in K562 cells.	bardoxolone methyl	0-18	mechanistic target of rapamycin kinase	Homo sapiens	103-107
29118925-0	2017	Bardoxolone methyl (CDDO-Me or RTA402) induces cell cycle arrest, apoptosis and autophagy via PI3K/Akt/mTOR and p38 MAPK/Erk1/2 signaling pathways in K562 cells.	bardoxolone methyl	0-18	mitogen-activated protein kinase 1	Homo sapiens	112-115
29118925-0	2017	Bardoxolone methyl (CDDO-Me or RTA402) induces cell cycle arrest, apoptosis and autophagy via PI3K/Akt/mTOR and p38 MAPK/Erk1/2 signaling pathways in K562 cells.	bardoxolone methyl	0-18	mitogen-activated protein kinase 3	Homo sapiens	121-127
29118925-0	2017	Bardoxolone methyl (CDDO-Me or RTA402) induces cell cycle arrest, apoptosis and autophagy via PI3K/Akt/mTOR and p38 MAPK/Erk1/2 signaling pathways in K562 cells.	bardoxolone methyl	20-27	AKT serine/threonine kinase 1	Homo sapiens	99-102
29118925-0	2017	Bardoxolone methyl (CDDO-Me or RTA402) induces cell cycle arrest, apoptosis and autophagy via PI3K/Akt/mTOR and p38 MAPK/Erk1/2 signaling pathways in K562 cells.	bardoxolone methyl	20-27	mechanistic target of rapamycin kinase	Homo sapiens	103-107
29118925-0	2017	Bardoxolone methyl (CDDO-Me or RTA402) induces cell cycle arrest, apoptosis and autophagy via PI3K/Akt/mTOR and p38 MAPK/Erk1/2 signaling pathways in K562 cells.	bardoxolone methyl	20-27	mitogen-activated protein kinase 1	Homo sapiens	112-115
29118925-0	2017	Bardoxolone methyl (CDDO-Me or RTA402) induces cell cycle arrest, apoptosis and autophagy via PI3K/Akt/mTOR and p38 MAPK/Erk1/2 signaling pathways in K562 cells.	bardoxolone methyl	20-27	mitogen-activated protein kinase 3	Homo sapiens	121-127
29118925-0	2017	Bardoxolone methyl (CDDO-Me or RTA402) induces cell cycle arrest, apoptosis and autophagy via PI3K/Akt/mTOR and p38 MAPK/Erk1/2 signaling pathways in K562 cells.	bardoxolone methyl	31-37	AKT serine/threonine kinase 1	Homo sapiens	99-102
29118925-0	2017	Bardoxolone methyl (CDDO-Me or RTA402) induces cell cycle arrest, apoptosis and autophagy via PI3K/Akt/mTOR and p38 MAPK/Erk1/2 signaling pathways in K562 cells.	bardoxolone methyl	31-37	mechanistic target of rapamycin kinase	Homo sapiens	103-107
29118925-0	2017	Bardoxolone methyl (CDDO-Me or RTA402) induces cell cycle arrest, apoptosis and autophagy via PI3K/Akt/mTOR and p38 MAPK/Erk1/2 signaling pathways in K562 cells.	bardoxolone methyl	31-37	mitogen-activated protein kinase 1	Homo sapiens	112-115
29118925-0	2017	Bardoxolone methyl (CDDO-Me or RTA402) induces cell cycle arrest, apoptosis and autophagy via PI3K/Akt/mTOR and p38 MAPK/Erk1/2 signaling pathways in K562 cells.	bardoxolone methyl	31-37	mitogen-activated protein kinase 3	Homo sapiens	121-127
29118925-2	2017	CDDO-Me (Bardoxolone methyl), a potent Nrf2 activator and NF-kappaB inhibitor, is a promising candidate for cancer treatment including leukemia.	bardoxolone methyl	0-7	NFE2 like bZIP transcription factor 2	Homo sapiens	39-43
29118925-5	2017	A total of 1,555 proteins responded to CDDO-Me exposure, including FANCI, SRPK2, XPO5, HP1BP3, NELFCD, Na+,K+-ATPase 1, etc.	bardoxolone methyl	39-46	FA complementation group I	Felis catus	67-72
29118925-5	2017	A total of 1,555 proteins responded to CDDO-Me exposure, including FANCI, SRPK2, XPO5, HP1BP3, NELFCD, Na+,K+-ATPase 1, etc.	bardoxolone methyl	39-46	SRSF protein kinase 2	Felis catus	74-79
29118925-5	2017	A total of 1,555 proteins responded to CDDO-Me exposure, including FANCI, SRPK2, XPO5, HP1BP3, NELFCD, Na+,K+-ATPase 1, etc.	bardoxolone methyl	39-46	exportin 5	Felis catus	81-85
29118925-5	2017	A total of 1,555 proteins responded to CDDO-Me exposure, including FANCI, SRPK2, XPO5, HP1BP3, NELFCD, Na+,K+-ATPase 1, etc.	bardoxolone methyl	39-46	heterochromatin protein 1 binding protein 3	Felis catus	87-93
29118925-5	2017	A total of 1,555 proteins responded to CDDO-Me exposure, including FANCI, SRPK2, XPO5, HP1BP3, NELFCD, Na+,K+-ATPase 1, etc.	bardoxolone methyl	39-46	negative elongation factor complex member C/D	Felis catus	95-101
29118925-9	2017	CDDO-Me caused mitochondria-, death receptor-dependent and ER stress-mediated apoptosis in K562 cells, also induced autophagy with the suppression of PI3K/Akt/mTOR signaling pathway.	bardoxolone methyl	0-7	AKT serine/threonine kinase 1	Homo sapiens	155-158
29118925-9	2017	CDDO-Me caused mitochondria-, death receptor-dependent and ER stress-mediated apoptosis in K562 cells, also induced autophagy with the suppression of PI3K/Akt/mTOR signaling pathway.	bardoxolone methyl	0-7	mechanistic target of rapamycin kinase	Homo sapiens	159-163
29118925-10	2017	p38 MAPK/Erk1/2 signaling pathways contributed to both apoptosis- and autophagy-inducing effects of CDDO-Me in K562 cells.	bardoxolone methyl	100-107	mitogen-activated protein kinase 1	Homo sapiens	0-3
29118925-10	2017	p38 MAPK/Erk1/2 signaling pathways contributed to both apoptosis- and autophagy-inducing effects of CDDO-Me in K562 cells.	bardoxolone methyl	100-107	mitogen-activated protein kinase 3	Homo sapiens	9-15
28275049-3	2017	In contrast, both Bar-Me and CF3DODA-Me induce reactive oxygen species in HL-60 and Jurkat leukemia cells, inhibit cell growth, induce apoptosis and differentiation, and decrease expression of specificity proteins (Sp) 1, 3, and 4, and cMyc, and these effects are significantly attenuated after cotreatment with the antioxidant GSH.	bardoxolone methyl	18-24	Sp1 transcription factor	Homo sapiens	193-230
28273344-10	2017	Importantly, CDDO-Me treatment reduced allergen-induced ATP secretion and IL-33 release by airway epithelial cells in vitro and protected mice from IL-33 release and asthma-like pathological changes in the lungs.	bardoxolone methyl	13-20	interleukin 33	Mus musculus	74-79
28273344-10	2017	Importantly, CDDO-Me treatment reduced allergen-induced ATP secretion and IL-33 release by airway epithelial cells in vitro and protected mice from IL-33 release and asthma-like pathological changes in the lungs.	bardoxolone methyl	13-20	interleukin 33	Mus musculus	148-153
28596283-3	2017	CDDO-Me (bardoxolone methyl) is a drug that inhibits the survival of leukemic cells by targeting different pro-survival molecules, including STAT3.	bardoxolone methyl	0-7	signal transducer and activator of transcription 3	Homo sapiens	141-146
28596283-4	2017	We found that CDDO-Me inhibits proliferation and survival of tyrosine kinase inhibitor-resistant BCR-ABL1+ cell lines and primary leukemic cells, including cells harboring BCR-ABL1T315I or T315I+ compound mutations.	bardoxolone methyl	14-21	BCR activator of RhoGEF and GTPase	Homo sapiens	97-105
28596283-4	2017	We found that CDDO-Me inhibits proliferation and survival of tyrosine kinase inhibitor-resistant BCR-ABL1+ cell lines and primary leukemic cells, including cells harboring BCR-ABL1T315I or T315I+ compound mutations.	bardoxolone methyl	14-21	BCR activator of RhoGEF and GTPase	Homo sapiens	97-100
28596283-5	2017	Furthermore, CDDO-Me was found to block growth and survival of CD34+/CD38- leukemic stem cells (LSC).	bardoxolone methyl	13-20	CD34 molecule	Homo sapiens	63-67
28596283-5	2017	Furthermore, CDDO-Me was found to block growth and survival of CD34+/CD38- leukemic stem cells (LSC).	bardoxolone methyl	13-20	CD38 molecule	Homo sapiens	69-73
28596283-9	2017	However, CDDO-Me was also found to increase the expression of heme-oxygenase-1, a heat-shock-protein that triggers drug resistance and cell survival.	bardoxolone methyl	9-16	heme oxygenase 1	Homo sapiens	62-78
28596283-11	2017	Moreover, SMA-ZnPP was found to sensitize BCR-ABL1+ cells against the combination "CDDO-Me+ tyrosine kinase inhibitor".	bardoxolone methyl	83-90	BCR activator of RhoGEF and GTPase	Homo sapiens	42-50
28886135-4	2017	Interestingly, treatment of patient PBMCs with the Nuclear Factor-Erythroid-2-Related Factor 2 (NRF2) agonist, CDDO-Me(bardoxolone methyl), reduced MCP-1 production but not IL-6 or Interleukin-10 (IL-10) secretion.	bardoxolone methyl	111-118	NFE2 like bZIP transcription factor 2	Homo sapiens	51-94
28886135-4	2017	Interestingly, treatment of patient PBMCs with the Nuclear Factor-Erythroid-2-Related Factor 2 (NRF2) agonist, CDDO-Me(bardoxolone methyl), reduced MCP-1 production but not IL-6 or Interleukin-10 (IL-10) secretion.	bardoxolone methyl	111-118	NFE2 like bZIP transcription factor 2	Homo sapiens	96-100
28886135-4	2017	Interestingly, treatment of patient PBMCs with the Nuclear Factor-Erythroid-2-Related Factor 2 (NRF2) agonist, CDDO-Me(bardoxolone methyl), reduced MCP-1 production but not IL-6 or Interleukin-10 (IL-10) secretion.	bardoxolone methyl	111-118	C-C motif chemokine ligand 2	Homo sapiens	148-153
28886135-4	2017	Interestingly, treatment of patient PBMCs with the Nuclear Factor-Erythroid-2-Related Factor 2 (NRF2) agonist, CDDO-Me(bardoxolone methyl), reduced MCP-1 production but not IL-6 or Interleukin-10 (IL-10) secretion.	bardoxolone methyl	111-118	interleukin 10	Homo sapiens	181-195
28886135-4	2017	Interestingly, treatment of patient PBMCs with the Nuclear Factor-Erythroid-2-Related Factor 2 (NRF2) agonist, CDDO-Me(bardoxolone methyl), reduced MCP-1 production but not IL-6 or Interleukin-10 (IL-10) secretion.	bardoxolone methyl	111-118	interleukin 10	Homo sapiens	197-202
28886135-5	2017	In enriched monocytes from healthy donors, CDDO-Me(bardoxolone methyl) also reduced LPS-induced MCP1/CCL2 production but did not alter IL-6 or IL-10 secretion.	bardoxolone methyl	43-50	C-C motif chemokine ligand 2	Homo sapiens	96-100
28886135-5	2017	In enriched monocytes from healthy donors, CDDO-Me(bardoxolone methyl) also reduced LPS-induced MCP1/CCL2 production but did not alter IL-6 or IL-10 secretion.	bardoxolone methyl	43-50	C-C motif chemokine ligand 2	Homo sapiens	101-105
28886135-7	2017	Hence, our findings with CDDO-Me(bardoxolone methyl) and Compound 7 are likely to reflect a generalizable aspect of NRF2 activation.	bardoxolone methyl	25-32	NFE2 like bZIP transcription factor 2	Homo sapiens	116-120
28275049-3	2017	In contrast, both Bar-Me and CF3DODA-Me induce reactive oxygen species in HL-60 and Jurkat leukemia cells, inhibit cell growth, induce apoptosis and differentiation, and decrease expression of specificity proteins (Sp) 1, 3, and 4, and cMyc, and these effects are significantly attenuated after cotreatment with the antioxidant GSH.	bardoxolone methyl	18-24	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	236-240
27780924-0	2016	CDDO-Me reveals USP7 as a novel target in ovarian cancer cells.	bardoxolone methyl	0-7	ubiquitin specific peptidase 7	Homo sapiens	16-20
27979484-4	2017	The effect of bardoxolone methyl (BM) on miR-21, miR-223-5p, and miR-125b in renal IR injury was evaluated in this study.	bardoxolone methyl	34-36	microRNA 21	Rattus norvegicus	41-47
27979484-4	2017	The effect of bardoxolone methyl (BM) on miR-21, miR-223-5p, and miR-125b in renal IR injury was evaluated in this study.	bardoxolone methyl	34-36	microRNA 223	Rattus norvegicus	49-56
27780924-3	2016	In this study, we identified synthetic triterpenoid C-28 methyl ester of 2-cyano-3, 12-dioxoolen-1, 9-dien-28-oic acid (CDDO-Me) as a novel inhibitor of USP7 but not of other cysteine proteases such as cathepsin B and cathepsin D.	bardoxolone methyl	120-127	cathepsin D	Homo sapiens	218-229
27780924-4	2016	CDDO-Me inhibits USP7 activity via a mechanism that is independent of the presence of alpha, beta-unsaturated ketones.	bardoxolone methyl	0-7	ubiquitin specific peptidase 7	Homo sapiens	17-21
27780924-3	2016	In this study, we identified synthetic triterpenoid C-28 methyl ester of 2-cyano-3, 12-dioxoolen-1, 9-dien-28-oic acid (CDDO-Me) as a novel inhibitor of USP7 but not of other cysteine proteases such as cathepsin B and cathepsin D.	bardoxolone methyl	120-127	ubiquitin specific peptidase 7	Homo sapiens	153-157
27780924-5	2016	Molecular docking studies showed that CDDO-Me fits well in the ubiquitin carboxyl terminus-binding pocket on USP7.	bardoxolone methyl	38-45	ubiquitin specific peptidase 7	Homo sapiens	109-113
27780924-6	2016	Given that CDDO-Me is known to be effective against ovarian cancer cells, we speculated that CDDO-Me may target USP7 in ovarian cancer cells.	bardoxolone methyl	11-18	ubiquitin specific peptidase 7	Homo sapiens	112-116
27780924-3	2016	In this study, we identified synthetic triterpenoid C-28 methyl ester of 2-cyano-3, 12-dioxoolen-1, 9-dien-28-oic acid (CDDO-Me) as a novel inhibitor of USP7 but not of other cysteine proteases such as cathepsin B and cathepsin D.	bardoxolone methyl	120-127	cathepsin B	Homo sapiens	202-213
27780924-6	2016	Given that CDDO-Me is known to be effective against ovarian cancer cells, we speculated that CDDO-Me may target USP7 in ovarian cancer cells.	bardoxolone methyl	93-100	ubiquitin specific peptidase 7	Homo sapiens	112-116
27780924-9	2016	Using the cellular thermal shift assay and the drug affinity responsive target stability assay, we further demonstrated that CDDO-Me directly binds to USP7 in cells, which leads to the decrease of its substrates such as MDM2, MDMX and UHRF1.	bardoxolone methyl	125-132	ubiquitin specific peptidase 7	Homo sapiens	151-155
27780924-9	2016	Using the cellular thermal shift assay and the drug affinity responsive target stability assay, we further demonstrated that CDDO-Me directly binds to USP7 in cells, which leads to the decrease of its substrates such as MDM2, MDMX and UHRF1.	bardoxolone methyl	125-132	MDM2 proto-oncogene	Homo sapiens	220-224
27780924-9	2016	Using the cellular thermal shift assay and the drug affinity responsive target stability assay, we further demonstrated that CDDO-Me directly binds to USP7 in cells, which leads to the decrease of its substrates such as MDM2, MDMX and UHRF1.	bardoxolone methyl	125-132	MDM4 regulator of p53	Homo sapiens	226-230
27780924-9	2016	Using the cellular thermal shift assay and the drug affinity responsive target stability assay, we further demonstrated that CDDO-Me directly binds to USP7 in cells, which leads to the decrease of its substrates such as MDM2, MDMX and UHRF1.	bardoxolone methyl	125-132	ubiquitin like with PHD and ring finger domains 1	Homo sapiens	235-240
27780924-11	2016	In conclusion, we demonstrate that USP7 is a novel target of ovarian cancer cells; targeting USP7 may contribute to the anti-cancer effect of CDDO-Me.	bardoxolone methyl	142-149	ubiquitin specific peptidase 7	Homo sapiens	35-39
27780924-11	2016	In conclusion, we demonstrate that USP7 is a novel target of ovarian cancer cells; targeting USP7 may contribute to the anti-cancer effect of CDDO-Me.	bardoxolone methyl	142-149	ubiquitin specific peptidase 7	Homo sapiens	93-97
27780924-12	2016	The development of novel USP7 selective compounds based on the CDDO-Me-scaffold warrants further investigation.	bardoxolone methyl	63-70	ubiquitin specific peptidase 7	Homo sapiens	25-29
27633142-7	2016	More importantly, activation of Nrf2 signaling by CDDO-Me significantly alleviated cyclophosphamide-induced myelosuppression, while this alleviation was diminished in Nrf2-/- mice.	bardoxolone methyl	50-57	nuclear factor, erythroid derived 2, like 2	Mus musculus	32-36
27693327-5	2016	At the same time, the activation of Nrf2 with D, l-sulforaphane (SFN) and CDDO-Me could repress the replication of SVCV, and knockdown of Nrf2 by siRNA could promote the replication of SVCV.	bardoxolone methyl	74-81	NFE2 like bZIP transcription factor 2	Homo sapiens	36-40
27480280-3	2016	We aimed to evaluate the ability of short-term treatment with the Nrf2 activator bardoxolone methyl (CDDO-Me) to protect against cisplatin-induced kidney cell toxicity.	bardoxolone methyl	81-99	NFE2 like bZIP transcription factor 2	Homo sapiens	66-70
27480280-3	2016	We aimed to evaluate the ability of short-term treatment with the Nrf2 activator bardoxolone methyl (CDDO-Me) to protect against cisplatin-induced kidney cell toxicity.	bardoxolone methyl	101-108	NFE2 like bZIP transcription factor 2	Homo sapiens	66-70
27480280-6	2016	Gene regulation (mRNA expression) studies revealed the ability of CDDO-Me to modify protective pathways including Nrf2 induced detoxifying genes [GCLC (increased 1.9-fold), NQO1 (increased 9.3-fold)], and an efflux transporter [SLC47A1 (increased 4.5-fold)] at 12h.	bardoxolone methyl	66-73	NFE2 like bZIP transcription factor 2	Homo sapiens	114-118
27480280-6	2016	Gene regulation (mRNA expression) studies revealed the ability of CDDO-Me to modify protective pathways including Nrf2 induced detoxifying genes [GCLC (increased 1.9-fold), NQO1 (increased 9.3-fold)], and an efflux transporter [SLC47A1 (increased 4.5-fold)] at 12h.	bardoxolone methyl	66-73	glutamate-cysteine ligase catalytic subunit	Homo sapiens	146-150
27480280-6	2016	Gene regulation (mRNA expression) studies revealed the ability of CDDO-Me to modify protective pathways including Nrf2 induced detoxifying genes [GCLC (increased 1.9-fold), NQO1 (increased 9.3-fold)], and an efflux transporter [SLC47A1 (increased 4.5-fold)] at 12h.	bardoxolone methyl	66-73	NAD(P)H quinone dehydrogenase 1	Homo sapiens	173-177
27480280-6	2016	Gene regulation (mRNA expression) studies revealed the ability of CDDO-Me to modify protective pathways including Nrf2 induced detoxifying genes [GCLC (increased 1.9-fold), NQO1 (increased 9.3-fold)], and an efflux transporter [SLC47A1 (increased 4.5-fold)] at 12h.	bardoxolone methyl	66-73	solute carrier family 47 member 1	Homo sapiens	228-235
27480280-8	2016	Immunofluorescence revealed localization of GCLC and NQO1 to the nucleus and cytosol, respectively, with CDDO-Me administered prior to or after cisplatin exposure.	bardoxolone methyl	105-112	glutamate-cysteine ligase catalytic subunit	Homo sapiens	44-48
27480280-8	2016	Immunofluorescence revealed localization of GCLC and NQO1 to the nucleus and cytosol, respectively, with CDDO-Me administered prior to or after cisplatin exposure.	bardoxolone methyl	105-112	NAD(P)H quinone dehydrogenase 1	Homo sapiens	53-57
27480280-9	2016	The findings of enhanced cell viability and increased expression of detoxifying enzymes (GCLC and NQO1) and the multidrug and toxin extrusion protein 1 (MATE1) efflux transporter (SLC47A1) in hPTCs exposed to CDDO-Me, suggest that intermittent treatment with CDDO-Me prior to or after cisplatin exposure may be a promising approach to mitigate acute kidney injury.	bardoxolone methyl	209-216	solute carrier family 47 member 1	Homo sapiens	112-151
27480280-9	2016	The findings of enhanced cell viability and increased expression of detoxifying enzymes (GCLC and NQO1) and the multidrug and toxin extrusion protein 1 (MATE1) efflux transporter (SLC47A1) in hPTCs exposed to CDDO-Me, suggest that intermittent treatment with CDDO-Me prior to or after cisplatin exposure may be a promising approach to mitigate acute kidney injury.	bardoxolone methyl	209-216	solute carrier family 47 member 1	Homo sapiens	153-158
27480280-9	2016	The findings of enhanced cell viability and increased expression of detoxifying enzymes (GCLC and NQO1) and the multidrug and toxin extrusion protein 1 (MATE1) efflux transporter (SLC47A1) in hPTCs exposed to CDDO-Me, suggest that intermittent treatment with CDDO-Me prior to or after cisplatin exposure may be a promising approach to mitigate acute kidney injury.	bardoxolone methyl	209-216	solute carrier family 47 member 1	Homo sapiens	180-187
27480280-9	2016	The findings of enhanced cell viability and increased expression of detoxifying enzymes (GCLC and NQO1) and the multidrug and toxin extrusion protein 1 (MATE1) efflux transporter (SLC47A1) in hPTCs exposed to CDDO-Me, suggest that intermittent treatment with CDDO-Me prior to or after cisplatin exposure may be a promising approach to mitigate acute kidney injury.	bardoxolone methyl	259-266	solute carrier family 47 member 1	Homo sapiens	153-158
27480280-9	2016	The findings of enhanced cell viability and increased expression of detoxifying enzymes (GCLC and NQO1) and the multidrug and toxin extrusion protein 1 (MATE1) efflux transporter (SLC47A1) in hPTCs exposed to CDDO-Me, suggest that intermittent treatment with CDDO-Me prior to or after cisplatin exposure may be a promising approach to mitigate acute kidney injury.	bardoxolone methyl	259-266	solute carrier family 47 member 1	Homo sapiens	180-187
27192495-3	2016	The Nrf2 activator DMF (Dimethylfumarates) has been approved by the FDA as a new first-line oral drug to treat patients with relapsing forms of multiple sclerosis, while a phase 3 study of another promising candidate, CDDO-Me, was terminated for safety reasons.	bardoxolone methyl	218-225	NFE2 like bZIP transcription factor 2	Homo sapiens	4-8
26908173-1	2016	Semisynthetic triterpenoids such as bardoxolone methyl (methyl-2-cyano 3,12-dioxooleano-1,9-dien-28-oate; CDDO-Me) (4) are potent inducers of antioxidant and anti-inflammatory signaling pathways, including those regulated by the transcription factor Nrf2.	bardoxolone methyl	106-113	NFE2 like bZIP transcription factor 2	Rattus norvegicus	250-254
26918785-4	2016	We show that CDDO-Me treatment inhibits expression of IL-10 and VEGF in stimulated human M2 macrophages and TAMs but increases expression of TNF-alpha and IL-6.	bardoxolone methyl	13-20	interleukin 10	Homo sapiens	54-59
26918785-4	2016	We show that CDDO-Me treatment inhibits expression of IL-10 and VEGF in stimulated human M2 macrophages and TAMs but increases expression of TNF-alpha and IL-6.	bardoxolone methyl	13-20	vascular endothelial growth factor A	Homo sapiens	64-68
26918785-4	2016	We show that CDDO-Me treatment inhibits expression of IL-10 and VEGF in stimulated human M2 macrophages and TAMs but increases expression of TNF-alpha and IL-6.	bardoxolone methyl	13-20	tumor necrosis factor	Homo sapiens	141-150
26918785-4	2016	We show that CDDO-Me treatment inhibits expression of IL-10 and VEGF in stimulated human M2 macrophages and TAMs but increases expression of TNF-alpha and IL-6.	bardoxolone methyl	13-20	interleukin 6	Homo sapiens	155-159
26918785-5	2016	Surface expression of CD206 and CD163, which are characteristic of M2 activation, is significantly attenuated by CDDO-Me.	bardoxolone methyl	113-120	mannose receptor C-type 1	Homo sapiens	22-27
26918785-5	2016	Surface expression of CD206 and CD163, which are characteristic of M2 activation, is significantly attenuated by CDDO-Me.	bardoxolone methyl	113-120	CD163 molecule	Homo sapiens	32-37
26918785-6	2016	In contrast, CDDO-Me up-regulates surface expression of HLA-DR and CD80, which are markers of M1 activation, and importantly potentiates macrophage activation of autologous T cells but inhibits endothelial cell vascularization.	bardoxolone methyl	13-20	CD80 molecule	Homo sapiens	67-71